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Multifactorial Pathways Contributing to the Development and 
Impact of Foot Problems in Systemic Sclerosis  
Abstract  
Systemic sclerosis (SSc) is a heterogeneous connective tissue disease 
characterised by vasculopathy, immune activation and fibrosis [1-3]. The multi-
system nature of the disease has a wide-ranging impact on the patient’s overall 
health on physical, psychological and psychosocial levels [4] [5-7]. While foot 
problems in patients with SSc have been previously described and that their 
presence is associated with disability [8-10], the impact of such problems and 
its major contributors has yet to be determined. 
The underpinning hypothesis of this thesis was that the development and 
impact of foot problems on the Quality of Life (QoL) of patients with SSc is 
multifactorial; involving a complex inter-relationship between disease, functional 
impairment, personal factors, environmental factors and psychosocial factors. In 
order to explore this hypothesis, a multiple methodological approach was 
employed. First, a literature review and a consultation with clinical experts was 
undertaken to identify the potential candidate factors that may contribute to foot 
problems. Second, a case-control, cross-sectional study of 121 patients with 
SSc and 51 healthy participants was undertaken in order to investigate the 
impact of factors that contribute to foot problems. Finally, the pathway by which 
the candidate factors that were identified as contributing to foot pathology 
impacted on the overall quality of life in people with SSc was explored.  Using 
data from the same 121 patients with SSc, structural equation modelling (SEM) 
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was used to explore the inter-relationships between multifactorial pathways 
associated with foot pathology and its impact on patients with SSc. 
The results from this thesis can be summarised as follows: i) patients with SSc 
have significant foot problems; ii) SSc has both a physical and psychological 
impact; iii) foot problems are affected by complex interrelations between 
multiple factors; and iv) foot problems are a significant contributor to the impact 
on the quality of life of patients with SSc.   
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May 2014
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Chapter 1                                                        
Introduction 
1.1 Background  
Systemic sclerosis (SSc) is an autoimmune rheumatic disease characterised by 
three principal features: i) vasculopathy; ii) immune activation with production of 
autoantibodies and alteration in immune cells; and iii) fibrosis of the skin and 
internal organs as a result of excessive matrix deposition [2, 11-15]. The 
prevalence of SSc in the UK is 8.21 per 100 000 [16], with onset as early as the 
second decade [16-18]. The impact of the early onset of SSc is reflected in the 
high societal costs: in 1997 the cost associated with SSc in the United States 
was $1.5 billion [19] with a proportionally similar cost estimated for the UK. 
 
Foot problems in SSc have been reported to be common and disabling [9, 
20]and include: Raynaud’s phenomenon, associated severe ischemia leading to 
apical digital ulceration, subcutaneous calcinosis, skin thickening, callus 
formation, foot ulcers, sensory loss, tendonitis, joint space narrowing, bone 
demineralization, joint subluxation, joint margin erosions and degenerative 
changes[9, 20, 21]. People with SSc have reported significant foot impairment 
and reduced foot health status [10], possibly influenced by the presence of pain, 
as it has been well established that pain is a predictor of physical functioning in 
patients with SSc [22]. The mechanisms by which foot pain is increased in 
people with SSc, and the factors contributing to the impact of foot problems in 
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this group have not been investigated systematically however. There is 
therefore a need to investigate and identify the factors that predict foot 
problems and their impact on the quality of life of patients with SSc.  
1.2 Hypothesis  
The research hypothesis that this programme of work explores is: 
The development and impact of foot problems on the QoL of patients with SSc 
is multifactorial; involving a complex inter-relationship between disease, 
functional impairment, personal factors, environmental factors and psychosocial 
factors.  
In order to explore this, a multiple-methodological approach was used.  
1.3 Aim 
The primary aim of this study was to identify the factors that contribute to the 
development and impact of foot problems in patients with SSc 
1.4 Objectives  
To achieve this aim, three objectives were identified: 
i) To identify the potential candidate factors that may influence foot 
pathology in SSc; 
ii) To investigate the candidate factors that contribute to foot pathology 
and explore their impact, and 
iii) To explore the relationships between factors that contribute to foot 
problems and their impact on the quality of life of patients with SSc.  
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1.5 Structure of the thesis  
The structure of the thesis is outlined in this section providing a summary of the 
content of each chapter.  
Chapter two is a review of the literature. This literature review informs the 
hypothesis and provides background information for the thesis. The literature 
review covers different areas of the disease, such as disease subsets, 
classification of SSc, epidemiology, aetiopathogenesis, pathophysiology, clinical 
manifestation and associated mechanism- with a focus on foot pathology and 
impact of foot pathology in SSc.   
 
Chapter three provides information about the varied methodologies employed in 
this thesis. This chapter explains in detail the methods underpinning each of the 
three phases of the study i.e. the literature review, the case-control cross-
sectional study and the structural equation modelling, and describes the 
conceptual framework for the methods used to identify the factors contributing 
to the developments and impact of foot problem in SSc.  
 
Chapter four describes the results obtained from the exploration of the factors 
contributing to the developments and impact of foot problem in SSc. This 
chapter describes in detail the results obtained from: the identification of the 
potential candidate factors that may influence foot pathology in SSc; the 
investigation of the candidate factors that contribute to foot pathology and 
exploration of their impact; and the exploration of the multifactorial pathways in 
foot pathology and its impact on quality of life. 
 15  
 
Chapter five provides a critical appraisal of the findings from the study, the 
implications of these findings, and an evaluation of the limitations of the study. 
In addition, this chapter discusses the contribution of this work to the existing 
literature and the recommendations of future research based of the findings 
obtained from this study.    
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Chapter 2                                                    
Background and Review of the Literature  
2.1 Background  
Systemic sclerosis (SSc) is a heterogeneous connective tissue disease characterised 
by vasculopathy, immune activation and fibrosis [1-3]. SSc is also known as 
scleroderma, meaning hardening of the skin, a hallmark of the disease, [23, 24] with 
skin involvement seen in the vast majority of the patients [25]. Several different terms 
have been used to describe the disease over the years, including scleroderma, 
systemic scleroderma, progressive systemic sclerosis and systemic sclerosis [23].  
2.2 Disease subsets  
The heterogeneous nature of the disease has made the development of classification 
criteria and definition of the different disease subsets for SSc a challenge. This is 
reflected in the number of the different attempts to develop criteria over the years, as 
presented in Table 2.1 (and discussed in section 2.3).
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Year and Author Classification Scheme 
1945  
Goetz [26] 
2 subsets: acrosclerosis and diffuse: based on skin thickening limited 
to extremities or includes trunk 
1962 
Tuffanelli and 
Winkelman [27] 
2 subsets: acrosclerosis: RP, acral skin involvement; diffuse SSc: no 
RP, skin involvement beginning centrally 
1964  
Winterbauer [28] 
CRST syndrome: calcinosis, RP, sclerodactyly, telangiectasia 
1969  
Barnett [29] 
3 subsets: limited, moderate, extensive, based on skin involvement of 
the fingers only, limbs and face, and involvement of the trunk, respectively 
1979 
 Rodnan [30] 
3 subsets: classical disease involving skin of the trunk, face and 
proximal extremities, and early involvement of esophagus, intestine, heart, 
lung and kidney; CREST syndrome; and overlap syndromes including 
sclerodermatomyositis and mixed connective tissue disease 
1986  
Giordano [31] 
6 subsets: I: sclerodactyly only; II: sclerodactyly and skin involvement 
of neck, lower eyelid, or axillae; III: skin involvement of hands and 
forearms ± legs ± face; IV: group III and arm and/or thigh skin 
involvement; V: group III and thorax; VI: group III and/or IV and/or V plus 
the abdomen. 
3 subsets: limited: skin involvement of fingers, face, neck, axillae; 
intermediate: skin involvement proximal to fingers; diffuse: truncal skin 
involvement 
1987 
Holzmann[32] 
5 subsets (Types I–IV) based on presence/absence of RP, sclerosis, 
extracutaneous manifestations, ANA 
1988 
 LeRoy [24] 
2 subsets: diffuse cutaneous SSc: onset of RP within 1 year; truncal 
and acral skin involvement; tendon friction rubs; early incidence of ILD, 
renal failure, diffuse GI disease, myocardial involvement; absence of ACA, 
abnormal ND; limited cutaneous SSc: RP for years, skin involvement 
limited to hands, face, feet, forearms or absent; late incidence of PAH, 
trigeminal neuralgia, calcinosis, telangiectasia; high incidence of ACA, 
abnormal NC 
1988  
Masi [33] 
3 subsets: digital: skin involvement of fingers or toes but not proximal 
extremity or trunk; proximal extremity: proximal extremities or face but 
not trunk; truncal: thorax or abdomen 
2001  
LeRoy and 
Medsger [34] 
4 subsets: limited SSc (LSSc) consists of (1) objective RP plus any one 
of NC changes or SSc selective autoantibodies or (2) subjective RP plus 
both NC changes and SSc selective autoantibodies; limited cutaneous 
SSc (lcSSc): criteria for LSSc plus distal cutaneous changes; diffuse 
cutaneous (dcSSc): criteria for lcSSc plus proximal cutaneous changes; 
diffuse fasciitis with eosinophilia: proximal cutaneous changes without 
criteria for lSSc or lcSSc 
2002           
Scussel-Lonzetti 
[35] 
4 subsets: normal skin, limited: skin involvement restricted to fingers, 
with RP, calcinosis, esophageal involvement and telangiectasia; 
intermediate: skin involvement of arms proximal to metacarpophalangeal 
but not trunk; diffuse: skin involvement of the trunk 
2002  
Ferri [36] 
4 subsets: sine scleroderma SSc: absence of cutaneous involvement 
with visceral involvement, NC changes and autoantibodies; limited 
cutaneous: skin involvement of fingers with or without involvement of 
neck, face, and axillae; intermediate cutaneous: skin involvement of 
upper and lower limbs, neck and face without truncal involvement, diffuse 
cutaneous: distal and truncal skin involvement 
2004  
Maricq [37] 
6 subsets: diffuse, intermediate, digital, scleroderma sine 
scleroderma, undifferentiated connective tissue disease with 
scleroderma, CREST syndrome 
 
Table 2.1 Classification of systemic sclerosis subsets Modified from Johnson et al, page 
1857[38] RP: Raynaud’s phenomenon; NC: nailfold capillary; ILD: interstitial lung diseases; GI: 
gastrointestinal; ACA: anticentromere antibodies; PAH: pulmonary arterial hypertension; LSSc: 
limited SSc. 
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Improved understanding as well as recognition of the heterogeneous 
autoantibody subsets associated with clinical manifestations has aided the 
phenotyping of disease subsets and the development of more refined criteria. 
This has also permitted the differentiation of SSc from other conditions within 
the SSc spectrum [1, 38, 39].    
Localized scleroderma is the most frequent form of scleroderma in childhood 
[40]. It is distinct from systemic sclerosis and includes areas such as plaque 
morphea, linear scleroderma and en coup de sabre. Varying degree of 
involvement and severity of skin and subcutaneous tissues occurs and may 
lead to significant functional and cosmetic deformity [23]. For the purpose of this 
literature review the focus will be on the systemic form of the disease, and the 
term used will be Systemic Sclerosis (SSc). 
2.3 Disease Classification / diagnosis criteria 
As noted previously, the heterogeneous nature of the disease has made the 
agreement of a disease classification difficult, and has influenced the 
development of the three different evolving classification/ diagnostic criteria.  
The first SSc classification was published by the American Rheumatism 
Association (ARA) in 1980 [41], which aimed to broadly distinguish SSc from 
non-SSc patients. However, this classification did not adequately address 
disease heterogeneity [42]. Eight years later, a second classification system 
was proposed by LeRoy et al. [24],which took into consideration the principal 
distinguishing nature of the disease and introduced the two subsets of SSc: 
limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc).  The 1988 
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classification was later supplemented with an additional subset of early or 
limited SSc which did not include the presence of cutaneous involvement; it was 
termed limited Systemic Sclerosis (lSSc) [43]. This subset of lSSc has not been 
widely accepted [42, 44]. The more widely used classification for patients who 
have SSc without cutaneous involvement is systemic sclerosis sine 
scleroderma (ssSSc) [45]. The addition of this subset is useful in clinical 
practice as some patients early in their disease may present without apparent 
skin involvement [38], as well as instances of established disease without the 
usual skin tightening.   
There has however remained the need for a validated classification criteria that 
in particular can detect early and limited scleroderma to enable early detection 
of SSc; as well as to standardise the criteria for patients’ inclusion into studies, 
enabling a more robust comparison of results across studies [1]. These needs 
have been fulfilled by the latest development of the 2013 American College of 
Rheumatology (ACR) and the European League Against Rheumatism (EULAR) 
criteria which have demonstrated better performance over the 1980 criteria [39, 
46-48], and the preliminary criteria for the very early diagnosis of SSc (VEDOS) 
[49] which has enabled the early detection of scleroderma.  
2.4 The prevalence of systemic sclerosis 
Estimates of the prevalence of SSc vary enormously from between 30 to 2,280 
per 1,000,000 population [50], with  higher estimates in North America and 
Australia when compared to Europe and Japan [51, 52]. In the northern 
countries of Europe (England and Iceland), the prevalence is lower, when 
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compared to countries in Southern Europe (France and Greece) [52, 53]. Some 
spatiotemporal clustering has also reported in Ontorio, Rome, and near 
London’s airports [52, 54].  
The prevalence of SSc in the UK ranges from 31 per million in the West 
Midlands [55] to 150 per million in South and West London [54]. There are no 
epidemiological data for the area of West Yorkshire, but the closest where 
epidemiological data have been reported from is the North East of England, 
with a prevalence of 88 (8.8 per 100 000) and 82 per 1,000,000 when adjusted 
for the entire UK [16, 56]. Of the 63.2 million people in the UK, 5,183 people 
potentially suffer from SSc. 
Epidemiological data from different areas of the world are summarised in Table 
2.2.  The incidence of systemic sclerosis is lower in native Nigerians than in 
African Americans. Oklahoma Choctaw Indians have an incidence of 472 cases 
per million population, which is higher than that of the Missouri Choctaw 
Indians. These differences may reflect distinct environmental exposures as well 
as differences in genetic predisposition. 
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Table 2.2: Geographical and time variation of prevalence and incidence of systemic 
sclerosis. Taken from Ranque et al, Page A313[51] 
 
As with other autoimmune disease, there is a higher female-to-male ratio in 
SSC, approximately 3:1 (ranging from 1 to 14:1) [50, 52, 56, 57]. In the North 
East of England the female to male ratio has been reported to be 3.9:1 [56].  
The onset of the disease varies according to gender and ethnic background but 
generally reaches its peak of incidence at the fifth decade. However, SSc can 
occur at any age, albeit rare in children and in the very elderly [16-18, 51, 52]. 
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2.5 Aetiopathogenesis of systemic sclerosis 
The aetiopathogenesis of the disease remains unclear but epidemiological and 
genetic data indicate complex interactions between the host genetic 
background and a variable contribution by environmental factors[2, 51, 58]. 
 Scleroderma risk factors  2.5.1
 There are a number of risk factors for developing SSc, including genetic, 
ethnic, and environmental risk factors, the later including occupation, infection, 
and non-occupational non-infectious factors. There is however, disagreement in 
the literature regarding which factors are considered the strongest contributors 
to the development of the disease. Some authors suggest that the major risk 
factor is genetic [58, 59] while others indicates that environmental exposure 
plays a large role [51].  
 Genetics  2.5.2
A strong argument for the contribution of genetic factors in the development of 
SSc is made through: family studies that have shown clustering of the disease 
(occurring more frequently than in the general population; 1.6% compared to 
0.026 % [58]); higher frequency of other autoimmune disorders as well as 
autoantibodies; geographical/ethnic variation and the association of certain 
human leukocyte antigens (HLAs) and major histocompatibility complex (MHC) 
alleles in the context of disease types and manifestations. In first-degree 
relatives, the relative risk of SSc increased by between 10 to 16-fold, (average 
13), which is further increased for siblings 10 to 27-fold increased risk (average 
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15). However, the absolute risk for each family member remains very low, at 
around 1% [18, 58, 59]. This risk increases slightly for families with African 
American ethnicity, which has a higher percentage of familial SSc (3%) when 
compared with caucasian families (1.5%) [59]. 
In addition to sibling studies, twin studies have also been conducted and 
revealed that both monozygotic and dizygotic twin pairs share the same risk of 
developing SSc, supporting a shared environmental risk factor; although, when 
the positivity of antinuclear antibody (ANA) was assessed in the same twin pairs 
the concordance rate was 100% in monozygotic and only 64% in dizygotic 
twins, indicating that genetic factors may play a variable role [60].   
These results suggest that genetics are involved in the development of the 
disease and that environmental exposure is a concomitant risk factor (Ranque 
and Mouthon, 2010). 
While the genetic predisposition of SSc does not follow a Mendelian pattern, 
there is evidence supporting the assertion that genetic factors are involved in 
both disease susceptibility and progression [58]. 
A large number of genetic variants have been implicated in SSc susceptibility 
and pathogenesis. The genes found to be associated with the disease have a 
modest but reproducible effect on susceptibility through populations, and many 
of them map to the same biological pathway[61]. In some cases, combinations 
of genetic variance have been associated with an additive risk for susceptibility 
[61, 62].  
Some of the genetic associations report single nucleotide polymorphisms 
(SNPs) in genes coding for:  
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• vasomotor regulatory factors i.e. angiotensin–converting enzyme, 
endothelin and nitric oxide synthase;  
• B-cell markers i.e. CD19; chemokines and chemokine receptors i.e. 
monocyte chemotactic protein-1 (MCP-1) and CXCR2;  
• cytokines i.e. interleukin-1a (IL-1a), IL-4 and tumour necrosis factor-a 
(TNF-a); 
• growth factors and their receptors i.e bone morphogenetic protein type II 
receptor (BMPRII), connective tissue growth factor (CTGF) and 
transforming growth factor-b (TGF-b); 
• an anti-oxidant i.e. glutathione S-transferase; and extracellular matrix 
(ECM) proteins i.e. fibronectin, fibrillin and secreted protein, acidic and 
rich in cysteine (SPARC) [2, 63, 64].  
There are other SNPs that have been identified to be present in patients with 
SSc but they will not be covered in this section as it is beyond the scope of this 
literature review.  
2.5.2.1 Ethnicity  
It is not clear at the time of writing, whether the effect of ethnicity on the disease 
reflects a genetic or an environmental input [65].  Studies conducted in the USA 
observed that the prevalence of SSc was higher amongst black people than 
white [66, 67]:  those from a black ethnic background have a worse prognosis, 
and are more likely to develop the disease at a younger age, have the diffuse 
subset, have higher incidence of inflammatory features and worse age-adjusted 
survival rate [66, 67]. 
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Studies undertaken in Australia and France reported a higher prevalence of 
SSc among people born in continental Europe than non-European (Northern 
and Sub-Saharan Africans, Asians, and Caribbean) [68]. However, when 
compared with patients from European descent, SSc occurs more frequently in 
black Americans, some Asians, and some Native Americans (Choctaw Indians) 
[51], who were also more likely to have the diffuse subset of the disease 
associated with worse survival  indicating worse survival [18].  
2.5.2.2 Environmental risk factors  
Differentiating the association between environmental exposure and SSc is 
challenging. To fully explain any association, the exposure to the environmental 
factor and the development of the disease has to occur chronologically. Most of 
patients with SSc have not had the exposure to the environmental factors and 
the majority of the exposed subjects do not develop SSc [69].   
Environmental factors can be classified in three categories: occupational, 
infectious, and non-occupational/non-infectious [70]. 
i. Occupational  
Several occupational factors have been identified as potential risk factors to the 
development of SSc.  
Crystalline silica was one of the first environmental factors identified as a risk 
factor, when inhaled as dust. People working with rock and soil, such as mining, 
quarry and pottery work, have high exposure to this element and an increasing 
risk of contracting the disease [69-74].  
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Solvents are also considered a risk factor when penetrating through the skin 
and airways. Solvents implicated included organic solvents tetrachloroethylene, 
trichloroethylene, perchloroethylene, carbone tetrachloride, benzene, paint 
thinners/removers (e.g toluene and turpentine), nail polish and glues (e.g. 
acetone, methyl acetate and ethyl acetate), degreasers (e.g. hexane and petrol 
ether) varnish, gasoline, and aromatic hydrocarbons [75-78]. 
Other elements that have been reported to have an associated risk are ketones, 
epoxy resins, white spirit, cement, pesticides, and welding fumes [77-79]. 
ii.  Infection  
Bacterial and viral agents have been considered as a risk factor for the 
development of SSc, particularly helicobacteria pylori, human cytomegalovirus, 
herpes viruses, retroviruses, Epstein-Barr Virus, toxoplasma gondii and 
parvovirus B19 [80-83].  Despite the different studies undertaken there is no 
strong evidence to conclude that SSc has a viral or bacterial origin [69, 81].  
iii. Non-occupational/ non-infectious factors  
Some drugs have been identified as potential risk factors because of the 
scleroderma–like symptoms associated with their use [84], including oestrogen 
replacement therapy in post-menopausal women [76], appetite suppressants  
(e.g. dexamphetamine, diethylpropion, fenfluramine, fenproporex, mazindol, 
methaqualone, and phenmetrazine) [85], carbidopa and L-5 hydroxytryptophan 
(5-HTP) [86], bleomycin [87] and gadolinium [88]. The evidence supporting the 
role of some of these drugs in the development of SSc is weak as it comes from 
single case studies or studies with small numbers. 
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A body of evidence suggests therefore that there may be many potential 
environmental triggers for the development and progression of SSc, although 
the hosts’ factors also determine the susceptibility of the host to any triggers 
[81].   
2.6 The pathophysiology of systemic sclerosis  
While much of the detail of the pathophysiology of SSc remains poorly 
understood, it is clear that the disease is typically characterised by three 
features, namely, vasculopathy, immune activation (presence of autoantibodies) 
and inflammation, and fibrosis. The complex interaction between these three 
factors leads to immunological disruption; obliterative fibrointimal proliferation of 
the small vessels with vasospastic episodes, resulting in ischaemia; and 
activation of resident connective tissue cells (e.g. fibroblasts, myofiblobasts, 
pericytes) with increased deposition of extracellular matrix constituents [3, 89-
91]. While the exact processes associated with SSc remain to be fully 
elucidated, research has identified key cells, molecular processes and factors 
driving these pathways, resulting in changes to the vasculature, immune 
activation and fibrosis (Table 2.3). 
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Table 2.3: Key processes of SSc pathophysiology and the respective driving cells and 
molecules. Adapted from Geyer et al ,Page 97 [3]  
 Vascular dysfunction 2.6.1
A hallmark of SSc is the clinical observation of Raynaud’s Phenomenon (RP), 
which occurs in up to 95% of patients with SSc [92]. RP is an exaggerated 
vasoconstriction response to cold or emotions (e.g. anxiety) seen in the general 
population as well as in patients with SSc [93, 94]. In addition, structural 
changes are seen in patients with SSc, illustrated by characteristic changes in 
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the capillaries of the skin (with haemorrhage, megacapillaries and loss of 
capillary density) [95]. These features imply insufficient vasodilatory capacity 
and also irreparable vascular damage. These vascular changes manifest on a 
clinical level prior to the development of fibrotic features in the skin, gut as well 
as major internal organ involvement such as lung and myocardial disease. 
Whilst the fibrotic and cellular and humoral autoimmune processes are also 
central features, the exact interplay and dynamics between these processes 
remains challenging to define. Nevertheless, the vasculopathy is considered a 
key event in the early pathogenesis of SSc [96] [89][90]. Indeed, in addition to 
the early clinical feature of RP, much of the related morbidity and mortality in 
SSc is related to underlying vasculopathy.  
Microvascular involvement  
The vascular pathology is predominantly a microvasculopathy, characterised by 
fibrointimal proliferation, with initial functional vascular injury (associated with 
disruption of the vessel’s structure and function), leading to structural changes, 
intimal proliferation and occlusion. This results in a decrease in blood flow and 
irreversible tissue damage [93, 97]. The consequences of the vasculopathy can 
be observed clinically in different organs, as mentioned earlier, but the most 
visible and earliest clinical signs are observed on the upper and lower limbs; in 
particular on the hands and feet with Raynaud’s attacks, tissue ischaemia and 
ulcerations.   
The cause of the initial endothelial damage and vascular injury is uncertain; 
several triggers have been postulated including viral infection, toxin, oxidative 
stress, or immune-mediated through endothelial autoantibody activity [89, 98]. 
The initial vascular injury is associated with a functional change with impaired 
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release of expected vasodilators such as nitric oxide and prostacyclins (leading 
to RP, reflecting an exaggerated, normal physiological response that is 
reversible). In contrast to healthy population however, an irreversible structural 
change ensues that can be largely attributed to marked release of endothelin-1 
(ET-1). ET-1 levels are increased in the blood and in bronchoalveolar lavage 
fluids from patients with SSc [99, 100]. It is a potent vasoconstrictor that also 
promotes leukocyte adhesion to the endothelium as well as vascular smooth 
muscle cell proliferation and fibroblast activation with consequent deposition of 
extracellular matrix. The consequent hypertrophic and fibrotic remodelling of the 
blood vessels (the process summarised as a vascular fibrointimal proliferation) 
[101-103] leads to progressive reduction of the vessel lumen. This results in the 
loss of vascular elasticity and luminal space [3, 104]. This process underlies the 
vascular occlusion and resultant tissue hypoxia and damage observed.  
The vascular damage in turns promotes expression of endothelial cell adhesion 
ligands. Endothelial cell damage then appears to trigger a chain of events 
leading to an initial innate and then adaptive response which is followed by the 
extravasation of inflammatory cells, initially mainly of the monocytic lineage and 
then a subsequently lymphocyte predominant infiltrate. Endothelial cell damage 
and activatation leads to the release of several regulators and mediators 
affecting smooth muscle cells and fibroblasts with a fibrosis of vascular and 
interstitial spaces [3, 104, 105]. The release of vasoactive mediators also 
increases microvascular permeability; these events correlating with the 
cutaneous oedematous phase often clinically observed in the early stage of the 
disease [3, 25]. The oedematous phase can be observed in both the upper and 
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lower limb, and the early involvement of the feet in the oedematous phase 
suggests the early effects of the disease on the foot pathology[9]. 
Furthermore, the endothelial damage impairs endothelial-dependent 
vasodilation which affects the balanced regulation of vessel vasoconstriction 
[106]; with also the underproduction of vasodilators (Nitric Oxide) [107, 108] and 
an increase of endothelium-derived vasoconstrictors (ET-1) [109, 110]; 
continuing the cycle of vascular dysfunction.  
 
These pathological vascular processes have clear effects on the peripheries 
including the feet. The functional and structural changes described earlier leads 
to thrombotic events in the small arteries, which produce complete occlusion 
and can result in ischaemic insult with hypoxia, necrosis and loss of tissue [111] 
[3, 104]. This process presents clinically in the form of cyanotic lower limbs and 
painful ischemic ulcers or gangrenous lesions on the feet (most frequently seen 
in the toes), which in turn can lead to amputation and reduced function [9, 112, 
113].   
The process of fibrotic intimal hyperplasia is characteristic of the small vessel 
vasculopathy, and although it is not as common in larger vessels it has also 
been reported to occur in major vessels having severe consequences such as 
lower limb amputation [114]. 
Tissue hypoxia created by capillary and/or arteriolar occlusion or breakdown is 
thought to trigger physiological reactions, such as angiogenesis and 
vasculogenesis, which attempt to restore the homeostasis in the affected area. 
In SSc however, both of these processes are dysregulated leading to an 
inappropriate repair process in response to endothelial cell injury or insult. This 
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dysregulation of angiogenesis is associated with the clinical observation of 
reduced capillary density as a result of an inability to replace damaged vessels 
[3, 115, 116] [115, 117-120]. The inability to repair damaged vasculature or 
create new vessels has an effect on tissue viability and impairs healing, thereby 
increasing risk of tissue damage and chronic ulcerations for patients with SSc.  
The structural damage caused by the process described above has an effect on 
the vascular function. The vessel function is further impaired by an imbalance 
vasoconstriction and vasodilatation, with a preference for vasoconstriction. The 
vascular pathogenesis contributing to the abnormal vasoconstriction in SSc is 
mostly related to the Raynaud’s phenomenon (RP) pathology. In patients with 
SSc the RP pathogenesis cannot be clearly differentiated from the structural 
vascular pathogenesis caused by the disease as their pathogeneses are 
interrelated [93, 121]. 
This exaggerated vasoconstriction is also affected by the neural abnormalities 
in the central and peripheral pathways of the autonomic nervous system. In RP 
the central mechanisms are thought to contribute mostly to vasospasm, but is 
the peripheral neural pathways which are considered more important on the 
effect to the vessels vasoconstriction [93]. The autonomic and sensory afferent 
nerves release neurotransmitters that control the vascular tone of the digits, 
which are in turn key factors in the mechanism of neural control and are 
affected in patients with RP [93, 122].  For example the calcitonin gene-related 
peptide (CGRP)- immunoreactive nerve fibres that supply blood vessels with 
vasodilators are reduced in number [123], leading to impaired vasodilation.  At 
the same time the activation of the arteriolar smooth muscle α2- 
adrenoreceptors (noradrenaline receptors), which are considered very important 
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in the regulation of digital vascular tone, increases on exposure to cold, causing 
vasoconstriction [124-126].  
In addition to the functional and structural vascular changes and neural 
abnormalities described above, there are associated intravascular factors such 
as defective fibrinolysis, platelet activation, increased blood viscosity, white 
blood cells activation, reduced red blood cells deformability and oxidant stress 
which will also contribute to the impairment of basal blood flow, particularly in 
the microcirculation, leading to tissue damage [93].   
Macrovascular involvement 
Whilst microvascular pathology is a central mechanism underlying SSc, tissue 
viability and reduced healing is also thought to be compromised by the 
pathological alterations in the macrovasculature [3, 127]. 
Although not as clear as with other autoimmune diseases such as rheumatoid 
arthritis and systemic lupus erythematosus, macrovascular involvement in SSc 
has been reported to be more prevalent when compared to controls [13]. 
Reports demonstrate increased arterial stiffness, carotid intima thickening and 
reduced flow-mediated dilatation, all of which are associated with increased risk 
of development of atherosclerosis; suggesting an excess cardiovascular risk for 
patients with SSc [128, 129]. The pathological alterations of the 
macrovasculature also lead to an increased prevalence of Peripheral Arterial 
Disease (PAD) in the upper and lower limb of patients with SSc [14, 15].  
Macrovascular damage progresses in tandem with worsening of the 
microangiopathy [15] [14]. Some discrepancies exist in accounts reporting the 
correlation between macrovascular damage and disease duration; with both 
existence of correlation [14] and non-existence [15] reported. 
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Occlusive microvasculopathy, as described above, is considered the principal 
vasculopathy in SSc. However, the presence of frank vascular inflammation in 
the form of vasculitis, with inflammatory infiltrates damaging the vessels, has 
also been identified as contributor to the vasculopathy in some patients with 
SSc[130]. The presence of frank vasculitis in SSc is considered to be rare and 
when present it is a co-existent feature of the disease as opposed to being part 
of the central pathology [131-133](D'Angelo et al., 1969). 
Different types of vasculitis affecting the various sizes of vessel have been 
reported to coexist with the occlusive vasculopathy [130]. The most prevalent 
vasculopathy present in patients with SSc is the Anti-Neutrophil Cytoplasmic 
Antibody (ANCA) associated vasculitis. It is considered primarily a necrotising 
small-vessel vasculitis, although it can also affect the medium-sized vessels 
[130]. The presence of vasculitis in patients with SSc has been reported to lead 
to severe ischaemia and peripheral neuropathy in the limbs [134] [133].  
 Immune system and Inflammation in SSc 2.6.2
2.6.2.1 Autoantibodies & SSc 
Autoantibodies are used to aid diagnosis and to assess the disease prognosis 
[135]. Autoantibodies directed to nuclear autoantigens (ANA) are present in 
patients, with a prevalence varying from 80 to 98% [136] [89]. They are directed 
to various antigenic targets. Two types of ANA most frequently associated with 
SSc are anti-centromere (ACA) and anti-topoisomerase I antibodies (ATA). 
These are found in over 50% of patients with SSc [137-139]. In addition, 
another ANA, anti-RNA polymerase III antibody (ARA), has also been identified 
  35  
in patients with SSc [135, 136, 140]. These autoantibodies have a high 
specificity and can be present exclusively from each other, although in some 
patients ACA and ATA can be present simultaneously; a small percentage (3- 
11%) of patients are ANA negative [135, 136, 140].  
In addition to the three ANAs commonly seen in SSc, there are other 
autoantibodies often producing nucleolar staining by indirect 
immunofluorescence (IIF) on HEp-2 cells that have been identified as being 
involved in the disease and to have a clinical correlation [141], see Table 2.4. 
However, they are not SSc-specific and therefore even though they might be 
useful to determine disease progression and prognosis they are not specific 
enough to be used for diagnosis. These include antibodies to fibrillarin (AFA), 
PM/Scl complex (anti-PMScl), Th/To, and to the RNA polymerase (anti-RNAP) 
family. Other autoantibodies have been more recently reported such as anti-
U1RNP, anti-Ku, and anti-Platelet-Derived Growth Factor Receptor (PDGFR) 
[142] [141, 143]. 
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Table 2.4: Summary of autoantibodies described in Systemic Sclerosis and their clinical 
correlations. Taken from Walker and Fritzler ,Page 581 [141] 
 
Although it remains unclear whether autoantibodies have a pathogenic role or 
are merely epiphenomena, they can be useful in aiding diagnosis as well as risk 
assessment and clinical management. For example, the presence of ACA is 
present in approximately 70% of patients with lcSSc disease subset [144] and 
carries an increased risk of developing pulmonary arterial hypertension (PAH) 
The presence of ARA is associated with an increase of SRC and ATA 
antibodies and is indicative of worse prognosis (with an increased risk of 
developing pulmonary fibrosis and mortality [145]); both of these antibodies 
being present in 45% and 27%, respectively, of patients with the dcSSc disease 
subset [89, 146].  
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2.6.2.2 Activation of the immune system in SSc and evidence of early 
inflammation 
The damage to the endothelium seen within the vascular pathway is followed by 
infiltration of inflammatory cells enabling the development of both innate and 
adaptive immune responses [147]. Histopathological evidence in early stage 
disease lesional skin demonstrates mononuclear cell infiltrates (mainly T cell, 
macrophages mast cells and occasionally B cells) before any evidence of skin 
fibrosis [148]. The involvement of inflammation in the pathogenesis of the 
disease can be observed in histological abnormalities from tissue of the 
different systems affected by the disease. Inflammatory infiltrates have been 
reported to be present in the interstitium and perivascular in muscle tissue, 
lower dermis and subcutis [149], subcutaneous fat [25]central and peripheral 
nerved lesions [150] [151], synovial membrane [152, 153] and subsynovium 
[154]. 
 
Evidence of T-cell activation in affected skin lesions with monoclonal and 
oligoclonal Tcell expansion and associated increased serum T-cell derived 
cytokines suggests an important role for these immune cells in the pathobiology. 
In addition, B-cells are also activated in the long term [142, 147, 155] leading to 
a chronic hyper-reactivity [156], with a hypergammaglobulinaemia and the 
presence of several autoantibodies in the blood. Whilst the role for SSc-specific 
autoantibodies is not clear, more recent studies suggest the biological activities 
and potential pathogenic roles of autoantibodies in patients with SSc. 
Antibodies specific for fibroblasts, endothelial cells, and PDGF receptors might 
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directly cause fibroblast or endothelial cell activation and contribute to tissue 
damage [3]. 
The inflammatory and autoimmune element of the disease therefore drives peri-
vascular inflammation, release of (predominantly Th2) cytokines that promote 
fibrosis, and the production of stimulatory autoantibodies. Consequently, this 
increases fibrogenesis and contributes to progression of vasculopathy and 
tissue remodelling [3]. Nonetheless, it still unclear whether the involvement of 
the immune system in SSc is part of the disease initiation and/or disease 
maintenance [89]. 
 Fibrosis 2.6.3
The prototypic hallmark of SSc is fibrosis, caused by excessive accumulation of 
collagen (produced by fibroblasts) and other connective tissue components in 
affected organs. It is the persistent activation of the genes encoding various 
collagens in SSc fibroblasts that distinguishes normal wound healing associated 
(controlled) repair with the uncontrolled fibrosis observed in systemic sclerosis 
[2].   
A prolonged and exaggerated activation of fibroblasts, together with 
maintenance of the fibroblast-mediated effect, ultimately causes the 
pathophysiologic alterations, which lead to fibrosis in SSc.  
Fibroblasts are recruited and activated by multiple cytokines and growth factors 
to generate myofibroblasts. Activation of fibroblasts and myofibroblasts leads to 
excessive deposition of collagen and other extracellular matrix (ECM) proteins, 
eventually resulting in tissue fibrosis, tissue contraction and permanent scarring 
[89]. Several cellular determinants of fibrosis have been identified including 
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pericytes, fibrocytes, other monocyte-derived fibroblast progenitors although 
their exact role continues to be an area of investigation. The principal molecular 
determinant of fibrosis however seems to be TGF-beta, secreted by 
monocytes/macrophages, T cells, platelets and fibroblasts. An increasing 
number of cytokines (IL-4/13), growth factors (CTGF, PDGF) and chemokines 
(MCP-1 and -3) have also been recognised in contributing to the fibrotic process 
[157]. 
 
The figure below describes the pathogenic features of the disease and the 
interrelations, which lead to the symptoms observed clinically. 
 
 
Figure 2.1 Pathogenic Features of Systemic Sclerosis. Adapted from Geyer et al, page 93 
[3],  
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2.7 Clinical manifestations of systemic sclerosis and 
associated mechanisms – focus on foot pathology 
SSc manifestations are multi-systemic and wide-ranging. Cardio-pulmonary, 
renal and gastrointestinal involvement commands attention in light of the 
increased morbidity and mortality associated with major internal organ 
involvement. These will be briefly discussed below but with subsequent 
emphasis on the integumentary, vascular, nervous and musculoskeletal 
systems as these elements of the disease have a direct and most significant 
effect on the foot pathologies. 
 Indirect contributors to foot pathology  2.7.1
2.7.1.1 Cardio-pulmonary system 
Primary cardiac involvement of the heart can affect all structures of the heart. 
Clinically evident cardiac involvement is associated with a poor prognosis (1-6) 
and a large proportion of SSc-related fatalities are attributable to cardiac 
causes. Whilst fibrosis is a central feature of SSc, clinical and pathological 
evidence suggests microvascular dysfunction is a primary process and one of 
the earliest features of disease. Repeated ischaemia and reperfusion damage 
(with replacement fibrosis and contraction band necrosis) can involve the 
pericardium, myocardium, and cardiac conduction system [158]. The patchy 
fibrotic lesions in the myocardium are the hallmark of the Scleroderma Heart 
Involvement (SHI) [132]. As well as myocardial fibrosis, a myocarditis may also 
develop, may co-exit with a peripheral myositis and may lead to a secondary 
fibrosis following resolution of the inflammatory process. The consequence of 
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SHI is most frequently seen as a left ventricular diastolic dysfunction; a systolic 
dysfunction is not as common in SSc but may also be observed [159, 160]. The 
left ventricular dysfunction can be exacerbated by the presence of coronary or 
hypertensive heart disease and can lead to heart failure.  Arrhythmias often 
underlie cardiac mortality. The mechanisms are multi-factorial, including direct 
effects of microvascular injury, the subsequent development of fibrosis as well 
as autonomic dysfunction. Systemic hypertension associated with Scleroderma 
Renal Crises (SRC) can also strain the heart while concomitant PAH can cause 
cor pulmonale, pulmonary overload of the right heart and failure [159, 161].  
Lung involvement in SSc accounts for the major cause of mortality. The two 
principal pathologies are pulmonary arterial hypertension (PAH) and interstitial 
lung disease (ILD) or pulmonary fibrosis.   
Isolated PAH is more common in patients with lcSSc, associated with the ACA. 
It is histologically similar to idiopathic PAH.  It is characterised by pulmonary 
vasculopathy and possibly vasoconstriction (as a consequence of an imbalance 
between vasodilators and vasoconstrictors) leading to increased pulmonary 
vascular resistance. The vascular obstruction as detailed earlier is a result of  
possible vascular smooth muscle proliferation caused by remodelling of the 
pulmonary vessels and coagulation abnormalities with thrombosis [162].  
ILD is more common in patients with dcSSc and may be complicated by the 
development of (secondary) pulmonary hypertension [163].  
Impaired lung and heart function will have an effect on the efficacy of soft tissue 
oxygenation therefore contributing to the severe effect that the vasculopathy 
already has on soft-tissue oxygenation of the limbs. 
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2.7.1.2 Renal system 
The scleroderma renal crises present as abrupt cardiovascular renal disease 
and is characterised by severe hypertension and hyperreninemia, retinopathy, 
microangiopathic hemolytic anemia, cardiac failure, convulsions and rapidly 
progressive renal insufficiency. This renal crisis with malignant hypertension 
and fast progressing real failure was the leading cause of death in SSc before 
the introduction of angiotensin-converting enzymes (ACE) [162, 164, 165].   
The disease pathology affects the kidneys by creating focal lesions of intima 
sclerosis and hyperplasia of the interlobular arteries, and fibrinoid necrosis of 
the walls of afferent arterioles and glomerular loops. Originally these lesions are 
present in focal areas although when they become extensive the vascular 
damage leads to a widespread focal cortical infarction. This leads to systemic 
hypertension and, fatally, fibrinoid necrosis of the arterioles of the kidney and 
other viscera [166].  
Chronic renal disease has been correlated to peripheral arterial occlusive 
disease (PAOD) and foot ulcers in patients with renal problems and diabetes 
[167, 168]. The presence of PAOD has also been reported in patients with SSc 
[129] however in this population the direct link between SRC, PAOD and foot 
ulcerations has not been reported.  
Renal failure is also known to be associated with peripheral neuropathy. 
Literature indicates that 60% of patients with renal failure develop 
polyneuropathy mostly as a result of ischaemia. The polyneuropathy affects the 
motor, sensory, autonomic and cranial nerves; nerves which are also 
predominantly affected in SSc neuropathy [169-171].  In patients with renal 
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failure the clinical presentation is of a distal sensory loss more pronounced in 
the lower limb, and an electrophysiology indicating axonal loss and secondary 
demyelination [172]. Similar presentation has been identified in patients with 
SSc and polyneuropathy as they have distal sensory loss with axonal 
degeneration and reduction of density of the myelinated fibres [151, 173]. 
However, even though ischaemia is noted to be one of the possible causes for 
neuropathy in SSc, the pathological mechanisms for neuropathy in SSc are not 
fully understood and there is a lack of literature indicating that there is a 
relationship between renal involvement in SSc and neuropathy.  
2.7.1.3 Gastrointestinal system 
The gastro-intestinal complications are usually extensive involving many 
regions of the gut, from the oesophagus to the anus. The oesophagus has been 
identified as the most commonly affected, but the anorectum, small bowel, 
colon, and stomach can also have functional problems [174]. Gastrointestinal 
dysmotility appears to be as a result of smooth muscle atrophy and fibrosis.  
The oesophagus is affected by oesophageal motor dysfunction and gastro-
oesophageal reflux. The distal two-thirds of the oesophagus is damaged 
causing oesophageal dysmotility leading to reflux and nocturnal acid 
breakthrough. Chronic reflux can lead to oesophageal injury and intestinal 
metaplasia or Barrett oesophagus [175, 176], which in turn can lead to 
oesophageal adenocarcinoma [162].  
In addition gastric, intestinal, colonic and anorectal dysmotility can cause 
pseudo-obstruction, bacterial overgrowth, defecatory disorders and in severe 
cases, malnutrition [177] [174, 176].  These gastrointestinal problems not only 
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carry a health risk for the patients but also have a negative impact on their 
quality of life [178].     
The direct implication of the gastrointestinal involvement in the occurrence of 
DU has not been described, however together with lung fibrosis, PAH and SHI, 
are the organ manifestations more commonly present in patients with DU [179, 
180]. It is well established that a lack of nutrients as a result of gastrointestinal 
dysfunction, and a lack of oxygen as a result of cardiovascular problems has an 
affect on the tissue viability and impaired healing [181-183]. 
 
 
 Direct contributors to foot pathology  2.7.2
2.7.2.1 Integumentary system  
The skin structure is multi-layered with interlayered boundaries. It is attached to 
underlying tissue and all the surrounding skin, and crossed by its epidermal 
appendages and vascular and neural tissues. The skin has different functions, 
providing support to internal structures, protection from mechanical trauma, 
acting as a barrier between the outside environment and the physiologic 
conditions within the body, and helping to regulate the body’s internal 
environment with the inclusion of physiological and immunological roles [184] 
The layers of the skin differ slightly in structure and function depending on the 
location on the body, being the thinnest over the eyelids and the thickest on the 
plantar of the foot. Its physical properties can be affected by the amount and 
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duration of stress that the skin is under. In addition to these normal stresses, 
pathologies such as SSc will confer an additional impact [185].  
In SSc, the skin is one of the organs most affected by the disease. The whole 
cutaneous connective tissue system is affected by the excess of fibrous 
collagen deposition, resulting in the accumulation of type I collagen and/ or type 
III collagen in the early stages of disease. The collagen-rich extracellular matrix 
replaces epithelial structures and specialized smooth muscle, leaving the 
affected tissue contracted [91]. 
The areas of skin affected differ between the disease subsets, with the 
exemption of the SSc sine scleroderma subset in which the skin is not affected. 
In the lcSSc subset, the skin involvement is limited to the face and below the 
elbows and knees, while in the dcSSc subset the skin involvement is acral and 
truncal – with involvement above elbows and knees +/- truncal area 
automatically categorising as dcSSc [24]. The skin of the feet can be involved in 
both subsets affecting 26% of the patients [9]. Histologically, skin involvement in 
SSc is central to the diagnosis of the disease; more recently however with a 
better understanding of the disease pathogenesis and clinical presentations, 
and in particular, to ensure early diagnosis, the involvement of the skin is no 
longer regarded as mandatory for the diagnosis. Defining instead subtypes that 
enable earlier diagnosis as well as to recognise subsets such as SSc sine 
scleroderma where many of the pathological processes are evident without skin 
involvement; has evolved recently [186].   
The clinical features of skin involvement may vary, reflecting different phases, 
starting with an oedematous phase, followed by a firm induration, and 
fibrosis[89].  
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The oedematous phase is present in the early stages of the disease when the 
papillary and reticular dermis presents with oedema. This phase has been 
reported to relate with the initial onset of the disease when the endothelium is 
damaged initially [3] (as described in section 2.6.1).  
After the oedematous phases skin is left tight and thickened as a result of the 
accumulation of collagen and other extracellular matrix constituents[187]. The 
collagen extends from the dermis to the subcutis in a compacted, homogeneous, 
hyalinised pattern replacing the subcutaneous fat and surrounding atrophic 
sebaceous glands. In addition, the lower dermis and the subcutis accumulate 
inflammatory infiltrates such as lymphocytes, plasma cells and macrophages 
[149] around the collagen bundles and blood vessels. These infiltrates also 
perfuse the subcutaneous fat and entrap the sebaceous glands [25]. The blood 
vessels in the skin are also affected by these pathological process, presenting 
with intimal proliferation, lumen occlusion and fibrosis[89]. With disease 
progression the skin lesions becomes relatively avascular and after 12 to 18 
months there is usually little or no inflammation present, but the late lesions are 
left sclerotic. In these lesions the collagen appears closely packed and the 
sweat glands are atrophic or absent and the collagen may replace the fat cells 
in the subcutaneous tissue [25].  
These different pathological elements leave the tissue fibrosed, contracted and 
scarred [89], features that can be observed clinically on the involved skin 
(Figure 2.2).  
There is also evidence that the pathological changes occur in the apparently 
“uninvolved” skin [187]. A progressive worsening of the skin occurs within the 
first two to four years, after this period, the progress usually starts to plateau 
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and may even show a slow improvement [187], although the damaged is 
irreversible in the majority of the cases.   
 
 
Figure 2.2 Fibrosis affecting the feet causing capillary compression during 
mechanical movement i.e plantarflexion 
Once the pathological process is established, the integumentary system 
undergoes structural and biomechanical changes. The pathological process 
affecting the skin leads to the loss of the skin’s mechanical and biological 
properties, which compromises the skin integrity, affecting tissue viability, 
healing and its ability to adapt to the pressures: for example fibrosis of the 
hypodermis in SSc has an impact on the mechanical properties of the skin by 
reducing extensibility [188]. The loss of skin extensibility together with the 
fibrosis of periarticular soft-tissue structures also has an effect on the joint 
function, which in the feet can result in impaired foot function [9, 189] [10]. 
The structural and biomechanical changes of the skin, together with joint 
pathologies can lead to development of flexor contractures. Flexor contractures 
leave the fingers and the toes in a fixed-flexed position which has a major 
impact on the patients' activities of daily living (ADLs) causing in turn a 
detriment to their quality of life [190]. These deformities not only impair the 
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movement of the affected joints, but also contribute to the risk of the 
development of ulcerations over the flexed joints and areas of skin tension. 
When ulcers develop over these regions then the ulcer aetiology becomes 
multifactorial. The skin is exposed to constant stress as a result of the 
deformities, and losses its ability to adapt to pressure due to the presence of 
fibrosis; this, combined with the vasculopathy causes these deformed and 
fibrosed areas to be at risk of ulcerations [117, 191].  
Ulceration can also occur in areas without deformity. The aetiology of this type 
of ulceration are commonly associated with skin fibrosis, hyperkeratosis, 
vasculopathy and/or the presence of calcinosis [192]. Once ulcers are present 
they are extremely painful and have a very slow healing rate. The healing rate is 
negatively affected by the amount of skin pathology, and to the ulcers can 
become chronic, increasing the risk of amputation [192]. Lower limb amputation 
as a result of refractory ulcers has an incidence of 0.67% [193] in patients with 
SSc. Even in cases where healing is achieved, the ulcerated area experiences 
tissue loss and scar tissue formation. The latter together with the presence of 
vasculopathy, adds to the impairment of the biomechanical properties of the 
local skin leaving the area even more prone to re-ulceration. 
 
Scarring of the skin not only occurs as a result of ulceration of the skin 
pathology, but also due to the wider pathology which causes the skin to become 
thicker and tighter as the disease progresses. These changes in the skin further 
impair the biomechanical properties affecting the musculoskeletal function of 
the body structures affected such as hands and feet [89, 91, 194]; skin atrophy 
in the feet has been reported to affect half of patients with SSc [9].  
  49
These pathological changes also affect the subcutaneous tissue causing fat-
pad atrophy, and in the later stages of the disease fat cells in the subcutaneous 
tissue might be replaced by collagen [25, 91].  In the feet this substitution can 
lead to subcutaneous fat-pad atrophy on the plantar aspect of the foot, which 
may contribute to the increased plantar foot pressures reported in SSc [10]. 
High plantar pressures and prolonged duration of loading through discrete 
areas of the foot have been associated with pain during walking in other 
systemic musculoskeletal conditions such as rheumatoid arthritis [195, 196]. It 
is plausible therefore to hypothesise that high plantar foot pressures could 
subsequently cause pain and functional impairment. This hypothesis has been 
proved in other disease [195, 196] and in SSc this is supported by preliminary 
supporting evidence obtained from a pilot work undertaken while developing the 
program of work described in this study [10].  
The impact caused by skin fibrosis is not only at a physical level but it also has 
a psychological impact. The skin fibrosis occurs in visible parts of the body and 
as the tissue becomes fibrosed, contracted and scarred [89] the patient’s body 
appearance can change causing a psychological impact as the patient becomes 
concerned about their body image. This psychological impact has been 
described from low appearance self-esteem to depression, anxiety and social 
withdrawal [197] [198].  
2.7.2.2 Vascular system 
The vascular system experiences functional and morphological changes in the 
circulation as described in section 2.61.  
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One of the most common vascular problems present clinically in patients with 
SSc is Raynaud’s Phenomenon (RP); between 90 to 98% of the patients with 
SSc suffers from this condition [199, 200]. This is a reversible, transient, 
vasospastic condition triggered by cold or stress. The RP can be divided into 
primary RP (idiopathic), or secondary RP (secondary to other disease/condition) 
[93]. Primary RP is associated with normal capillary architecture in contrast to 
secondary RP, where clear abnormalities are recognised; the most well 
described changes have been observed in patients with SSc. Specific SSc nail 
fold capillaroscopy (NFC) patterns, early, active or late vasculopathy have been 
reported [201-203]. The SSc NFC pattern correlates with SSc disease duration 
severity and is predictive of future organ damage [204, 205] [206, 207] 
In SSc RP is usually the first presenting clinical feature supporting the concept 
that the vasculopathy is one of the earliest pathological processes. In 70% of 
patients with SSc the RP can be one of the first clinical symptoms observed 
[200], and it can manifest up to 20 years prior to the presence of other disease 
symptom [208].  
Approximately 10% of the general population suffers from RP and never 
develop any disease (primary RP) [121, 199], although the risk of developing 
SSc increases (hazard ratio 9.34) in those patients that have RP and ACA 
antibodies [209]. 
The clinical presentation of the RP can be divided into three phases. The initial 
phase is the ischaemic phase, where the digits present with a pallor 
discolouration (white) reflecting vasospasm; this phase is followed by the 
deoxygenation phase, where the digits are cyanotic (blue discoloration); and in 
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the final phases, the reperfusion phase, the digits present rubor (red) 
expressing the compensatory vasodilation[93, 121, 199] (Figure 2.3).  
 
 
Figure 2.3 Raynaud’s phenomenon deoxygenation phase.   
RP is thought to also affect organs and other body parts [93, 199]. Reversible 
vasospasm may possibly occur in the terminal arterial supply of the 
gastrointestinal tract, kidneys, lungs and heart and is a precursor of the 
structural lesions of the microcirculation [125, 210]. Clinically RP is more visible 
on the external parts of the body such as the ears, tongue, nipples, nose and 
digits [211, 212], the latter being the most commonly and severely affected. In 
the feet RP has been reported to affect 43%(n=100) of the patients and 
necrotising RP, characterised by digital ulcers, to affect 8%.  
 
Clinically, the severity of the SSc vasculopathy can be appreciated in fingers 
and toes by the presence of digital ulcers (DU) and necrosis which can lead to 
tissue loss, fingers and/or toes amputation and significant functional impairment 
[213]; heavily impacting on the patient’s quality of life [214].   
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The proportion of patients with SSc reported as affected by DU varies 
depending on the study, with a reported ranging from 26.2% [180] to 50% [215]. 
The fingers and to a lesser extent the toes are most commonly affected by 
ulcerations but ulcers can occur elsewhere. Alivernini et all [180], in a study of 
130 SSc participants reported that 3.8 % of the participants developed other 
ulcers not involving the digits. The prevalence of foot ulcers in a population of 
50 patients with SSc was described to be 26% [8].  
The multifactorial aetiology of ulceration reflects the complex interplay of the 
pathologies with significant impact on foot pathology. The structural and 
functional pathology affecting the microvasculature can lead to ulcers on the 
apices of the digits (Figure 2.4), over the extensor surfaces of the joints and on 
the lower leg [112, 192, 216]. Other factors contributing to the risk of developing 
ulceration in people with SSc include calcinosis, impaired skin biomechanics 
due to fibroses or hyperkeratosis [192], and neuropathy. The latter, though 
lacking a formal body of evidence, has been reported in a case study of 
neurotropic ulcerations present in a patient with peripheral sensory neuropathy 
and SSc [217]. 
 
Figure 2.4 Ischaemic ulcer on the apex of the hallux. 
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The presence of ulcers creates a significant risk to the person with SSc- the 
healing process is jeopardised by the vascular and skin pathology, thus the 
ulcer can become chronic and/or infected. Infection further contributes to poor 
healing and increases the risk of deeper infection, including osteomyelitis and/or 
necrosis, which in severe cases can lead to septicaemia and/or ultimately 
amputation [112, 113, 180, 218]. Amputation can also be caused by the 
presence of gangrene as a result of vasculopathy[191]. Autoamputation of 
fingers and toes as a result of necrosis is often seen in 14-29% [219], while 
lower limb amputation following foot ulceration has been reported in 6% of 
cases in a study of 50 patients with SSc [8]. 
In addition, the presence of macrovascular disease has a compounding adverse 
effect on the blood supply to the lower limb as it leads to the presence of PAD 
[14, 15]. In the lower limb the PAD can be symptomatic in the form of painful 
intermittent claudication with a prevalence of 21% [13]. The presence of 
intermittent claudication has also been found to coexist with ischaemic heart 
disease and cerebrovascular disease with a prevalence of 15.2% and 6.5% 
respectively[13]. The presence of PAD can further compromising tissue viability 
and ulcer healing [9, 15, 113].  
 
In contrast to the mainly neuropathic ulceration associated with conditions such 
as diabetes mellitus, ulcers in people with SSc are often extremely painful and 
can take many months to heal. The mean time to heal ranges from 25 to 281 
days, depending on the type of DU, but it has been reported to be as long as 
810 days in some cases[192]. The presence of pain and functional impairment 
  54
as a result of ulceration or amputation has a highly negative impact on the 
patient’s quality of life [218, 220].  
The development and the healing of the ulcers in patients with SSc can be 
aggravated by the presence of vasculitis with the already existent occlusive 
vasculopathy. Vasculitis in SSc has been reported to lead to severe ischaemia, 
ulcerations, necrosis and amputations; the latter more commonly seen when the 
vessels of the digits are involved [133].  
In addition, in some cases vasculitis has also been identified as a possible 
factor that plays a role in the pathogenesis of the neurological lesions [221, 222]. 
It has been postulated that vasculitis affects the arteriae nervorum leading to 
necrosis of the nerve bundles. The damaged nerves present with diffuse 
degeneration below the lesion area [223] and depending on the nerve affected, 
this can cause peripheral neuropathy [151]. Clinical and pathological findings 
show asymmetric neuropathy or multiple mononeuropathies[151]. These 
neuropathic presentations are characteristic of nerve involvement in necrotizing 
vasculitis presentations [224].  
2.7.2.3 Neurological system 
In the past the involvement of the nervous system in SSc has been considered 
a rare event [225]. However, over the years increasing evidence of its 
occasional involvement in the disease has emerged. Central nervous system 
(CNS) involvement is rare, with the peripheral nervous system (PNS) mainly 
affected. The focus in this literature review will be on PNS pathology and also 
the psychiatric and psychological changes in SSc.  
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The pathophysiological mechanisms involved in the cause of neuropathy are 
not fully defined. However the three central components, vasculopathy, 
inflammation and fibrosis underlining SSc pathogenesis also appear to underlie 
the bases for the pathogenesis of the nerve fibre degeneration. The 
vasculopathic involvement comprises different pathophysiological mechanisms: 
mucoid degeneration of the peripheral nerves, obliterative microangiopathy and, 
occasionally, a co-existent vasculitis. Mucoid degeneration of the peripheral 
nerves starts with the pathological process in which the vessel’s endothelium is 
injured. Injury to the endothelium of the vasa nervorum causes thickening of the 
basal laminal and the adventitial oedema causing microangiopathy. This 
microangiopathy leads to an increase in the vessel’s permeability of plasma 
with subsequent deposition of mucoid material in the nerves causing 
neuropathy [173, 226, 227]. In addition, obliterative microangiopathy causes 
chronic lower grade ischaemia, which has been suggested to be a plausible 
cause of subclinical nerve dysfunction; as its presence will be expected to result 
in axonal loss [21]. The presence of vasculitis involving the vasa nervorum has 
also been identified to cause mononeuritis multiplex in patients with SSc, 
although vasculitis as a cause of neuropathy in SSc has been reported to be 
rare [131, 221].  
The role of inflammation in the development of neuropathy in SSc is not clear, 
with conflicting reports and opinions. Some studies report that there is no 
inflammatory element involved in the process of neuropathy in SSc [21, 114, 
173, 228] while others report evidence of inflammation involvement [151] [150, 
169] . Evidence seems to indicate that the contribution of inflammation to the 
neuropathy might be partially through its involvement in the disease 
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vasculopathy, as the biopsies specimens in central and peripheral nerve lesions 
show presence of a chronic perivascular lymphocytic inflammation, 
inflammatory cells within the vessels wall and microglial activation [150] [151]. 
Both mononeuritis multiplex and sensorimotor neuropathy have been identified 
in SSc as neuropathies that might be caused by involvement of an inflammatory 
element. Inflammation also plays a role in trigeminal neuropathy and 
compression neuropathies, as both of these appear to be related to the SSc 
oedematous phase [150, 151]. However, the oedematous phase is not the only 
cause of compression neuropathies in SSc, with deposition of collagen in the 
carpal tunnel, calcium deposits and hypertrophied synovial sheaths and/or 
active arthritis have also been described as underlying contributors [21, 229]. 
Interestingly, in SSc compression neuropathies that present with carpal and 
cubital tunnel syndrome-like symptoms, it has been hypothesised that the cause 
could be a result of vascular or autoimmune-dependent neuropathy rather than 
compression as such; as imaging technology has failed to identify the diffuse or 
focal nerve enlargements commonly seen in carpal and cubital tunnel syndrome 
[229].    
Finally, fibrosis affects the connective tissue that surrounds the nerve and nerve 
fibres, structures known as the epineurium and perineurium. Once the 
epineurium and perineurium are fibrosed it causes strangulation of the nerves 
due to incarceration in collagen, causing neuropathy [173, 226, 228].  
The histopathological characteristics of damaged nerves have been evaluated 
in biopsy specimens of nerve lesions and of skin from the fingers, lower thigh 
and leg. The biopsies from the nerve lesions demonstrated a significant 
reduction in the density of the myelinated fibres [151, 173]; while the biopsies 
  57
from the skin showed a significant loss of myelinated and unmyelinated sensory 
autonomic nerve fibres (A-delta fibres and C-Fibres), associated with a 
reduction in the vascular bed [230]. In the latter study the authors suggested the 
role of ischaemia as the cause of the reduction of the number of nerve fibres, 
although they also suggested that immune-mediated or metabolic causes might 
also be relevant [230]. It should be noted that all these mechanism proposed in 
the development of neuropathy have been derived from case studies and/or 
from studies with small numbers of participants (n=2-12), and confounding 
factors in the development of neuropathy such as vitamin deficit, concomitant 
drugs and diseases [231], were not adjusted for. Therefore, further evidence 
supporting these proposed pathological mechanisms is needed before any firm 
conclusions can be drawn. 
In systemic sclerosis neurological complications have been reported to occur 
between 1% - 40% [150]. 
2.7.2.3.1 Peripheral Nervous System 
Within the PNS, both the autonomic nervous system (ANS) and the somatic 
nervous system (SoNS) are affected by the pathogenesis of the disease [150, 
231, 232]. The SoNS is commonly referred to in the literature as peripheral 
nervous system, therefore for the purpose of this literature review and to avoid 
confusion, the autonomic nervous system will be referred as ANS and the 
somatic nervous system as peripheral nervous system (PNS).  
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i. Autonomic Nervous System  
In SSc ANS dysfunction is characterised by a parasympathetic under-activity 
and sympathetic overdrive [150, 232]. The most widely reported clinical 
symptoms involving the ANS are increased and diminished heart rate, and 
blood pressure variability. The ANS dysfunction also contributes to the wide-
ranging clinical sequelae including abnormal sympathetic skin responses, 
Raynaud’s phenomenon, gastrointestinal motor dysfunction, oesophageal 
dysmotility, impotence, cardiac abnormalities and hypohidrosis [233] [150, 230, 
234, 235].  
ii. Peripheral nervous system 
Peripheral nervous system abnormalities have been reported to be present in 
up to 50% (but only n=14 in the study) of patients with SSc[233]. However, the 
prevalence of PNS abnormalities varies depending on the study - 34% (n= 32) 
in one study [169]; and as low as 5.6% (n=125) in another [236]. In SSc, 
peripheral neuropathy has been documented as developing between 0-25 
(mean 12.4) years from disease onset [151]. The clinical presentation of the 
peripheral neuropathy has been reported to be generally distal with a non-
length dependent pattern to the sensory symptoms, more sensory than motor, 
and mostly multiple mononeuropathy or asymmetric in involvement (suggesting 
multifocal pathology) [151, 233]. It has also been suggested to be independent 
of skin fibrosis, as abnormal sensory thresholds have been observed in 
unaffected skin [233], and not to correlate with disease duration [171, 233]. 
Peripheral neuropathy has however also been reported to be present with early 
neurological signs of sensory-motor mononeuropathy that later extends to the 
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rest of the body with a typical distal polyneuropathy and a greater involvement 
of the lower limbs [173].  The variation in the clinical presentation of the 
neuropathies may be as a result of the diversity of the design and methodology 
of the studies describing these features.  
A systematic review investigating at neurological involvement in SSc [150] 
reviewed 61 studies/case reports (n= 1628). The most commonly reported PNS 
involvement was trigeminal neuropathies (16.52 %), followed by peripheral 
sensorimotor polyneuropathies (14.25%) and entrapment neuropathies (9.25%). 
The authors also described asymptomatic peripheral neuropathy in some cases 
(17.14%). Subclinical peripheral neuropathy has been described in the 
presence of mononeuropathy and polyneuropathy with a pattern of a distal 
peripheral neuropathy [169-171]. The sensory deficit has been shown to be 
subclinical in the majority of the patients and to be worse in the feet than in the 
hands [237]. When sensory symptoms are present they can vary from 
lancinating pains, burning, allodynia, paraesthesia, pruritis, through to loss of 
sensation, and the symptoms have been reported to be more prominent in the 
extremities [233].  
Amongst neuromuscular syndromes, myopathies are also frequently present, 
affecting 51% (n=229) of patients in one study. In studies that included 
electroneuromyography, myopathy was the prevailing finding (56.55%) followed 
by sensory abnormalities (14.83%) and motor abnormalities (13.45) [150]. The 
myopathies tend to affect mostly proximal muscles[150], although myopathy 
has also been reported in distal muscles such as the anterior tibial muscle [169]. 
Muscle biopsies taken from the anterior tibial muscle revealed neurogenic 
structural alteration such as group atrophy and fibre type grouping, leading to 
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hypertrophy of small and large fibre types in the anterior tibial muscle [169]. In 
addition electromyography revealed signs of chronic denervation in distal leg 
muscles, both findings indicating lower limb involvement in the myopathy. Any 
neurogenic and structural abnormalities in the muscle fibres can have a 
negative effect on the biomechanical function of the body part involved; when 
the muscles of the lower limb are involved it can have an impact on the patients’ 
ambulation and consequently on their daily activities.    
Peripheral neuropathy in SSc is mostly reported as affecting in cranial, truncal 
and upper extremity nerves. Foot involvement in the peripheral neuropathy has 
been reported in different studies [173, 233] but has been investigated only in 
one study [237]. The paucity of studies assessing peripheral neuropathic 
involvement of the feet may be as a result of an incomplete investigation of the 
patients or because as mentioned earlier, the peripheral neuropathy in the feet 
is mostly asymptomatic and is therefore unnoticed [21]. 
Schady et al [21] (n=29) reported the presence of subclinical peripheral nerve 
dysfunction in the feet and hands, being worse in the feet. The foot involvement 
was reported to be predominantly of a sensory defect, affecting more touch [171, 
238] than small fibre modalities such as pain and temperature [237]. Tactile 
sensitivity in the feet was impaired in 50% of the patients but with mainly a 
subclinical presentation [237]. This study does not only highlights the elevated 
number of patients with SSc that have peripheral neuropathy, but more 
importantly it revealed the fact that the peripheral neuropathy does not 
necessarily present with clinical symptoms. This is potentially problematic if 
patients are unaware of a loss of sensitivity to harmful stimuli, which may put 
them at risk of injury.  
  61
2.7.2.3.2  Psychiatric syndromes and psychological symptoms 
Different psychiatric syndromes and psychological symptoms have been 
reported in SSc. A systematic review carried out on the neurological 
involvement in SSc, which included 90 studies/case reports (n=6028), identified 
that psychiatric manifestations were present in 2712 patients.  Amongst the 
psychiatric pathologies dysthymia, suicidal ideation, psychoticism and paranoid 
ideation were reported, but their presence was considered to be very rare, with 
the exception of the dysthymia[239]. Amongst the psychological symptoms 
depression and anxiety were the most predominant, with a prevalence of 30-
40% for depression and 25-64% for anxiety [150]. Analysis of two SSc 
databases, encompassing 2780 subjects, implied a relative risk of 1.5 for both 
depression and anxiety [150]. The presence of these clinical features has been 
identified as having a negative impact on the patient’s life, as impaired 
psychological function has been associated with reduced quality of life [240].    
2.7.2.4 Musculoskeletal system  
Musculoskeletal involvement in SSc is very common and some 90% of patients 
with SSc have musculoskeletal complaints. Complaints range from intermittent 
small and large joint arthralgia to chronic polyarthritis [241, 242], and muscle 
involvement. Joint symptoms have been reported to be present in 66% of 
patients with SSc [243], and muscular symptoms in half of the patients; the 
latter with a predominance of muscle weakness and myalgia [169]. 
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2.7.2.4.1 Intra-articular and periarticular structural pathologies 
The musculoskeletal system can be involved in the disease at an early stage. 
Up to 20% of patients with SSc report joint symptoms as early as one year or 
more prior to diagnosis and a third within the same year of diagnosis [243]. 
Articular manifestations in early SSc can range from minimal arthralgia to a 
polyarthritis of a chronic or intermittent nature. These articular manifestations 
may present as a stiff, painful, symmetrical arthropathy, which is clinically 
indistinguishable from that of Rheumatoid Arthritis (RA) [241, 243]. The 
arthropathy and the joint symptoms are not exclusive to early disease, they also 
can present during the course of the disease; in halve of the patients with SSc 
joint symptoms presented after diagnosis [243] [244].  
The mechanisms involved in the articular changes have not been fully identified 
but different factors have been proposed. For example, the articular space 
narrowing has been reported to occur as a result of chondral atrophy secondary 
to chronic deformity and disuse rather than being related to joint inflammation 
as seen in RA [241]. Equally, there are other contradictory data supporting the 
role of inflammation in the SSc arthropathy. The synovial membrane has been 
shown to have superficial fibrin deposition, focal microvascular obliteration and 
chronic inflammatory cell infiltration [152, 245]. Inflammatory infiltrates have 
also been found in the subsynovium and perivascular tissues [154], and the 
amount of inflammatory infiltrates has been reported to correlate with the 
presence of rheumatoid factor (RF) [246]. The association of RF and arthritis in 
patients with SSc is not fully supported by all the studies. Schmeiser et all [247], 
Blocka et all [241]  and La Montagna [9] found no correlation between RF 
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antibodies and arthritis in their studies, therefore no conclusions can be draw 
supporting  the role of RF and arthropathy.  
Clinically, joint inflammation has been reported in 91% of the patients [248]. 
However, this high figure from this one small study is likely to be due to 
selection bias, as data were obtained from patients with a current or past history 
of articular symptoms, and seven patients had overlap disease with RA. In a 
study with a larger sample size (n=7286) much lower values for the prevalence 
of synovitis have been reported with synovitis affecting only 1 in 8 patients with 
SSc [244]. 
An interesting finding by Auvouac et al [244] revealed the presence of synovitis 
is associated with increased levels of acute-phase reactants, markers of severe 
vascular disease and muscle weakness. The presence of raised acute-phase 
reactants indicates systemic inflammation and has a strong association with 
synovitis. This finding is supported by Schumacher et al [152] who found, in 
synovial biopsies of patients with SSc, the presence of inflammatory cell 
infiltration, associated with focal microvascular obliteration and fibrin deposition.  
Even though the arthropathy present in SSc has similarities with the arthropathy 
seen in RA on a clinical and laboratory level [249], synovial histopathological 
analysis has shown less proliferation of lining cells than that seen in RA 
arthropathy. The usual proliferation of synovial hyperplasia and pannus 
formation typical of RA does not occur in the SSc arthropathy. Although, in SSc 
this can be confounded by the presence of severe destructive joint disease 
[152]. Instead what can be observed in synovial lining cells is the presence of 
fibrin accumulation, with atrophy of the synovial cells leading to a fibrosis, 
similar to that present in the dermis, and obliterative microvascular angiopathy, 
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similar to that reported in other tissues in SSc [152, 154, 241, 250]. Such 
synovial joint involvement can have an effect on the patient’s quality of life, as 
synovial fibrosis has been reported to associate with joint pain and tenderness, 
and/or pain during joint motion [154].  
 
Avascular necrosis related to vasculitis and neuropathic arthropathy both also 
have been reported as causes for articular changes in SSc [251, 252]. These 
causes have been referred to as plausible mechanisms for arthropathy[241, 
253], although as previously discuss vasculitis is not a common feature of SSc 
and there is not strong evidence in the literature supporting these theories, as 
these mechanisms only have been reported in case studies.   
Articular and periarticular pathology in SSc affects the hands more than the feet 
[9, 241, 254], but the prevalence in the feet cannot be considered low. In a 
study of 76 patients with SSc the most common articular arthropathy in the feet 
was joint-space narrowing with a prevalence of 35% of the distal IP joints and 
13% of the proximal IP joints, followed by subchondral sclerosis 21%, 
subluxation/luxation of phalanges 13%, juxtaarticular demineralisation 7%, and 
erosion 3% [189]. The prevalence of erosions was reported to be higher in two 
different studies with smaller sample size 12% (n=46, n=33) [241, 254]). 
Erosions were reported to affect the MTP joints and talo-navicular joints, while 
joint-space narrowing affected the distal and proximal IP, MTP and ankle joints 
[9, 254]. The prevalence of the juxtaarticular demineralisation also has been 
reported higher, 42%, but in this study the location in the feet was not specified 
[243].  
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The presence of erosions in the MTP joints[254] [189] could be expected to be 
associated with the increase of plantar foot pressures identified in patients with 
SSc [10], as erosions have been previously reported to be associated to 
abnormal plantar pressures in patients with RA [196, 255]. 
 
In 13% of the patients with SSc arthropathy is considered to be a cause of 
severe destruction of multiple joints of the hands and feet [256]. In the feet the 
arthropathy presents with a significant degenerative pattern in 18% of the 
patients, a fibrotic pattern in 8% and inflammatory pattern in 7%. This 
significantly higher prevalence of the degenerative pattern in the arthropathy of 
the feet might be as a result of the weight-bearing nature of the feet, which 
could become a risk factor for the development of arthropathy[189].  
Perhaps this degenerative nature of the disease reflects the nature of other 
arthropathies that also have been reported in patients with SSc, such as erosive 
osteoarthritis (OA), which affects 18% of SSc patients and primary OA affecting 
13%; both of which impair flexion of the joint affected[153, 243]. In this study the 
joints reported to be affected by the two types of OA were the distal 
interphalangeal joints (IP) [243] [153]. Erosive arthritides in the feet have been 
reported in between 7% [256] and 12% [254], [241]) of the patients with SSc, 
and are associated with the presence of arthritis in the hands.Thus patients with 
SSc that present clinicaly with arthitis in their hands it is likely that their feet will 
also be affected. Erosions associated with SSc have been described as small 
and discrete by Allali et al [254], and bilateraly asymmetrical and sometimes 
located dorsally by Bassett et al [256]. Allali et al [254] reported that the erosive 
changes in the joints show a radiological picture compatible with erosive OA. 
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Another clinical feature occurring as a result of articular and periarticular 
involvement in SSc is flexion contractures. Flexion contractures can have a 
multifactorial aetiology. As previously described skin fibrosis can contribute to 
the development of the flexion contractures adding to the loss of dexterity of the 
digits. Flexion contractures are considered one of the most predominant clinical 
features in SSc [256], with a prevalence as high as 90% [241] and can affect 
fingers, toes, wrists and less frequently shoulders, elbows, and knees [252] 
[241] [243] [257]. As noted previously, when data from studies with larger 
sample sizes were analysed, the presence of flexion contractures did not 
appeared to be as prevalent as other studies previously reported. Avouac et 
al[244] obtained data from the EUSTAR registry, involving 7286 participants, 
and found a prevalence of 31% for flexion contractures, which was considerably 
less than what was previously reported in studies with smaller sample size i.e. 
90% (n=65) prevalence [241]. In Avouac et al 's study the location of the flexion 
contractures was not reported, thus data regarding its prevalence in the toes 
were missing. Only two studies have reported the prevalence of flexion 
contractures of the toes, showing a prevalence of 5% [189] and 15% [9]. 
Another study focusing on peripheral joints [241], assessed the feet but did not 
report data on flexion contractures because they  reported found difficult to 
interpret these changes in the feet, possibly because of the resemblance to 
other foot pathologies such as claw toes and hammer toes.  
Flexion contractures occur as a result of joint destruction turning into ankylosis 
and fibrotic changes in the skin and periarticular structures (figure 2.5); they can 
lead to measure functional disability [244],[189, 258]. The structural changes 
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caused by the flexion contractures in the feet and its impact in foot function can 
be observed on the impaired foot mechanics during gait. 
 
 
Figure 2.5  Flexion contractures of the toes and bilateral acro-osteolysis of the 1
st
 toes. 
 
In patients with flexion contractures the disability can be made worse by the 
presence of a more severe peripheral vascular and muscular disease, with 
elevated acute-phase reactant, and the presence of higher fibrotic propensity 
including pulmonary fibrosis, as all of these features are associated with flexion 
contractures [244] [189].  
In SSc, periarticular structures in particular may be affected, causing tendon 
friction rubs. This feature is present in 11% of the patients with SSc and in some 
patients tendon friction rubs present together with flexion contractures and 
synovitis [244]. The presence of these three features was associated, 
independently of each other, with systemic inflammation and with severe 
vascular, muscular, renal, and interstitial lung involvement [244], indicating that 
those patients with musculoskeletal involvement might be a discrete subset 
  68
presenting with more aggressive disease, and consequently the disease having 
a greater impact on their quality of life.   
The relationships between articular involvement and the different SSc disease 
subsets remains an area of controversy however, and some authors report that 
there is not a relationship with articular involvement and clinical or serological 
SSc subsets[9], while others report articular manifestations to be more 
prevalent in the dcSSc subset and to be associated with disease activity and 
elevated acute–phase reactants [244].  
 
Any arthropathy/arthralgia is worsened by the involvement of the periarticular 
soft–tissue. Tendons are key periarticular structures affected in SSc: in flexion 
contractures, the tendon develops an extensive fibrosis; in tendon friction rubs, 
the tendon presents with fibrinous deposits on the surface of the tendon sheath; 
and in tenosynovitis the tendon sheath becomes inflamed [259] [9, 253]. All 
three clinical features have been reported to affect the feet, however the 
prevalence has only been reported on tendon contractures 6% and tendon 
friction rubs 10% [9]. In the feet the tendons affected by tendon contractures 
and tenosynovitis are the flexor toe tendons, while the extensor toe tendons and 
the anterior and posterior tibial muscle tendons have been reported to be 
affected by tendonitis [259] [9, 253]. Tendon friction rubs affect the anterior and 
posterior tibial muscle tendons, toe flexors and extensor tendons, the Achilles’ 
tendon, and the tendons on the dorsum of the foot; from the latter the specific 
tendons involved were not specified [9, 248, 253]. These three clinical features 
contribute to the functional impairment of the joints and to the arthralgia; 
particularly to the latter as in the feet arthralgia is present in 36% of the patients 
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and is significantly more frequent than in the hands [9], possibly as a result of 
the weight-bearing nature of the feet, as they are exposed to greater forces and 
repetitive strains.  
 
Clinically, the joints affected present with tenderness, pain on palpation and/or 
effusion, without synovial thickening [241]. Stiffness and arthralgia have been 
reported as two of the most common clinical symptom in patients with SSc; and 
more than two-thirds of patients have morning stiffness of 30 minutes or greater, 
and 32% consider their joint pain of a moderate significance, while 20% of a 
great significance [243, 253].  
When inflammation is present the pattern of the joint inflammation is commonly 
symmetrical and polyarticular, with 61% of the patients presenting within these 
characteristics, 22% of the patients present with oligoarticular involvement and 
17% with a monoarticular involvement [243]. The distribution of the clinically 
inflamed joints suggests a higher prevalence in the metacarpophalangeal 52%, 
followed by the wrist and knee 43%, distal IP 39%, proximal interphalangeal (IP) 
joints 34%, shoulder 30%, MTP 26%, ankle 8% and elbow joints 4%[243].  
Conversely, in a study carried out by Misra et al [248], the prevalence of ankle 
joint inflammation was 61%, which suggests that the ankle joint may be the 
most affected joint by inflammation, reiterating the foot involvement in the 
disease and highlighting the need for exploring further foot pathologies in SSc. 
The presence of inflammation in the MTP and ankle joint has an impact on the 
joint’s function and consequently on patient ambulation, who probably will adopt 
an antalgic gait to alleviate the pain pressures during walking [10], as also seen 
in disease such as RA [260].  
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In SSc, restricted range of movement (ROM) has been reported in several joints, 
43% patients have restricted ROM of the wrist, 13% of the elbow, 26% of the 
shoulder, 7% of the ankle, 4% of the knee and hip [243]; the impaired ROM of 
the ankle, knee and hip can also have an effect in the patient’s gait.   
Both restricted ROM and inflammation can have a direct or indirect impact to 
the refined function of the joint and in some cases the impairment can cause 
significant disability. In patients with SSc, disuse of the joints has lead to loss of 
muscle-mass [257], particularly the disuse of the knees, ankle, elbows, wrists, 
metacarpophalangeal(MCP) and proximal IP [257] contributing further to 
function impairment [261]..  
Joint involvement in SSc has not only been identified clinically but patients with 
SSc also perceive clinical symptoms, such as stiff joints together with pain and 
fatigue, as the symptoms most frequently associated to their disease [262]. In 
addition, joint involvement has been reported to contribute to the patients’ 
physical disability.   
2.7.2.4.2 Muscle pathology  
Muscle pathology (a myositis or a myopathy) may occur in between 39% [257] 
to 96% [263] of patients. It tends to affect mostly the proximal musculature and 
the muscles of the forearms and hands, and presents as myopathy or, less 
frequently, myositis [263] [253]. However, the frequency of myopathy varies 
depending on its definition [253].  The appearance of muscle disease in SSc 
may be insidious and is frequently characterised by muscle weakness and 
myalgia [169].  
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In general the most common symptoms reported, by over 60% of the patients 
with muscle involvement, are fatigability and weakness [169, 257]. These two 
symptoms are not specific to the muscle involved however and the symptoms 
related to muscle are generalised muscle aching, reported in 11% of the 
patients, muscle tenderness in 4% of the patients and cramps in 2% [257]. 
Although in some cases severe muscle atrophy and weakness are present 
without any symptoms [257], which could be an indication of neuropathy or 
disuse.  
The most frequent histological abnormalities reported to affect the muscles are 
interstitial and perivascular fibrosis affecting 25% of the cases, followed by 
interstitial and perivascular inflammatory infiltrates affecting 15%, and myofibril 
atrophy, necrosis and degeneration, all three together, affecting one fifth of all 
SSc patients [257]. The abnormalities that appear to be specific to muscle fibres 
pathology in SSc are atrophy, necrosis, and eosinophilic floccular degeneration, 
while the interstitial tissue shows irregularly distributed islands of peri- and 
epimysial fibrosis and increased interstitial fat [257] [263]. In the interstitium 
signs of inflammatory cellular infiltrates, such as lymphocytes and less 
frequently neutrophilic leucocytes have been found [257] which indicates a 
pathway of inflammation in SSc-related muscle disease.  
In the case of active inflammation in the muscle, the inflammatory myositis is 
accompanied by muscle weakness, very high muscle enzyme concentrations 
and abnormal electromyography (EMG) results, and is characterised by its rapid 
progression and its disabling impact. The proportion of SSc patients affected by 
inflammatory myositis is low (17%) when compared to the 80% who are 
affected by a milder slow progressive myopathy. This slow progressive 
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myopathy presents with muscle weakness, interstitial fibrosis and variation in 
diameter of muscle fibres, and mild elevation of muscle enzymes, but does not 
have active inflammation, or abnormal EMG results [263].  
In SSc, muscle weakness and loss of muscle mass correlates with the presence 
of elevated aldolase levels and creatinuria, which in turn indicate the severity of 
muscle cell degeneration [257]. Muscle fibre degeneration and inflammatory 
cellular infiltrates are present in other causes of myopathy and are not exclusive 
to the SSc pathology, but the presence of interstitial fibrosis in muscle fibres is 
found more commonly in SSc than in other causes of myopathy (Medsger et al., 
1968), reflecting the nature of the pathogenesis of the disease.  
Other pathological processes can contribute to the morphology alterations of 
the muscle fibre such as denervation or neurogenic atrophy from myopathy [169, 
257]. It should be considered sometimes the cause for myopathy might not be 
local-driven disease pathogenesis affecting muscle tissue and that there may 
be secondary factors at play including disuse such as that seen as a result of 
arthropathy or other secondary SSc features that lead to general debilitation; 
such as poor nutrition (due to malabsorption), renal failure or congestive heart 
failure due to myocardial and pulmonary fibrosis[259] [257, 264]. 
The presence of co-morbidities leading to general debilitation is common in 
patients that have myopathy, because skeletal myopathy frequently affects 
patients with dcSSc, who already have organ involvement secondary to SSc. It 
has been shown that those patients with pulmonary fibrosis already have a 
higher risk of developing skeletal myopathy and that skeletal myopathy is 
associated with cardiac disease [265] [266]. Thus the combination of the 
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myopathy and organ involvement might be expected to have a greater impact 
on patients’ function.  
2.7.2.4.3 Other musculoskeletal abnormalities  
In addition to the muscular, intra-articular and periarticular pathologies, other 
abnormalities affecting the musculoskeletal system have been identified in the 
feet of SSc patients. Diffuse osteopenia has been reported to affect 44% of the 
patients [189], valgus deformity 26% [189], calcaneal spurs 22% [189], 
subcutaneous calcinosis 30% [241], reabsorption of distal phalanges 12% [189], 
tarsal degenerative changes 4% [189],ankylosis 3% [241], pencil-in-cup 
deformity 1% [189] and periostitis. The latter prevalence was reported together 
with the hands as 12% [241]. 
The extent of calcinosis and reabsorption of distal phalanges in the feet has 
been reported to be lower in different studies, ranging from 6% to 18% [8, 9, 
241, 254]. The presence of soft-tissue atrophy over the distal phalanges seems 
to be associated with bone reabsorption of the turfs of the distal phalanges, 
although the underlying bone loss is always greater than the soft-tissue change 
[256].  
When including other areas of the body such as fingers, forearms, elbows and 
knees, the prevalence of soft-tissue calcifications has been reported to be 
present in 50% of the patients with SSc [267, 268]. Soft-tissue calcifications can 
be disabling for the patient, as they develop usually near bony prominences and 
in periarticular tissues, particularly at sites of chronic irritation or microtrauma. 
Occasionally, calcium gets deposited within the joint causing severe joint 
destruction [256]. Although sometimes the presence of soft-tissue calcification 
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might not necessarily be troublesome to some patients, in others it can cause 
local inflammation, pain and /or functional impairment, particularly when the 
areas affected involve periarticular areas and/or joints, as it interferes with joint 
range of movement and consequently daily life activities. Superficial calcinosis 
can ulcerate the skin and lead to chronic ulcerations and/or secondary infection 
[259, 269, 270] (Figure 2.6). 
 
 
Figure 2.6 Chronic ulceration above the medial malleolus caused by 
calcium deposits affecting patient’s walking.    
 
The effect of functional impairment of the lower limb as a result of the 
musculoskeletal involvement can be observed in the patient’s gait, as walking 
speed and stride length is reduced in patients with SSc. Both of these 
parameters are indicative of functional disability and patients with SSc have 
been found to correlate with the S-HAQ [10]. Overall the prognosis of the 
disease depends on the degree of visceral involvement but the musculoskeletal 
involvement is considered a major cause of morbidity and disability [271] and 
foot pathology contribute to the disability [10]. 
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As a consequence of these interrelated pathological processes, the presence of 
foot impairment and reduced foot-health status has been reported in patients 
with SSc, with a systematic relationship between the impact of the disease and 
the level of foot-related impairment, measured by both patient- reported 
measures and objective measures of function [10, 220].  
2.8 Impact of foot pathology in systemic sclerosis   
In SSc the multi-system nature of the disease has wide-ranging impact on the 
function and structure of the systems affected, causing impairment to the 
patient on physical, psychological and psychosocial levels, leading to disability 
[4] [5-7].    
However, disability does not always reflect disease severity, as clinical severity 
or disease factors do not have a linear relationship with the psychological 
impact [272-274]. This indicates that the patient’s perceived impact of a disease 
is a complex interaction between the physical factors, psychosocial factors, the 
patient’s personality and the patient’s perception of the disease [262, 275]. 
This complexity is illustrated by the relationship between the factors that have 
been correlated with disability. Some clinical features have been reported to 
correlate with physical disability or with psychological disability, while others 
have an impact on both levels. However, these associations differ between 
studies [5, 22, 261, 274-276]. Physical disability has been found to correlate 
with patient-reported joint pain on motion, clinician–determined joint tenderness 
and number of tender points, joint contractures, digital ulcers, extremity ulcers 
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(other than digital), dyspnoea, high skin score, and gastrointestinal involvement 
[274] [5, 261, 276]. Some of these clinical symptoms have also been identified 
as being associated with impaired psychological function. For example digital 
ulcers have been reported to cause increased aesthetic burden [214]; lung 
difficulties has been associated with anxiety, and the overall disease severity of 
the SSc with depression[197]. Both depression and anxiety also have been 
associated with other physiological and psychosocial factors such as pain, 
fatigue, social support, emotion-focused coping helplessness, fear of disease 
progression, fear to negative evaluation and attractiveness [197, 277].  
Even though clinical severity or disease factors do not have a linear relationship 
with the psychological impact [272-274], in patients with SSc functional disability 
has been reported to be a significant predictor of distress[278]. 
To capture the impact of the disease the published studies have used different 
participants-reported outcomes measures (PROMs) such as generic PROMs 
capturing physical, psychological and psychosocial impairment and disease-
specific PROMs capturing elements specific to patients with that particular 
disease [276] [262]. However, the impact of the disease on the patients’ quality 
of life, reflecting psychosocial impairment, has only been captured by generic 
PROMs as opposed to disease-specific PROMs, possibly not reflecting the true 
level of the psychosocial impact in this population. To capture the true 
psychosocial impact of the disease, a needs- base disease-specific quality of 
life (QoL) [279] PROM should be used. By capturing the disability at a physical, 
psychological and psychosocial level the overall impact of the disease is 
assessed at a biopsychosocial level, as recommended by the World Health 
Organisation (WHO) [280].  
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There is evidence supporting the disabling effect that different clinical features 
of SSc have on the patients, including the physical disability caused by the 
presence of foot problems [8, 10]. However, there are no published data 
reporting the impact of foot problems on the quality of life of patients with SSc.
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2.9 Summary  
SSc is a complex connective tissue disease characterised by vasculopathy, 
immune activation and fibrosis. The pathogenesis of the disease affects 
different systems such as integumentary, vascular, neurological, 
musculoskeletal, cardio-pulmonary, renal, and gastrointestinal systems. The 
multi-system nature of the disease leads to widespread secondary effects 
including foot problems and related disability. Foot-related disability has an 
impact on patients’ physical and psychosocial function, affecting patient QoL. 
Although the empirical description of foot involvement in patients with SSc is 
well documented, the factors that contribute to foot pathology and its impact on 
the quality of life of this population has not been well reported.  
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Chapter 3                                                        
Methodology 
3.1 Introduction  
Chapter three describes the methodologies used in this thesis. First, a literature 
review and a consultation with experts was undertaken to identify the potential 
candidate factors that may contribute to foot problems (chapter 2). Then 
patients with SSc were compared to healthy volunteers in a case-control cross-
sectional study to investigate further the candidate factors that contribute to foot 
problems and explore their impact on the QoL of people with SSc; the impact of 
foot problems was quantified via participant-reported outcome measures 
described in section 3.3.2.2, and the candidate factors that contribute to foot 
problems were identified through detailed clinical investigations described in 
section 3.3.2.1. Finally, structural equation modelling was used to explore the 
multifactorial pathways in foot pathology and its impact on quality of life (section 
3.4). An outline of this study design is presented in Figure 3.1 and each phase 
of the study is explained in detail in this chapter.
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Figure 3.1: Outline of study design 
 
Ethical approval was obtained from the Leeds (East) Research Ethics 
Committee (Ref 10/H1306/14) and all the patients provided written informed 
consent in accordance with the Declaration of Helsinki (updated 2008). 
3.2 Phase One: Identification of potential candidate factors.  
The potential candidate factors that may contribute to foot problems were 
identified through published literature and a consultation with two clinical 
experts: a podiatrist and a consultant rheumatologist, both of whom, specialise 
in SSc. This process provided a comprehensive identification of physical and 
physiological potential candidate factors, the former affecting the integumentary, 
vascular, neurological and musculoskeletal systems. The published literature 
also provided the theoretical construct for the SEM. This literature was 
synthesised in chapter 2.  
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3.3 Phase Two: Investigation of the candidate factors that 
contribute to foot pathology and exploration of its impact  
The potential factors obtained from phase one were further investigated using a 
case-control cross-sectional study. In this study, detailed clinical assessments 
and patient reported outcomes measures (PROMs) were used to explore the 
nature and impact of foot problems in SSc and to compare them with a group of 
healthy volunteers.   
This case-control cross-sectional study provided data from which, after 
undertaking an exploratory analysis (section 4.3.2.1), the final set of candidate 
factors for the SEM were selected. 
 Participant recruitment  3.3.1
There is little consensus on the appropriate sample size for SEM. The required 
sample sizes reported range from 100 participants to several thousands[281], 
but what seems to be established is that large sample sizes are needed. SEM 
requires at least between 100 and 500 cases, but if the population studied is 
restricted in size then samples of less than 200 participants have been 
considered acceptable, although lower than 100 is not acceptable [282].  
Given that SSc is a relatively rare condition, a planned recruitment of 150 cases 
was considered appropriate and feasible. After two years of active recruitment 
the number of patients with SSc recruited was 121, the majority of the 
participants that declined the invitation to take part in the study did so due to ill 
health. This number was considered acceptable for using SEM, as it is larger 
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than the minimum 100 cases. A further 51 healthy controls were also recruited 
for the case-control cross-sectional study yielding a total sample of 172.  
In the absence of existing data on which to base the power calculation for the 
case-control cross-sectional study, we opted to use published guidelines for 
moderate effect size (Cohen’s d=0.5, where “d” is the difference in means 
divided by the SD). Using a standard two-group comparison of means 
approach, this is equivalent to powering using a ratio of 1:2 for mean:SD. For 
example we could use values of 5 and 10 for the means in each group 
(difference 5), and SD=10. To achieve 80% power at the 5% level of 
significance, assuming a 3:1 ratio of cases to controls, this would require 42 
controls and 127 cases. Note that it is immaterial which values are used for the 
means and SD, provided the ratio equates to d=0.5 [283].       
3.3.1.1 Identification and recruitment  
Recruitment of cases was undertaken at Chapel Allerton Hospital (Leeds 
Teaching Hospitals NHS Trust). The main health carer (consultant 
rheumatologist or podiatrist as appropriate) made the first approach to SSc 
patients attending for their routine care at the connective tissue disease clinics 
and/or the foot health clinic. Patients indicating a willingness in principle to 
participate were given a brief verbal explanation of the study, a written 
information sheet and the consent form. Potential participants were advised to 
read the information sheet and consent form and to discuss with family, friends 
and/or their GP as they deemed appropriate. If they decided that would like to 
take part in the study, they completed an expression of interest form, provided 
at the bottom of the patient information sheet, and returned it to the research 
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team in a freepost envelope. Once the team received the slip, the patient was 
contacted by telephone to arrange an appointment.  
Recruitment of the healthy participants was undertaken through the patients 
with SSc, using a technique referred to as “bring a friend” where patients were 
asked to nominate a healthy friend/relative of the same gender and same age 
(+/-2years) who was willing to participate. This recruitment strategy has been 
described previously in the literature as an effective method of matching for 
socio-economic, ethnicity and other demographic factors. In order to keep a 
balance, age and gender was monitored but the selection was not specific.  
When the SSc patients were given their information sheet and consent form 
they were also given a copy to help them recruit a healthy participant. The 
method followed subsequently was the same as described for the cases. 
3.3.1.2 Inclusion/Exclusion Criteria 
This case-control study targeted a broad range of people with SSc, including 
those with severe foot involvement as well as those with minimal or no foot 
involvement. As such, the inclusion criteria were broad and exclusion criteria 
minimal as described in Table 3.1.  
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Inclusion criteria for the patients with SSc Inclusion criteria for the healthy 
participants 
 Age ≥18 years old 
  
 Physician diagnosis of SSc (ARA/ACR 
1980 criteria) 
 
 Willingness to participate in the study 
 
 
 Age ≥18 years old  
 Generally good health  
Exclusion Criteria for both groups: 
 History of lower limb orthopaedic or vascular surgery in the 12 months prior to 
taking part in the study. 
 
 Inability to understand or comply with the protocol. 
Table 3.1 Selection criteria for both groups. 
 
As the recent ACR/EULAR classification criteria for SSc were still in 
development when recruitment took place, the diagnostic criteria used for 
patients inclusion in this study was based on a positive diagnoses of SSc as per 
the ARA/ACR (1980) criteria [41]or, if this criteria was not fully met, Consultant 
diagnosis of SSc was accepted. The criteria used for the subset classification 
was the lcSSc, dcSSc and SSc sine Scleroderma [24, 284] (Table 3.2), as 
these subsets criteria have been used for diagnostic and research proposes for 
the last three decades. 
A summary of participant recruitment and inclusion at different phases of the 
study is presented in figure 3.2. 
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Criteria reference Criteria for the classification of SSc 
American 
Rheumatology 
Association (ARA) 
preliminary Criteria 
for the Classification 
of Definite Systemic 
Sclerosis(1980) [41, 
285] 
Major Criterion: 
Proximal sclerosis 
 
 
Minor Criteria: 
Sclerodactyly 
Digital pitting scars or loss of substance on the distal finger pad 
Bibasilar pulmonary fibrosis 
To meet the criteria for the SSc diagnosis the patients has to fulfil the major criterion or any combination of 2 or more minor criterion. 
SSc Subsets 
according to LeRoy 
et al. (1988) [24] 
Limited Cutaneous SSc:  
Raynaud’s phenomenon for years at presentation 
  
Skin sclerosis limited to hands, feet, face, and forearms, 
or absent  
Significant late incidence of pulmonary hypertension 
Trigeminal neuralgia 
Calcinosis  
Telangiectasia   
Dilated nailfold capillary loops, usually without capillary 
dropouts 
Diffuse Cutaneous SSc: 
Onset of Raynaud’s phenomenon within 1 year of onset 
of skin changes  
Truncal and acral skin involvement  
Presence of tendon friction rubs  
Early and significant incidence of interstitial lung 
disease, oliguric renal failure  
Diffuse gastrointestinal disease 
Myocardial involvement  
Presence of anti-DNA, topoisomerase I (anti-Scl-70) 
antibodies  
Absence of anticentromere antibodies  
Nailfold capillary dilatation and destruction 
Overlap 
Syndromes 
 
Either diffuse 
or limited 
SSc with 
typical 
features of 
one or more 
of the other 
connective 
tissue 
diseases 
Systemic Sclerosis 
Sine Scleroderma 
[284] 
  ssSSc if the patient has all of the following features: 
1)Raynaud’s phenomenon or a peripheral vascular equivalent (digital pitting scars, digital-tip ulcers, digital-tip gangrene, abnormal 
nailfold capillaries) 
2)Positive ANA 
3)Any of the following: distal esophageal hypomotility, small bowel hypomotility, pulmonary interstitial fibrosis, primary pulmonary 
arterial hypertension (without fibrosis), cardiac involvement typical of scleroderma, or renal failure consistent with scleroderma 
renal crisis. 
4)No other defined connective tissue or other disease as a cause of 1), 2), or 3). 
Table 3.2 Diagnostic criteria 
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Figure 3.2: Study Flow Chart. RO= Rheumatology Outpatients 
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 Data collection  3.3.2
Recruitment and data collection was undertaken over two years (February 
2011- February 2013), through the four seasons so as to allow for seasonal 
variation, which has an effect on some of the symptoms such as RP [286] [287].  
The candidate (BAP) carried out the data collection, aided by a research 
assistant (RAW), and all took place within one visit.  
Two types of data were collected: participant-reported data and clinical data. 
Participant-reported data comprised of demographics, smoking history (pack 
years), comorbidities, medication, surgery history and standardized patient 
reported outcome measures (PROMs). With the exception of the PROMs, the 
rest of the participant reported data was obtained from all the participants 
including controls, and for the patient group it was cross-referenced with their 
medical notes. The patients also provided data regarding the presence of 
current or past skin ulcers and calcium deposits.  
Clinical data was collected to identify the factors that contribute to foot 
problems. The participants undertook detailed clinical assessments of the 
integumentary, vascular, neurological and musculoskeletal features of the lower 
limb. A detailed description of the clinical assessment and the PROMs used is 
presented in section 3.3.2.1 and 3.3.2.2 respectively. 
3.3.2.1 Detailed clinical assessments of the lower limb  
The detailed clinical assessments of the lower limb assessed four different body 
systems: integumentary, vascular, neurological, and musculoskeletal system. 
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The tests used to assess these systems were the modified Rodnan Skin Score 
(mRSS), Ankle Brachial Pressure Index (ABPI), qualitative Doppler waveform 
analysis, Von Frey monofilament, vibration threshold, thermal threshold, thermal 
pain threshold, analysis of foot function during walking, plantar foot pressures, 
and ultrasound measurement of the heel and plantar 3rd MTPJ soft-tissue 
thickness, All these tests are summarised in Table 3.3. 
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System Clinical Assessment Assessment Overview 
Target 
Pathology 
S
k
in
 
mRSS 
The mRSS is used to assess the extent 
of skin involvement in the patients with 
SSc by assessing skin thickness by 
clinical palpation [288, 289] 
Skin fibrosis 
V
a
s
c
u
la
r 
ABPI 
Brachial pressure and ankle pressure are 
taken. To obtain the ankle pressure the 
Dorsalis Pedis (DP) and Posterior Tibial 
(PT) arteries’ pressures are taken and 
the highest value amongst them is used 
to calculate the ABPI [290-292] 
Presence 
and severity 
of peripheral 
arterial 
disease[293] 
Qualitative Doppler 
waveform analysis 
The Doppler waveform from the DP and 
TP arteries is performed. The waveforms 
can be categorized according to 
appearance, which indicates the 
presence or absence of peripheral 
arterial disease [290-292] .  
Peripheral 
arterial 
disease 
N
e
u
ro
lo
g
ic
a
l 
Von-Frey monofilaments 
The mechanical threshold for light 
touch/pressure is assessed using the 
method of limits [294, 295]  
Large fibre 
peripheral 
sensory 
neuropathy 
Vibrameter 
The vibration detection threshold is 
determined by the detection of 
appearance of the vibration stimuli on the 
dorsal area of the first metatarsal [295, 
296] 
Large fibre 
peripheral 
sensory 
neuropathy 
Thermal threshold 
The thermal threshold is used to detect 
the sensation for warmth and cold using 
the method of limits.[295, 297, 298]) 
Small fibre 
peripheral 
sensory 
neuropathy 
Thermal pain threshold 
The thermal pain threshold is used to 
detect the sensation for heat-induced 
pain using the method of limits[295, 297, 
298].  
Small fibre 
peripheral 
sensory 
neuropathy 
M
u
s
c
u
lo
s
k
e
le
ta
l 
Eight camera three-
dimensional, high 
resolution motion capture 
system (VICON, Oxford, 
UK) integrated with twin 
Birtek force plates for 
appending force data 
Joint motions and forces are feed into a 
multi-segment foot model (modified 
Oxford Foot Model [299]) defining joint 
motion and force interactions in detail 
[300] [299]   
Abnormal 
pattern in 
gait and foot 
function 
Plantar Pressure 
(Novel EMED-ST) 
To obtain high-resolution measures of 
pressure and force distributions on the 
plantar aspect of the foot [301].  
Abnormal 
plantar foot 
pressures 
High-resolution ultrasound 
To quantifies soft-tissue thickness at the 
plantar aspect [302] 
Soft-tissue 
atrophy 
Table 3.3 Summary of clinical assessments
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3.3.2.1.1 Assessment of the integumentary system.  
The modified Rodnan Skin Score 
The mRSS is used to assess the extent of skin involvement in the patients with 
SSc. The results from this test are used to quantify the extent of skin 
involvement and to differentiate the SSc patients into two diagnostics groups, 
limited or diffuse sclerosis [43, 194]  
This tool is a valid outcome measure to assess skin thickness by clinical 
palpation. It has been shown to have face, content, discriminant, convergent 
and divergent validity [288, 289, 303-306]. However, the inter-observer 
variability is regarded clinically to be fairly high even though it has been 
reported to have acceptable inter-observer and intra-observer reliability [305]. 
Hence, the validity of this tool has been established only when the same 
investigator does the assessment of the skin [289]. In this study the candidate 
was trained in performing mRSS and carried out the skin assessment in all the 
cases. 
3.3.2.1.2 Assessment of the vascular system 
Only the presence of macrovascular pathology was assessed as the 
assessment of microvascular disease proved overly challenging and ultimately 
not feasible to perform within the available time frame. This is further explained 
in the discussion.  
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The vascular system was assessed for Peripheral Arterial Disease (PAD). This 
was achieved by using the ABPI test and the qualitative Doppler waveform 
analysis.  
The equipment used to assess the ABPI and the qualitative Doppler wave forms 
is a bidirectional Doppler (Smartdop 30EX, Koven Technology,Inc., St Louis, 
MO) with a 8 MHz probe. It is used to detect arterial blood flow in the 
extremities, assessing systolic pressures in the upper and lower limbs and 
automatically calculating the associated ABPIs.  
Ankle Brachial Pressure Index 
Reduction of ABPI values (<0.9mmHg) is of diagnostic value for the presence 
and severity of Peripheral Arterial Disease (PAD), and a good predictor of 
cardiovascular events [293, 307].  
The validity of the ABPI in detecting stenosis of a 50% or more reduction in the 
diameter of the lumen has been published in the literature [308-310]. The 
studies done by Lijmer et al [308], Fowkes [310] and Feigelson at al[309] 
reported on the sensitivity and specificity of the ABPI against lower extremity 
angiography. The studies used an ABPI threshold of 0.91, 0.90, 0.80 (mmHg) 
respectively, and found that the sensitivity of the ABPI was 79%, 95%, 89% and 
the specificity 96%, 100%, 99% respectively. Furthermore, the ABPI has been 
shown to have a positive predictive value of 90%, a negative predictive value of 
99%, and an accuracy of 98%[309]. This indicates that the ABPI is an accurate 
diagnostic measure for the presence of the PAD in the lower limb.  
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The use of the ABPI remains an important tool in the vascular assessment 
particularly those with atypical presentations [311], this being the case in this 
study group. 
The bilateral ABPIs were acquired after the participants rested as 
recommended [312] on a clinical couch in a reclined position for 30 min and for 
10 min in a supine position. The brachial pressure was assessed followed by 
the ankle pressure. To obtain the ankle pressure the Dorsalis Pedis (DP) and 
Posterior Tibial (PT) arterial pressures were taken. The fact of obtaining two 
different values from two arteries of the foot, causes some controversy on 
regards of which ankle pressures should be used for the calculation of the 
ABPIs i.e. the higher value, the lower value or the average value of the two 
[290-292, 313, 314].  
For the purpose of this study the higher-pressure value was used. It was 
considered the most adequate of all three options because by using the higher 
value, to obtain a pathological ABPI both arteries must have significant 
occlusive disease. Moreover, patients with SSc can have luminal stenosis as a 
result of their microvascular arterial pathology [3, 218], and the higher-pressure 
value is more sensitive to detect luminal stenosis [290]. In addition, the 
American College of Cardiologists and the American Heart Association 
recommend using the highest value of the ankle pressure to be conservative in 
the diagnosis of PAD [315].  
The ABPI calculation was obtained by dividing the ankle pressure by the 
brachial pressure. ABPI values ranging from 0.00-0.40 mmHg are considered 
severe PAD; from 0.41-0.90 mild to moderate PAD; 0.91-0.99 borderline 
(equivocal); 1.00-1.30 Normal; and >1.30 non-compressible [315].   
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When the ABPI values are above 1.30 or the patient has an ankle systolic blood 
pressure of >20 mmHg or 20% higher than the brachial systolic pressure, the 
patient is considered to have calcified arterial walls, which are poorly 
compressible [315]. If the arteries are non-compressible it can prevent accurate 
assessment of the ABPI [315].  
Qualitative Doppler ultrasound waveform analysis 
The qualitative Doppler waveform analysis provides haemodynamic information. 
The sensitivity and specificity of this method for detecting PAD in the lower 
extremities has been reported in the published literature. Walton et al [316]  
reported a sensitivity of 87% and a specificity of 88%; while Sensier et al [317]  
reported slightly higher sensitivity 95% and lower specificity 80% with an overall 
accuracy of 87%.The latter values for sensitivity and specificity are similar to 
those of Eiberg et al [318], of 98% and 81% respectively. However, the 
limitation of the Doppler waveform is that in the presence of stenosis of less 
than 50%, this modality loses sensitivity. Thus the presence of a minimal or 
moderate lesion as categorized by Walton et al. [316] might not be detected. 
This insensitivity might be as a result of the flow disturbance not being 
transmitted as far as the area of insonation [316]. 
The waveforms can be categorized by their appearance, which indicates the 
presence or absence of PAD. There is little consensus in how the different 
waveforms can be categorized however and different studies have used 
different systems. They do all have in common a description of the waveform in 
relation to the level of PAD.   
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The waveform categorization used in this study was one used more commonly 
in research and clinical settings; to categorize the waveforms as triphasic, which 
indicates absence of PAD; biphasic indicating presence of moderate disease; 
and monophasic indicating severe PAD[319, 320]. The triphasic waveform 
presents with a primary wave in systole (sharp systolic uprise and fall) followed 
by a short reverse flow, and a tertiary wave in diastole (diastolic forward flow). 
The spectral window through the pulse cycle is narrow in the absence of PAD; 
the biphasic waveform preserves the systolic upraise and fall, and the reverse 
flow, but the tertiary waveform in diastole is absent. In the biphasic wave, the 
spectral window is broadening; and in the monophasic waveform the waveform 
becomes damped (low amplitude and low curve upstroke and fall), the reverse 
flow is lost, and the spectral broadening is extensive [316-319] (Figure 3.2). In 
the presence of occlusion the waveform becomes extremely dampened with no 
reverse flow wave [316, 320]. 
The Doppler waveform from the DP and TP arteries were evaluated after the 
patient was resting for 10 min in a supine position, and three consecutive pulse 
waveform were acquired using the hand-held Doppler with a 8 MHz ultrasound 
probe (Smartdop 30EX, Koven Technology,Inc., St Louis, MO) A frequency of 
>5 MHz transducer (8-10 MHz transducer) is more useful to image superficial 
vessels such as pedal arteries [321]. Following acquisition the qualitative 
waveform analysis was performed by visual interpretation of continuously 
displayed waveforms, using the thriphasic, biphasic and monophasic 
description defined previously.  
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Figure 3.3  Lower limb arterial waveforms patterns: (A) thriphasic  (B) biphasic (C) 
monophasic. Imaged modified from Verim et al, page 249 [322]   
3.3.2.1.3 Assessment of the neurological system  
The neurological system was assessed for the presence of peripheral sensory 
neuropathy. The assessments involve bilateral lower limb quantitative sensory 
examinations of the somatic sensory nerve fibres, the functions of which 
includes sensation for touch, vibration, temperature and pain. The nerve fibres 
tested are the large diameter myelinated (A-alpha and A-beta) which carry 
motor function, touch and vibration sense; and the small diameter myelinated 
(A-delta) and unmyelinated (C) nerve fibres, which carry temperature and pain 
sensation, and autonomic function [323, 324].  
To assess the large diameter myelinated nerve fibres, the tests were conducted 
using graded Von-Frey monofilaments to assess touch sensation, and the 
Vibrameter to assess vibration sensation.  
Von-Frey monofilaments 
The mechanical threshold for light touch was determined using calibrated nylon 
Von-Frey monofilaments (SENSELab, Somedic, Sweden) according to the 
method of limits [294, 295]. The test was carried out on eight different foot 
areas: the apex of all five the toes, the dorsum of the foot, and plantar aspect of 
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the foot i.e heel and ball of the feet. The test was done with the participant‘s 
eyes closed. The monofilament was placed on the anatomical area that was 
being tested and then a force was applied till the monofilament buckled. The 
higher the number of the Von-Frey monofilament the greater the nominal force 
(grams) needed to buckle the monofilament, and the greater the pressure 
(g/mm2) exerted. The environmental humidity and temperature has an effect on 
the structural composition of the nylon monofilament affecting the buckling force 
of the monofilament. The higher the humidity and temperatures, the lower the 
loading applied by the monofilament [325]. Nonetheless, the monofilaments 
recover their initial calibration when stored at the same environmental 
conditions[325]. The humidity and temperature were recorded before the test 
started to control for environmental variables, and the monofilaments were 
stored in the same environmental conditions to minimize the effect of these 
environmental factors to the monofilament performance.  
The test started with number 6 Von-Frey filaments (monofilament diameter 0.18 
mm, pressure exerted 3.3 g/mm2). If the monofilament was not felt in some of 
the anatomical areas, the test was repeated using the monofilament in an 
ascending manner until the participant was able to feel the monofilament in that 
area. After number 6, the next Von-Frey filament grade used was number 9 
(monofilament diameter 0.26 mm, pressure exerted 7.3 g/mm2) then the 
numbers used were applied in ascending order by one extra grade at the time 
to a maximum pressure of 137.3 g/mm2, produced by the Von-Frey filament 
grade number 19 (monofilament diameter 1.01mm)  
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The mechanical threshold for light touch using the Von-Frey monofilament has 
been shown to have high test-retest reliability, of 0.89, and a high inter-observer 
reliability 0.88 as indicated by the Pearson’s product-moment correlation [297]. 
Vibrameter 
The vibration detection threshold was assessed with a “Vibrameter” (Type IV) 
(SENSELab, Somedic, Sweden) using the method of limits. The vibration 
detection threshold was determined by the detection of onset of the vibration 
stimulus on a bony prominence [296, 326], in this study the location being the 
dorsal area of the first metatarsal shaft. The appearance threshold method has 
been shown to have less variance than that of the disappearance threshold 
[296].  
The vibratory stimulus was delivered at a frequency of 100/120 Hz and the 
measurement of the stimuli ranged between 2:0 to 399.9 microns. The 
vibrameter delivered stimuli of increasing intensities starting from the base line 
value of 0µm (of displacement) at a rate of 1µm/s. 
The vibration perception threshold test was used as recommended as part of 
the battery of the quantitative sensory testing in clinical trials [295, 296, 326, 
327].   
Thermal threshold and thermal pain thresholds 
To quantitatively assess the small diameter myelinated (A-delta) and 
unmyelinated (C) nerve fibres for small fibre neuropathy the thermal threshold 
and thermal pain thresholds were measured objectively using the Modular 
Sensory Analyzer (MSA) Thermal Stimulator, (SENSELab, Somedic, Sweden). 
This computer-controlled device generates and documents response to highly 
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repeatable thermal stimuli, such as warmth, cold, and heat-induced pain. The 
method of limits was again used to detect the thermal threshold and thermal 
pain threshold. This approach is widely used in neurological research and has 
been shown to be a reliable method for detecting small fibre neuropathy[295, 
297, 298]. The stimuli are transmitted through a thermode (25 x 50mm), which 
in this study was placed dorsally and plantarly over the metatarsophalangeal 
(MTP) joints of both feet.  
The detection of the cold and warm threshold was measured, before the 
thermal pain threshold, by the perception threshold test [328]. This test was 
used with the setting “mix stimulus”, which consists of five cold stimuli followed 
by another five heat stimuli. The mean and standard deviation of the five 
different sensory thresholds was used as the final threshold value.  
In the “mix stimulus”, the time intervals between the five stimuli were set 
randomly, time ranging between four to six seconds. The stimuli baseline 
temperature for both threshold tests was 32°C. The cold stimuli could decrease 
until reaching 10°C, and the heat stimuli could increase until reaching 50°C.. 
The slope i.e. the rate of change of the thermode temperature, is 1°C/s for the 
decrease to cold stimuli or increase of heat stimuli, and 3°C/s for returning to 
the baseline temperature of 32°C.  
In the pain threshold test only one noxious “heat stimulus” was produced.  
The thermal threshold and thermal pain threshold both have been shown to 
have high test-retest reliability, and high inter-observer reliability. For the cold 
detection threshold the correlation is 0.76 and 0.75 respectively, for the warm is 
0.85 for both, and for the heat pain threshold is 0.88 and 0.87 respectively as 
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indicated by the Pearson’s product-moment correlation; with no systematic 
difference between means, therefore reflecting agreement [297].  
The sensitivity and specificity of the thermal threshold test and heat pain 
threshold are less clear [329, 330]. However, Shukla et al [298]reported a 
sensitivity of 72% on the thermal threshold test in detecting small fibre 
neuropathy, and this method has been widely used in clinical trials assessing 
small fibre neuropathy in different diseases, including SSc [171, 331].   
3.3.2.1.4 Assessment of the musculoskeletal system  
The musculoskeletal system was assessed for dynamic investigation of foot 
function, plantar pressures and quantification of compromise intra-articular and 
extra-articular structures. These features were assessed using the following 
tests: analysis of foot function during walking, plantar foot pressure, and 
ultrasound evaluation of plantar soft-tissue thickness. 
Foot function during walking 
To assess the dynamics of the foot function, the participants underwent a 
detailed analysis of foot function during normal walking. This was carried out 
using an eight camera, three dimensional, high resolution motion capture 
system (VICON, Oxford, UK) capturing at 390Hz and integrated with two Birtek 
force plates for appending force data sampled at 1000Hz. Joint motions and 
forces were fed into a multi-segment foot model (modified Oxford Foot Model 
[299]  defining joint motion and force interactions in detail [299, 300].  Figure 3.4 
shows the outputs obtained from the high-resolution motion capture system and 
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the Birtek force plates at three different stages during stance phase i.e heel 
strike, midstance, and push-off.  
To define the multi-segment foot model of the foot, reflective markers were 
placed on the skin in specific anatomical locations, as described by Stebbins et 
al. in the modified Oxford Foot Model method (mOFM) [299]. The mOFM 
comprises a tibial segment, a hindfoot, a forefoot, and a hallux. The original 
OFM was developed by Carson et al [299, 300] to be used in adults. However, 
this multi-segment foot model was later on improved by Stebbins et al. when it 
was modified to be used in children, and has since been applied to foot 
deformities in children and adults [299]. The mOFM has been reported to be 
reliable during adult gait, thus making its use acceptable in assessing dynamic 
foot function in adults [332]. Figure 3.3 shows the placement of the reflective 
markers using the modified OFM method  
The data capture protocol consists of one static trial and three dynamic trials. 
For capturing data in the static trial, the participant’s foot is placed in an 
anatomical position defined as the Foot Posture Index (FPI) “0” [333]. For the 
dynamic trials, the participant walks several times along a 10m walkway until 
the participants assumed a natural gait, then three trials were captured and the 
trial deemed most representative of the participant’s gait from consistency 
graphs was analysed. 
Data was analysed using V3D software and six candidate variables were 
extracted: stance time, vertical ground reaction force 1 (heel-strike), vertical 
ground reaction force 3 (propulsion), Ankle ROM, hindfoot vs shank ROM and 
forefoot vs hindfoot ROM. 
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Figure 3.4  Participant walking through the three different stages of the stance phase of gait ( i.e heel strike, midstance and push-off) during gait 
data capture. Reflective markers placed using the modified OFM method. 
  
Figure 3.5  Outputs obtained from the high resolution motion capture system (VICON) and the Birtek force plates, at three different stages during 
stance phase; starting from left to right the photos represent heel strike, midstance and push-off. Green image represent the dynamic model created by the 
program from data obtained form the reflective markers and captured by the infrared cameras, the red arrow represent the direction and strength of the ground 
reaction force. 
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Plantar foot pressures  
Plantar foot pressures were recorded using the Novel EMED-ST pressure 
platform (Novel GmbH, Munich Germany) to obtain high-resolution measures of 
pressure and force distributions under the foot. To obtain the plantar pressures, 
the patient walked barefoot over the pressure platform for six walking trials, at a 
self-selected normal walking speed, and three representative steps were 
collected from each foot and averaged and used for the analysis. A minimum of 
two steps gait initiation was used to ensure adequate reliability [301, 334, 335]. 
The use of the Novel EMED-ST pressure platform to obtain plantar pressures 
has been extensively reported in the literature [301, 334-337]. This plantar 
pressure system quantifies the plantar pressures, and discriminates between 
normal and abnormal loading patterns on the plantar aspect of the foot [336, 
337] (Figure 3.5).  
The parameters obtained from this plantar pressure system (i.e. Peak pressure, 
contact area, contact time, pressure–time integral, force–time integral, and 
instant of peak pressure) have been shown to be repeatable, thus they can be 
used as a part of the assessment of foot pathology [336, 337]. This method has 
been previously used to quantify plantar pressures in different rheumatic 
diseases including SSc [10, 195, 338].  
The pressure parameters extracted for this study were the maximum mean 
pressure under the 3rd MTP joint and heel, and the mean force under the 3rd 
MTP joint and the heel.  
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Ultrasound  
A High-resolution diagnostic GE Voluson ultrasound machine (GE Healthcare, 
Chalfont, UK) with an 18 Mhz probe was used to quantify objectively, the soft 
tissue thickness at the plantar aspect of the MTP joints and the heel (Figures 
3.6 and 3.7). Ultrasound is an established diagnostic imaging technique, widely 
used in patients with musculoskeletal diseases, which allows objective 
measurement of soft tissue dimensions at sub-millimetre resolution. Ultrasound 
has been reported to be a useful and objective tool for quantifying thickness of 
the epidermis, dermis and subcutis in patients with SSc [302, 339]. In order to 
Figure 3.6  Plantar foot pressure prints. Pink areas indicate higher pressures 
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determine consistency of the US measurements, an assessment of the 
candidate’s own intra-rater reliability was undertaken and is reported in 
Appendix 1. 
Ultrasound, has been used previously in SSc studies to identify the 
musculoskeletal pathologies mentioned above i.e. thickness of the epidermis, 
dermis and subcutis [189, 253, 259, 340], and it plays an important role on the 
diagnosis of musculoskeletal pathologies [244, 341-343]  
 
 
Figure 3.7 Measurement of the plantar soft-tissue thickness under the 3
rd
 MTP joint, 
using ultrasound B mode image. 
 
 
Figure 3.8 Measurement of the plantar soft-tissue thickness under the heel, using 
ultrasound B mode image 
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3.3.2.2 Exploration of the impact of SSc  
To capture the impact of the disease the participants completed six PROMs 
exploring specific domains:  the MOS 36-items Short-Form health survey (SF-
36), the Hospital Anxiety and Depression Scale (HADS), the Scleroderma 
Health Assessment Questionnaire (SSc HAQ), the SSc Quality of Life (SSc 
QoL), the Raynaud’s condition score (RCS), and the Manchester Foot Pain and 
Disability Index (MFPDI). The healthy participants completed the same 
questionnaires with the exception of the disease specific questionnaires i.e. SSc 
HAQ and SSc QoL. The six outcomes measure are summarised in Table 3.4, 
and described in this section. 
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Table 3.4 Patient-reported outcome measure 
 
Patient 
Reported 
Outcomes 
Measures 
Type of 
outcome 
measure 
Domains 
What does it 
measures? 
MOS SF-36  
[344, 345] 
Generic  
1-Functional status  
2-Well being  
3-Overall evaluation of 
health 
Patient’s perceived 
general health status  
Hospital Anxiety 
and Depression 
Scale 
[346]  
Generic 
1-Anxiety  
2-Depresion  
The symptoms and 
severity of anxiety 
and depression  
SSc HAQ  
[347] 
Disease 
specific 
1-Function/Disability 
2- Pain  
3-Vascular symptoms  
4-Digital ulcerations  
5-Gastrointestinal 
symptoms  
6-Lung symptoms  
7-Patient’s perceived 
overall disease severity 
Disease specific 
health status, by 
assessing 
functional 
limitations general 
and organ-specific 
symptoms.   
SSc QoL [279]) 
Disease 
specific 
1-Disease impact on 
health and well-
being[279] 
Needs-base quality 
of life 
RCS 
[348] 
 
Symptom 
specific  
1-Raynaud’s attacks 
activity  
2-Raynaud’s attacks 
impact 
Daily frequency and 
duration of the 
Raynaud’s attacks, 
and the level of 
difficulty that the 
patient experience as 
a result of the 
Raynaud’s attacks.   
MFPDI 
[349] 
 
Region 
specific 
1-Foot & ankle pain  
2-Foot & ankle disability 
3-Foot & ankle 
appearance 
Activity related foot 
and ankle disability 
and pain, and 
appearance. 
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MOS SF-36 
The SF-36 was used to assess general health status in order to compare the 
impact of SSc with not only our healthy volunteers, but also with other 
conditions. This health survey is a validated generic outcome measure 
designed to examine a person’s perceived health status, and to identify how a 
particular condition causes health to deviate from the “healthy standard” [344, 
345]. It consists of one multi-item scale measuring eight health 
concepts/variables. These eight variables can be divided in three domains: i) 
The functional status domain which comprises physical functioning, role 
limitations because of physical health problems, social functioning, role 
limitations because of emotional problems; ii) the well-being domain containing 
general mental health (psychological distress and psychological well-being), 
bodily pain, vitality (energy/fatigue); and iii) the overall evaluation of health 
domain comprised by the variable general health perception. In addition to the 
one multi-item scale it also includes a single-item measure of the health 
transition or change [344, 345].  
The SF-36 scales can also be grouped in two summary measures the physical 
component summary and the mental component summary (McHorney et al., 
1993). The score obtained from the questionnaire varies from 0 worst health 
state measurable by the tool to 100 best health state[345, 350, 351]. 
The SF-36 version used in this study was version one and the software used to 
score the questionnaire was QualityMetric Health Outcomes(tm) Scoring 
Software 4.0. The licence was obtain through QualityMetric Health Outcomes  
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Hospital Anxiety and Depression Scale (HADS) 
The HADS was used to measure domain specific health status of anxiety and 
depression. This questionnaire is a self-assessment scale, which measures the 
symptom severity and distinguish cases of anxiety and depression i.e scores ≥8 
from non-cases i.e scores <8 [346, 352]. The domains of anxiety and 
depression symptoms are measured by 14 items, seven for each subscale 
measuring the two domains. Each item has four responses with scores ranging 
from 0 to 3. The HADS is a reliable measure of anxiety and depression and has 
been reported to be a valid measure of the severity of these mood disorders 
[346, 353]. To prevent influence from somatic disorders and from serious 
mental disorders, this scale excludes symptoms related to physical disorders 
(symptoms of somatic reference), and those that might arise from mental 
diseases [346]. The HADS has been used in previous studies as an outcome 
measure to assess anxiety and depression in patients with SSc [197, 354]. 
License to use the HADS was obtained from GL Assessment. 
SSc HAQ 
The SSc HAQ was used to assess disease specific health status in terms of 
functional ability. This tool is composed by two outcomes measure the “short” 
Health Assessment Questionnaire Disability Index (HAQ-DI) including the 
Visual Analogue Pain Scales (VAPS) [355], and five specific Scleroderma-
Visual Analogue Scales (Scleroderma-VAS) [347]. The SSc-HAQ measures 14 
domains: eight on function/disability measured by the HAQ-DI (dressing, 
arising, eating, walking, hygiene, reach, grip, and common daily activities); one 
on pain measured by the VAPS [356]; and five on individual scleroderma organ 
system symptoms which are measured by the five scleroderma-specific VAS 
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(vascular problems [Raynaud’s Phenomenon (RP)], digital tip ulcers, Gastro 
Intestinal (GI) symptoms, lung symptoms (usually shortness of breath), and 
overall disease severity from the patients perspective) [347]. 
The HAQ-DI was originally developed to measure function/disability (physical 
disability) in people with Rheumatoid Arthritis [355, 356] but it has been shown 
to be a valid and reliable measure of disability in patients with SSc, as its 
domains pertains to activities of daily living [357-359]. The fact that the HAQ-DI 
[356] was not developed originally for patients with SSc creates limitations of its 
use, as it does not capture disabilities caused by some disease features such 
as muscle weakness and skin tightness [359]. Nonetheless, the five 
Scleroderma-VAS add incremental content validity to the HAQ-DI because it 
contains SSc specific domains that contribute to the conceptual framework of 
disability in SSc, allowing to capture disability secondary to internal organ 
involvement [359]. Therefore, the SSc HAQ can be used to assess general and 
organ–specific symptom as well as functional limitations in patients with SSc 
[359] [358, 360]. 
It needs to be noted that the SSc-HAQ is not a composite outcome measure 
and so the scores from the Scleroderma-VAS are reported individually, and are 
not added to the HAQ-DI scores (Johnson et al., 2005). On the other hand, the 
HAQ-DI score is a composite score falling between 0 to 3 in an ordinal scale, 0 
interpreted as (no impairment in function) to 3 (maximal impairment of function). 
The 15cm Scleroderma-VAS are scored by measuring the centimetres from the 
left anchor (no pain/ no limitation) to the patient’s mark. The VAS scores can be 
converted to equivalent scores on the no impairment to maximal impairment 
scale, where each centimetre is equivalent to 0.2 points converting the result 
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into an ordinal scale of 0 (no impairment in function) to 3 (maximal impairment 
of function) equivalent to the HAQ-DI (Johnson et al., 2005 ; Steen and 
Medsger, 1997). However, in this study the Scleroderma-VAS were converted 
and treated as 10cm VAS in order for a more sensitive measure to be included 
in the structural equation modelling.   
SSc QoL 
The SSc QoL is a needs-based quality of life outcome measure developed 
for patients with SSc. The needs-based model is based on the understanding 
that individuals are driven or motivated by their needs, and that life gains its 
quality from the ability and capacity of individuals to satisfy their needs [361, 
362]. The needs-based definition of quality of life (QoL) is a different construct 
to our physical ability or health status; as QoL is a complex interaction between 
the ways in which people perceive their health and how it relates to other 
aspects of their lives that are non-medical. Therefore the construct of the SSc 
QoL does not depend on a medical model but reflects the issues that are 
important to the patient independent of the physician’s understanding of quality 
of life [363]. 
The SSc QoL questionnaire is a self–assessment scale consisting of 29 items 
that measures the impact of SSc on health and well-being and cover four 
overarching themes identified by SSc patients:  emotion, physical adaptation, 
impact on/with others and impact on self. 
Each item has two responses scoring either 0 (true) or 1 (not true). The total 
score is obtained by adding up the scores, with a maximum score of 29; the 
higher the score the worse the quality of life [279]. The SSc QoL is a reliable 
tool which has been used previously in a randomized control trial (RCT) [364].  
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License to use the Scleroderma Quality of Life Scale Questionnaire 2006 was 
obtained from the University of Leeds.  
Raynaud’s Condition Score (RCS) 
The Raynaud’s Condition Score (RCS) is a symptom specific outcome 
measure. This tool measures the daily frequency and duration of the Raynaud’s 
attacks, and the level of difficulty that the patients experience as a result of the 
Raynaud’s attacks. The RCS integrates the impact and activity of RP [348]. The 
level of difficulty is measured by a numerical scale, which scores ranges from 0 
(no difficulty) – 10 (extreme difficulty). It has been shown in previous studies 
that the RCS is a valid and reliable outcome measure of the impact caused by 
the Raynaud’s phenomenon attacks [289, 348].  
The RCS and the RP-10cm VAS, which is incorporated into the SSc HAQ, are 
both validated tools to assess Raynaud’s phenomenon activity in RP associated 
to SSc. However, the RCS has been shown to have face, content, criterion, 
discriminant, and construct validity, and to bare superiority over the RP-10 cm 
VAS [289, 348]. 
The use as outcome measures of the RCS, SF 36, SSc HAQ in Scleroderma 
and Raynaud’s phenomenon clinical trials, has been recommended by the 
Scleroderma Clinical Trials Consortium and the Outcomes Measure in 
Rheumatology Clinical Trials  (OMERACT) [289, 306, 348] 
Manchester Foot Pain and Disability Questionnaire /index (MFPDI) 
The Foot Pain and Disability Index (FPDI), more commonly referred as 
Manchester Foot Pain and Disability Questionnaire (MFPDQ), is used to assess 
the foot specific health status. The MFPDQ is a validated, multidimensional, 
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generic, self-administered instrument use to assess foot pain and disability. The 
MFPDQ measures activity related foot and ankle disability and pain, and 
appearance [349, 365].  There are two versions of the MFPDQ. The original 
version developed by Garrow et al. [349], which consists of 19 items, and a 
modified version which consists of 16 items [365].  For the propose of this study 
the original version by Garrow et al [349], the 19 item version, was used.  
The total score from the questionnaire is calculated by summing the scores 
from each item. The minimum score obtainable is 0 and the maximum is 38, the 
higher the scores the grater the foot pain and disability. Each item is rated in an 
ordinal scale:  None of the time = 0; on some days = 1; and on most/every day= 
2. The participants were considered to have foot problems if they had scored at 
least one of the 10 MFPDI function items experienced on most /every day; as it 
is an indicator of disabling foot pain reflecting impaired physical function [366]. 
Licence to use the MFPDI was obtained from ISIS Outcomes (Oxford, Uk). 
 
These generic and disease specific questionnaires evaluated the physical and 
psychological disability perceived by the patients. In this context, the term 
disability was used with the meaning described by the International 
Classification of Functioning, disability and health (ICF) in the biopsychosocial 
model. Disability, involves dysfunctioning at one or more of the three levels of 
human functioning: at the level of body or body part, the whole person, or the 
whole person in a social context. Therefore, disability is composed by 
impairments (problems in body function or structure), activity limitations 
(difficulties that an individual might have in executing activities) and participation 
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restrictions (problems an individual may experience in involvement in life 
situations) [280, 367]. 
On the next stage of phase two, after the patients completed the 
questionnaires, the patients underwent a series of detailed clinical assessments 
of the lower limbs. These assessments were used to identify the potential 
candidate factors that contribute to foot problems.  
In summary, the data collected from the clinical assessments captured the 
potential factors that cause foot problems, while the data from the 
questionnaires captured and quantified in detail the extent of the physical, 
psychological and psychosocial SSc related impact. These data provided the 
inputs to the exploratory analysis used to identify the candidate factors for the 
Structural Equation Modelling (SEM) explained in phase three. 
Prior to undertake the statistical analysis the candidate completed a PgCert in 
Health Research and a three-day course in Structural Equation Modelling with 
Amos. 
 Strategy for data analysis 3.3.3
Prior to the SEM testing carried out in phase three, summary statistics were 
used to describe the demographics and clinical features of the sample. From 
the clinical assessments, only data from the dominant foot was included in the 
statistical analysis. 
Exploratory analysis and regression analysis was used to select the candidate 
factors for the SEM. Analysis was undertaken using SPSS (Version 20) 
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3.3.3.1 Comparison of SSc patients and healthy participants 
The data obtained from the quantification of the impact and the clinical 
assessments was used to compare the patients with SSc with the controls in an 
exploratory analysis. The between-groups comparison of the data helped inform 
the identification of the candidate factors for the later modelling with those 
factors that showed the more significant differences or bigger effects sizes 
between the groups being prioritised for the SEM, along with further variables 
that were strongly associated with the theoretical construct of the model.  
i. Summary statistics  
For the case-control cross-sectional study and for the SEM data summary 
statistics were checked for each variable and consisted of frequency 
distribution, measures of central tendency of the data i.e. mean and median, 
and measures of dispersion of the data i.e. Standard Deviations (SD), 
interquartile range and ranges. Summary statistics were used together with a 
bootstrapping technique, which provides an estimate of the sampling 
distribution within our cohort. Assessment of normal distributions and outliers in 
the data were undertaken. 
ii. Exploratory statistics 
Exploratory statistics were employed to check for assumptions of normality and 
homogeneity of variance for each variable, and to assess which statistical tests, 
i.e. parametric or non-parametric, test would be more appropriate to explore the 
data. The assumption of normality was assessed graphically by histogram, and 
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box-plots and confirmed by statistical testing of significance of skewness and 
kurtosis. This statistical test uses the corresponding z-scores of skewness and 
kurtosis to compare against values that indicate whether skewness and kurtosis 
are not different from 0 (a normal distribution). The assumption of homogeneity 
of variance was assessed graphically by using a boxplot of the variable data for 
the two groups and statistically by using the Hartley’s Fmax known as variance 
ratio. The boxplot also indicated the presence of any outliers that could have 
influenced the results.  
In order to compare the SSc patients with healthy participants, a t-test was used 
for interval variables that met the assumptions of normality and homogeneity of 
variance. For the interval variables that did not meet the assumptions, a non-
parametric test for independent samples, the Mann-Whitney test, was used. 
The Mann-Whitney test was also used for the ordinal variables and the 
Pearson’s Chi-Square (χ2) test for categorical variables. For the latter test the 
assumptions of independence and expected frequencies ≥5 were met [368].  
 With the non-parametric tests the Monte Carlo (2-tailed) method was used to 
calculate the p-value, while the bootstrap method was used for the parametric 
tests.  
The effect size was calculated using Cohen d and Pearson’s correlation 
coefficient for normally distributed variables [368, 369]. While for the non- 
normally distributed variables only Pearson’s correlation coefficient was used, 
as Pearson’s correlation coefficient is the recommended test to calculate the 
effect size when using the non-parametric Mann-Whitney test [283, 368]. 
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3.3.3.2 Exploratory analyses of the potential factors for the SEM   
Structural Equation Modelling (SEM) is a powerful modelling approach used to 
explore the relationships between several independent and dependent 
variables. SEM is a sophisticated method for examining correlations and 
relationships between several dependent and independent variables. For 
example, correlation is used to explore the relationship between two variables, 
and this analysis will provide a value (r or Rho) indicating the strength of the 
association. The disadvantage of the correlation is that only one relationship 
between two variables can be evaluated at a time and the variables are each 
considered in isolation. Therefore, if we wanted to explore the combined impact 
of several independent variables (such as foot pain, foot function and 
depression) on a dependent variable (such as QoL) then regression analysis 
would be used. Regression analysis offers the ability to measure the impact of 
each independent variable on the dependent variables when considering all the 
variables together (ß weights), and it also provides an estimate of how much of 
the dependent variable is explained by all independent variables combined (R2). 
Regression is constrained by three major issues however: the first is that only 
one dependent variable can be explored at a time; the second is that the 
direction of a relationship is treated in only one direction  (such as depression 
impacts on QoL and not that QoL may impacts on depression); and finally, 
regression does not take into account error associated with the outcome 
measures.  
SEM offers a solution to some of the issues that are inherent in multiple 
regression techniques. SEM is a sophisticated modelling approach, extending 
the power of simpler techniques such as regression to allow quantification of 
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complex interactions between factors. It is composed of two basic elements 
path analysis (i.e multiple regressions, which is concerned with the relationships 
between measured or observed variables of interest) and factor analysis (which 
considers the extent to which items or measures capture latent variables) [370].  
SEM is driven by a conceptual theory about a set of variables and their 
relationship. This method requires a theoretical model underlined by a 
hypothesis that is to be tested by the model. It is very important that the model 
is hypothesis driven, either by evidence from the literature or by a conceptual 
understanding of the variables, as SEM involves an iterative analysis technique 
where relationships between variables can be changed in order to fit the model 
[371] 
Conventional statistical analysis was undertaken using SPSS (Version 20) and 
SEM modelling using AMOS (Version 21). 
3.3.3.2.1 Multiple regression analysis- Methods 
The multiple regression analysis methods section is divided in two parts: data 
preparation for the regression model and multiple regression methods.  
i. Data preparation for the regression model 
To identify which factors would be included in the SEM, regression analyses 
were undertaken in order to understand how variables were related to foot 
function, foot pain and quality of life. Data were assessed for collinearity, 
linearity and hetroscedasticity, independent errors/residuals, outliers and 
missing data. 
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Collinearity 
All variables entered into the models were assessed for multicollinearity. Three 
different methods were used to identify collinearity between variables: 
correlations coefficients, Variance Inflation Factor (VIF) and the VIF related 
tolerance statistic. For the correlation matrixes the following tests were used, 
depending on the type of variables. Spearman’s correlation coefficient was 
used when one of the variables was continuous but non-normally distributed, 
and when the variables were ordinal or categorical. Point-biserial correlation 
was used when one of the categorical variables was a discrete dichotomous 
variable. Any variables that had a correlation coefficient of 0.8 or greater were 
considered to be collinear and were excluded from the model, as this indicates 
redundancy for the model. However, the correlation coefficient method misses 
subtle forms of collinearity therefore for the multiple regression models the VIF 
and the VIF related tolerance statistic, which indicates if two predictors have a 
strong linear relationship, were also assessed. The models were only accepted 
if the VIF was ≤ 10 and the tolerance statistic was > 0.20 [368].  
Relationships between variables that were considered collinear were excluded, 
as they were redundant for the model.  
Linearity and heteroscedasticity / heterogeneity of variance  
The assumptions of linearity and heterogeneity of variance of the outcome 
variable was assessed by using a plot of standardised residuals against 
standardised predicted values known as zpred vs zresid plot. For the predictor 
variables these assumptions were assessed by partial plots, which are 
scatterplots of the residuals of the outcome variable and each of the predictors 
when both variables are regressed separately on the remaining predictors. The 
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partial plots were also used to identify any obvious outliers that could have 
influenced the predictor’s regression coefficient. 
Independent errors/ residuals  
After the model was created the Durbin- Watson test result was checked to 
assess that the residuals in the model were independent, specifically whether 
adjacent residuals were correlated. A value of 2 was considered that the 
residuals were uncorrelated, greater than 2 was considered a negative 
correlation and lower than 2 a positive correlation. 
Outliers and missing data 
Data from each variable were explored graphically using a boxplot; this allowed 
the identification of outliers and extreme scores.   
Case-wise diagnostics were also undertaken to check the residuals for 
evidence of bias. For each regression model, the case-wise diagnostics were 
examined for extreme cases and any cases that had a standardised residual 
less than -2 or greater than 2 were considered outliers and were investigated 
further. However, the model was still considered adequately accurate if 5% of 
the cases had a standardised residual outside ±2 or 1% had a standardised 
residual outside ± 2.5; although any cases with a standardised residual value 
above 3 were investigated further as they were caused for concern.      
Any outliers were checked to see whether they were exerting undue influence 
over the parameters of the model. To assess the overall influence of a single 
outlier on the model as a whole, the Cook’s distance statistic was used, and any 
outlier having a Cook’s distance value > 1 was considered influential to the 
model.  
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To combat the effects of the outliers, and the problems with violation of the 
assumption of normality, a robust statistical method was used, the bootstrap. 
The bootstrap method overcomes these problems by estimating the properties 
of the sampling distribution from the sample data.  
For those variables that also had problems with normality and linearity 
transformation of their data were also undertaken.   
Missing data in the multiple regression models was addressed by excluding the 
cases listwise.  
ii. Multiple regression models- Methods 
In preparation for the SEM the multivariate relationships between each of the 
variables were explored using multiple regression analysis. The regression 
models were assessed to refine the selection of the candidate factors for the 
SEM. 
The force entry multiple regression method was used to identify significant 
relationships between the predictors and the outcomes and the direction of the 
relationships, and the data obtained was used subsequently to inform the 
theoretical model for the SEM.  
The force entry multiple regression method enters all the predictors into the 
model simultaneously. This method is appropriate when there is a lack of 
evidence to rank the variables in order of importance in predicting the outcome 
[368]. Prior to the current study there was not enough published evidence of the 
impact of foot problems in patients with SSc to rank the variables in order of the 
importance of predicting the outcome. 
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Sixteen different multiple regression models were constructed, four for each of 
the systems assessed clinically (i.e. integumentary, vascular, neurological, and 
musculoskeletal), and sequentially using the QoL, HAQ, MFPDI function and 
MFPDI pain variables as outcomes. These PROMs scores were the closest 
representations of relevant aspects of the conceptual variable of overall 
“impact”, the latent variable to be assessed in the SEM. The predictor variables 
were comprised of the clinical assessment variables that represented each of 
the four different systems under investigation. From the predictor variables, 
those that had the greatest contribution to the regression models would be 
prioritized as candidate factors for the SEM. 
Other variables considered potential confounders were also added into the 
multiple regression models so that they could be adjusted for. These variables 
consisted of demographic variables (age and gender), disease activity variable 
(disease duration and disease subset), comorbidities (number of comorbidities) 
and BMI. 
The results obtained from the exploratory analysis, together with the regression 
model data were used to inform the decisions about which clinical variables 
would be included in the SEM. 
3.4 Phase three: Multifactorial Pathways  
 The pathway-modelling phase was designed to explore the role of candidate 
factors in the multifactorial pathway of foot pathology and its impact on quality of 
life. This was achieved by using Structural Equation Modelling (SEM).   
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For this phase, only the data from the 121 patients with SSc was included, as 
the data from the healthy participants was collected only for use as comparator 
data in the case-control cross-sectional study. 
 Overview of Structural Equation Modelling  3.4.1
SEM is an analytical technique which incorporates the strength of factor 
analysis, path analysis and regression in a single model that can be tested 
statistically, permitting the evaluation of relationships amongst latent variables 
[281, 370]. Latent variables are variables that cannot be directly measured and 
SEM defines them in terms of behaviour believed to represent this variables. 
This model is a powerful tool to identify the direct and indirect mediating effects 
of multiple factors to a latent variable, such as the concept of “impact” of foot 
problems in patients with SSc (Figure 4.2) [372]. Furthermore, SEM permits 
multiple dependent variables to be explored at a time, and variables can be 
treated as dependent and independent variables. Thus, SEM treats the 
direction of the relationship between variables as potentially bidirectional. It 
includes reciprocal and mediating relationships and provides estimates of 
measurement error [370, 372, 373].  
In contrast to other multivariable methods, SEM allows hypothesis testing as it 
offers a confirmatory rather than an exploratory approach to data analysis. 
Thus, data can be analysed for inferential purposes instead of descriptive 
purposes. The confirmatory approach applies only to pre-specified models and 
is lost once the initial model does not fit the data and the researcher has to 
modify the model.  Consequently, if this occurs the subsequent SEM analysis 
cannot be used as evidence for causation as it has lost its strictly confirmatory 
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application. If the initial model requires modification then the purpose of the 
model becomes “model generation” with the aim of producing a model with 
three properties: it makes theoretical sense, it is reasonably parsimonious and 
its correspondence with the data is acceptably closed[282] . 
The causal relationships being explored in this study was represented by a 
series of structural (i.e. regression) equations, and they were modelled 
pictorially for clearer theoretical conceptualization. The pictorial model 
represents the latent variables, ie those which are indirectly measured by 
observed variables (e.g. QoL), by an oval shape; while the directly observed 
variables (e.g. plantar pressures) are represented by a rectangular shape. In 
addition, residuals or error terms in SEM are explicitly represented in the 
diagram as latent variables. This is because error variance is not directly 
observed in the raw data and needs to be estimated using the whole model and 
the data [282]. 
Each hypothesized relationship was concurrently tested at the same time as the 
entire system of variables, to determine the extent to which it was consistent 
with the data. The goodness of fit was then used to test the acceptability of the 
hypothesised relationships in the model; if the goodness of fit was inadequate 
the model was rejected [372]. Note however, that before a model was rejected, 
the relationships between variables were changed to try to obtain a better 
model (i.e. model generation), and all the changes were made in light of 
evidence from the literature or using a conceptual understanding of the 
variables [374].  
SEM was considered the best statistical multivariable model for this study as it 
allows the analysis of observed and latent variables, thus allowing the 
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evaluation of the contributory effects of different factors to the outcome 
variables i.e. the factors contributing to foot pathology and the factors 
contributing to the impact of foot pathology on the QoL of patients with SSc.  
 Hypothesis testing  3.4.2
To explore the multifactorial pathways in foot pathology and its impact on quality 
of life, following our initial exploration of one model (Chapter 4), three initial 
models were designed exploring foot function, foot pain, and the impact of foot 
pathology on the QoL of patients with SSc.These models were based on the 
International Classification of Functioning, disability and health (ICF) and 
supported by the literature and the results obtained from the exploratory 
analysis.  
The hypothesis to be tested was that the impact of foot problems on the QoL of 
patients with SSc is multifactorial; involving a complex inter-relationship 
between disease, impairment, personal factors, environmental factors and 
psychosocial factors.   
 Measures for the model in relation to the ICF  3.4.3
Using the ICF framework as the basis for building the SE model, allowed the 
impact of foot problems in patients with SSc to be measured at a 
biopsychosocial level; as recommended by the WHO [280, 367]. The ICF 
framework was developed around a biopsychosocial model of disability. This 
model integrated the social model (where disability is a socially created problem 
and not an attribute of an individual) and the medical model (where disability is 
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a feature of the person directly caused by disease, trauma and other health 
conditions). The biopsychosocial model of the ICF encompasses the following 
components:  body function and structure, activity, participation, environmental 
factors and personal factors (Figure 3.8).  
 
Figure 3.9 ICF framework adapted from WHO [280] 
 
 
In this study the ICF frameworks was used as a structure for the identification of 
potential variables that contribute to foot pathology and to its impact on the QoL 
of patients with SSc. A summary of the constructs and outcomes measures 
considered in the SE models is present on Table 3.5
Contextual factors  
Health condition  
(Disorder or disease) 
Activity  Participation 
Personal 
Factors  
Environmental 
Factors  
Body function & 
Structure 
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Construct ICF construct Measure 
Demographics  Personal factor  
Personal factor  
Personal factor 
Age  
Gender  
Ethnicity  
Disease characteristics  Health condition  & environmental factors 
Health condition 
Health condition 
Body function and structures & health condition 
Body function and structures & health condition 
Body function and structures & health condition 
Body function and structures & health condition 
BMI 
Disease duration 
Disease subtype  
mRSS 
Plantar soft -tissue thickness  
Vascular assessments  
Neurological assessments  
Disease interference 
characteristics  
Health condition  
Health condition 
Health condition 
Health condition 
Health condition & environmental factors  
VAS Breathing problems  
VAS GI problems interference  
VAS DU interference  
VAS overall disease severity  
VAS Raynaud’s interference  
Co-morbidities Health condition Number of comorbidities  
Environmental factors  Environmental factors 
Health condition  & environmental factors 
Pack years  
BMI 
Pain Body function and structures 
Body function and structures 
MFPDI Pain 
VAS Pain  
Function Activity  
Activity 
Body function and structures & health condition 
SSc HAQ  
MFPDI Function  
MSK assessments  
Anxiety  Body function and structures HADS Anxiety  
Depression  Body function and structures HADS Depression  
QoL No corresponding factor,  
but embodies all the factors above 
SSc QoL 
Table 3.5 Summary of constructs and outcomes measures considered in the SE model 
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 Strategy for analysis of the data  3.4.4
3.4.4.1 Data preparation for the SEM  
To prepare the data for SEM modelling, the variables were explored using 
exploratory statistics as described in section 4.3. The variables were further 
explored using correlations and regression models, which together with a 
coherent theoretical construct of the model obtained from the literature, helped 
determine the candidate variables that were to be included in the original pre-
specified SEM model. Statistical analysis was undertaken using SPSS (Version 
20), and AMOS (Version 21). 
Prior to use in the SEM, the candidate variables were tested for the required 
assumptions. SEM is related to multiple regression and therefore the 
assumptions that need to be considered are similar; the data needs to be 
interval and to have multivariate normality. Furthermore, there should be no 
missing data, extreme outliers or evidence of multicollinearity.  
Assumptions and missing data  
The data was explored to evaluate the validity of these assumptions as 
described in section 3.3.3.2.1.  In addition, additional diagnostic statistics 
derived as part of the SEM modelling further assess the assumption of 
multivariate normality using Mardia’s coefficient, which provides the multivariate 
Kurtosis values. Values between 1 and 10 indicate moderate non-normality, 
while values >10 indicated severe non-normality. When non-normality was 
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found the bootstrap statistic was used [281, 282, 372]. Missing values were 
estimated by AMOS using the Maximum Likelihood estimation [372].  
Outliers  
To detect outliers, two methods were used: a graphical and a statistical method. 
Data from each variable were explored graphically using a boxplot; this allowed 
us to identify the presence of outliers and extreme scores. While AMOS case-
wise diagnostics provided the Mahalanobis distance. This statistical method 
identifies any cases for which the observed scores differ substantially from the 
centroid of scores for all cases [372].  
To combat the effects of outliers and the problems with non-normality, the 
bootstrap method was again used. 
Collinearity 
Prior to entering the variables in the SEM model, all 45 potential candidate 
variables for the SEM were assessed for multicollinearity using correlation 
matrixes. For the correlation matrices the following tests were used depending 
on the type of variables. Spearman’s correlation coefficient was used when one 
of the variables was continuous but non-normally distributed, and when the 
variables were ordinal or categorical. Point-biserial correlation was used when 
one of the categorical variables was a discrete dichotomous variable. Any 
variables that had a correlation coefficient of 0.8 or greater were considered to 
be collinear and one of those two variables was excluded from the model, as 
this indicates redundancy for the model. Relationships between variables that 
were considered collinear were excluded as they were redundant for the model. 
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3.5 Structural Equation Modelling (SEM)  
After the candidate factors were selected, they were used in the different SE 
models developed. The data from these variables were imported to AMOS via 
an SPSS database, as opposed to using a matrix correlation. This data format 
provided more flexibility in the range of analytical tests that could be applied, 
such as the use of bootstrapping technique.    
An initial model was applied and the SE models were assessed using a series 
of “fit” statistics summarised in Table 3.6 These statistics consist of Chi-Square 
(χ2), Goodness of Fit Index (GFI), Comparative Fit Index (CFI) and Root Mean-
Square Error of Approximation (RMSEA). The χ2 measures the fit between the 
expected model and the data collected. A significant test indicates that there is 
a discrepancy between the expected model and the observed data, while a 
non-significant test indicates a good fit. The GFI measures the variance and 
covariance present in the data and the model being tested. Values for this test 
ranges from 0 to 1, any value ≥0.90 are considered an acceptable model fit and 
1 a perfect fit. The CFI compares the existing model fit with an independent 
model /null model, which assumes that the variables in the model are 
uncorrelated. Results between 0.90 and 0.95 are considered a satisfactory fit 
and results >0.95 a good fit [371].  
The RMSEA test is an absolute test, as it does not require a comparison with a 
null model. It is interpreted as the amount of information within the empirical 
covariance matrix that cannot be explained by the proposed model. A good 
model fit is indicated by a result of <0.05 however a result of ≤0.08 still be 
considered an adequate fit, and values >0.10 is an invalid model [375]. Out of 
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the four fit tests, the RMSEA and the CFI are considered the most robust, as 
they are least affected by sample size. 
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 Statistical test Interpretation Fit Test Criteria Affected by sample size 
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Chi-Square (χ2) Measures the fit between the 
expected model and the data 
collected 
Non significant χ2 Difficulty in achieving non-
significance in large sample size, 
as small deviations are labelled as 
significant  
Root Mean-Square 
Error off 
Approximation 
(RMSEA). 
Assessed the amount of information 
within the empirical covariance 
matrix that cannot be explained by 
the proposed model 
Good fit<0.05  
Adequate fit ≤0.08  
Invalid model >0.10  
Is one of the tests least affected by 
sample size It is considered a 
robust test  
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Goodness of Fit 
Index (GFI), 
Measures the variance and 
covariance present in the data and 
the model being tested 
Good fit >0.95 
Adequate fit ≥0.90  
Invalid model <0.90 
When degrees of freedom are 
large relative to sample size, GFI is 
biased downward unless the 
number of parameters is also very 
large  
Comparative Fit 
Index (CFI) 
Compares the existing model fit with 
an independent model /null model, 
which assumes that the variables in 
the model are uncorrelated 
Good fit >0.95  
Adequate fit 0.90 - 0.95 
Invalid model <0.90 
Is a robust test in relatively small 
samples 
      Table 3.6 Summary table of fit statistics used in Structural Equation Model 
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To build the SEM model a series of iterative steps were undertaken: 
1. The model was generated   
2. The output notes generated by the model were assessed to check that 
the assumptions had been met. 
3. The fit statistics were assessed to check whether the model had a good 
fit. 
4. The diagnostic information was assessed to see whether the model 
could be improved:  
a. The regression weights showed whether the relationships 
between variables were significant. Non-significant (p=>0.05) 
paths were removed; commencing with those that had highest 
values.  
b. The modification indices suggested any modifications that would 
improve the model. The modifications were undertaken in a 
hierarchical fashion, the relationships with the highest modification 
indices were included first.  
c. The standardised residuals covariance matrices were checked 
and any value ≥ 2.50 indicated that the relationships were not well 
captured by the model. Thus, a new relationship between the two 
variables suggested was added to the model.  
5. After each modification was made to the model, the model was re-
evaluated by checking the fit statistics and model diagnostics.  
All the modifications suggested by the model were made, applying the 
theoretical construct as opposed to blindly using the modifications that the 
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model diagnosis suggested. Thus any modification suggested that was not 
clinically sound was not included. 
This process was repeated until the optimal model was produced.  
The methods chapter has described the three methodologies used in this thesis 
i.e literature review, the case-control cross-sectional study and the Structural 
Equation Modelling. These varied methodologies allowed to achieve the three 
study’s objectives: i) the identification of the potential candidate factor that 
influenced foot pathology in SSc; ii) the investigation of the candidate factors 
that contributed to foot pathology and exploration of their impact; ii) and the 
exploration of the multifactorial pathways in foot pathology and its impact on 
quality of life. Results from this study are described in Chapter Four.  
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Chapter 4                                                         
Results 
4.1 Overview  
This chapter presents the results of the studies that explore the multifactorial 
pathways contributing to the development and impact of foot problems in 
systemic sclerosis (SSc). The aim of this thesis was to identify the factors that 
contribute to the development and impact of foot problems in patients with SSc. 
To achieve this aim, we identified three objectives: first, to identify possible 
factors that may have an impact on or are associated with foot problems; 
second to investigate the candidate factors that contribute to foot pathology and 
explore their impact; and third, to explore the relationship between factors that 
contribute to foot problems and their impact on the quality of life of patients with 
SSc. The objectives were met by using clinical and statistical methods as 
outlined in chapter three and presented in Table 4.1 
Table 4.1 Summary table of the thesis’ objectives and methodological approaches 
Phase Objectives Summary of Methodological Approach 
1 
To identify the potential 
candidate factors that may 
influence foot pathology in SSc 
Review of literature 
Consultation with experts 
2 
To investigate the candidate 
factors that contribute to foot 
pathology and explore their 
impact 
Cross-sectional study comparing patients 
with scleroderma and healthy participants 
3 
To explore the multifactorial 
pathways in foot pathology and 
its impact on quality of life 
Structural equation modelling exploring 
the pathways that contribute to foot 
function impairment, foot pain, and their 
impact on the quality of life of patients 
with SSc 
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4.2 Phase One: Identification of potential candidate factors.  
The potential candidate factors that may contribute to foot problems were 
identified through published literature and a consultation with two clinical 
experts: a podiatrist and a consultant rheumatologist, both of whom, specialise 
in SSc. Several databases, including Embase and Embase Classic (1947 to 
2010), Ovid MEDLINE(R) (1946 to 2010), Allied and Complementary Medicine 
(1985 to 2010) Science Direct (1995 to 2010) and PubMed.gov (1920 to 2010) 
were searched for terms related to SSc and the foot and SSc pathology, 
including foot pathology, gait parameter, vasculopathy, neuropathy, 
musculoskeletal involvement, skin fibrosis and variations thereof. The search 
provided with a list of the potential candidate factors (Table 4.2), which were 
then reviewed through consultation with the two clinical experts. The experts 
were then asked to identify candidate factors that met the following criteria: 
(i) Factors that were of relevance to the clinical pathology that patients 
with SSc commonly present with; 
(ii) Factors that were considerate of the pathophysiological mechanisms 
that underlay the disease that potentially contributed to the 
development and/or impact of foot problems, and  
(iii) Factors that when tested for posed no great burden or discomfort on 
the patient. 
The consultation provided the identification of physical and physiological 
potential candidate factors, the former affecting the integumentary, vascular, 
neurological and musculoskeletal systems. A summary of the potential 
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candidate factors is present in Table 4.2 and a description of the test and 
methods used to assess these factors is present in Chapter 3 
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Physical, psychological 
and psychosocial 
categories 
Original selection of the potential candidate 
factors considered prior to the experts 
consultation 
Potential candidate factors selected in phase 1 
Systems explored    
Integumentary Skin fibrosis Skin fibrosis 
Integumentary* Soft-tissue calcification Number of current and past calcium deposits 
Integumentary/ vascular  Ulcerations Number of current and past ulcerations 
Integumentary Changes in skin pigmentation  Not selected  
Integumentary Changes in skin hydration Not selected  
Nails Nail pathology Not selected  
Vascular Raynaud's phenomenon Raynaud’s phenomenon 
Vascular Peripheral arterial obstructive disease  Presence and severity of peripheral arterial disease 
Vascular Microvascular disease  Blood changes in the microvascular bed of the toes 
Vascular Vascular calcification No selected 
Neurological  Peripheral nerve dysfunction  Small and large fibre peripheral neuropathy  
Neurological  Mononeuropathy  Not selected  
Neurological  Autonomic neuropathy Not selected  
MSK Abnormal plantar foot pressures Abnormal plantar foot pressures 
MSK Abnormal pattern in gait and foot function Abnormal pattern in gait and foot function 
MSK Subcutaneous and fat-pad atrophy Soft-tissue thickness  
MSK Erosions  Not selected  
MSK Osteopenia Not selected  
MSK Osteomalacia Not selected  
MSK Bone demineralisation Not selected  
MSK Juxta-articular osteoporosis Not selected  
MSK Calcaneal spurs Not selected  
MSK Arthritis Not selected  
MSK Joint space narrowing Not selected  
MSK Joint cystic lesions  Not selected  
MSK Acro-osteolysis  Not selected  
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Physical, psychological 
and psychosocial 
categories 
Original selection of the potential candidate 
factors considered prior to the experts 
consultation 
Potential candidate factors selected in phase 1 
MSK Periarticular fibrosis Not selected  
MSK Flexion contractures of the toes  Not selected  
MSK Friction rubs  Not selected  
MSK Tendonitis Not selected  
MSK Joint subluxation Not selected  
MSK Muscle weakness and atrophy Not selected  
PROMs  
  
Psychological  Symptom severity and of anxiety and depression Symptom severity and of anxiety and depression 
Physical/ Psychosocial 
Health related QoL- Patient’s perceived general 
health status  
Health related QoL  
Psychosocial 
Needs-base QoL- Disease impact on health and 
well-being 
Needs-base quality of life  
Physical  
Disease specific health status, assessing 
functional limitations, general and organ-specific 
symptoms 
Disease specific health status, by assessing 
functional limitations general and organ-specific 
symptoms 
Physical/ Psychosocial Activity related foot and ankle disability and pain. Activity related foot and ankle disability and pain. 
Physical/ Psychosocial 
Raynaud’s attacks activity  
Raynaud’s attacks impact 
Raynaud’s attacks activity  
Raynaud’s attacks impact 
Table 4.2 Summary of the potential candidate factors selected from the literature and through experts’ consultation. PROMs: patient 
reported outcomes measures; QoL: quality of life  
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4.3 Phase Two: Investigation of the candidate factors that 
contribute to foot pathology and exploration of its impact 
The results described in this section are the results obtained from the case-
control cross-sectional study, where the outcomes of the detailed clinical 
assessments of the lower limb and the PROMs were compared between 
patients with SS and healthy participants. The results from this phase helped 
inform which of the candidate factors were selected for the structural equation 
modelling. 
 Participant profile  4.3.1
In order to understand the prevalence and impact of foot pathology in SSc, 174 
participants were recruited from February 2011 to February 2013, from the 
Connective Tissue Disease Clinic at the Rheumatology Outpatients Department 
in Chapel Allerton Hospital, Leeds Teaching Hospitals NHS Trust.  Of the 174 
participants, 122 were patients with SSc and 52 were healthy volunteers. Two 
participants were withdrawn from the study: one SSc patient as a result of 
misdiagnosis and one healthy participant because shortly after recruitment he 
disclosed that he was in remission from an autoimmune inflammatory disease 
From the remaining 172 participants, 121 were patients with SSc and 51 
healthy participants. Participant details are included in Table 4.3. The majority 
of the participants were northern-European. Ethnic diversity was limited in the 
study despite recruitment being done in an area that over-represents ethnic 
minorities in comparison to the national average. In the patient group, there 
  140
were more female participants, which reflects the higher female to male ratio 
characteristic of the disease (mean ratio of 3:1 [16]). In terms of specific disease 
subtypes, 96 (79%) patients had lcSSc while 24 (20%) had dcSSc and only 1 
(0.8%) had SSc sine scleroderma. 
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Characteristics 
Patients with SSc 
n=121 
Healthy participants 
n=51 
Age (years)*  57 (12.3) 50 (14.4) 
Male /Female; n  15/106 8/43 
Ethnicity; n (%):   
White British  102 (84%) 38 (74%) 
White Irish  2 (1.7%) 0 
White other  5 (4%) 3 (6%) 
Indian  6 (5%) 4 (7.8%) 
Pakistani 5 (4%) 0 
White and black Caribbean 0 1 (2%) 
Caribbean 0 1 (2%) 
African 0 2 (3.9%) 
Other ethnic group  1 (0.8%) 2 (3.9%) 
BMI (Kg/m
2
)* 26.29 (5.6) 25.45 (3.9) 
Smoking status; n (%)   
Current smoker  15 (12.9%) 5 (10.2%) 
Ex-smoker  41 (35%) 14 (29%) 
Never smoked  75 (65%) 35 (71%) 
Pack years**  12.50 (6.8 to 23.2) 13 (4 to 35) 
Number of comorbidities * 4.65 (2.4) 1.04 (1.4) 
Disease duration (years)* 9.50 (7.4) n/a 
Disease subtype; n (%)  n/a 
Limited SSc  96 (79%) n/a 
Diffuse SSc  24 (20%) n/a 
SSc sine Scleroderma  1 (0.8%) n/a 
 mRSS** 2 (0 to 5) n/a 
Number of patients with current or past history of 
ulcers  
59 (49%) n/a 
N
o
 of patients with current ulcers 18 (15%) n/a 
Number of patients with current or past history of 
calcium deposits  
57 (48%) n/a 
N
o
 of patients with current calcium deposits 39 (32%) n/a 
Number of medication  7.29 (4%) 1.27 (1.8) 
Immunosuppressant: n (%) 29 (24%) 0 
      Methotrexate 26 (21%) 0 
Mycophenolate Mofetil 3 (2.5%) 0 
Pulse Cyclophophamide 0 0 
Hydroxychloroquine 0 0 
Steroids 26 (21%) 0 
Calcium channel blockers  65 (54%) 2 (4%) 
ACE inhibitors  48 (40%) 4 (8%) 
Beta-Blockers 4 (3%) 4 (8%) 
Bosentan  3 (2.5%) 0 
Sildenafil  6 (5%) 0 
Iloprost (within 3 month prior to the study) 22 (18%) 0 
Other medications unclassified  5.47 (3.5) 1.02 (1.54) 
Table 4.3: Demographic characteristics of the study participants. * Mean (Standard deviation); ** 
Median (interquartile Range); BMI: Body Mass Index; mRSS Modified Rodnan Skin Score 
  142
 Missing data 4.3.2
Overall there was a very small amount of missing data. Out of a total of 51 
variables across all participants, there were only missing data from six individual 
variables, of which 16 values (0.18%) were missing from 11 participants. From 
these 11 participants, 9 were patients with SSc from whom 14 (0.22%) values 
were missing.  
4.3.2.1 Detailed clinical assessments of the lower limb 
The results obtained from the clinical assessments were analysed using 
exploratory statistics to identify the clinical factors that had the potential to 
differentiate between patients with SSc and healthy participants. The results are 
grouped in sections according to the system being assessed.  
4.3.2.1.1 Integumentary system  
The disease specific mRSS was described using summary statistics and 
description of the median and the interquartile range. The skin involvement in 
this SSc cohort was relatively mild as the median mRSS score was 2/51.  
mRSS scores were not derived for the controls and so no direct comparisons 
are presented (Table 4.4). 
Variables 
Patients 
with SSc 
n=121 
Healthy 
participants 
n=51 
Test 
statistics 
P value 
 
Effect 
size 
mRSS** 
(Score range 0-51) 
2 (0 to 5) n/a n/a n/a n/a 
Table 4.4: Integumentary tests statistical analysis summary.** Median (interquartile 
Range); mRSS Modified Rodnand Skin Score 
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4.3.2.1.2 Vascular system  
The median ABPI values were normal for both groups. The SSc group had a 
median ABPI of 1.10 vs a median of 1.13 observed in the healthy participants 
group. The result indicated a between groups median difference in scores of 
0.03. This difference was statistically non-significant but had a small effect size 
(r= 0.11).  Analysis of the dorsalis pedis (DP) and tibialis posterior (TP) arterial 
waveforms showed a statistically significant difference in the proportion of 
participants in each group who had non-detectable/ monophasic arterial 
waveforms and in between group participants having biphasic/triphasic arterial 
waves (Table 4.5). Pearson’s χ2 was also significant indicating the presence of 
an association between SSc and abnormal pathological arterial waveforms. The 
strength of these associations was evaluated using by Cramer’s statistic; which, 
out of a possible maximum score of 1, indicated a medium association of 0.22 
(p=0.005) for DP arterial waves and 0.24 (p=0.001) for TP arterial waves. The 
odds of having non-detectable/monophasic DP arterial waveform was 0.32 with 
exposure to the disease (SSc) and 0.06 without exposure to SSc; with an Odds 
Ratio (OR) of 5.33. For the TP arterial waves the odds of having a non-
detectable/ monophasic wave was 0.21 with exposure to the disease and 0 
without exposure. Due to the odds of having a non-detectable/monophasic TP 
arterial wave for the healthy participants being 0 it was not possible to derive an 
OR for this variable. A summary of all the vascular findings is presented in 
Table 4.5. 
All the assumptions required for the Pearson’s chi-square χ2 were met: 
independence was achieved by each participant only contributes to one cell of 
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the contingency table; the expected frequencies were ≥5 and all expected 
counts were >1 and no more than 20% were <5 [368].  
 
Variables 
Patients 
with SSc 
n=121 
Healthy 
participants 
n=51 
Test 
statistics 
P 
value 
 
Effect 
size 
ABPI** 1.10  
(1.02 to 1.18) 
1.13 
(1.06 to 1.20) 
U = 2632 0.126 r=0.11 
DP arterial waves       
No-detectable and 
monophasic  
30(24.8%) 3(5.9%) χ
2
=8.275 0.005 CS=0.22 
r=0.22 
Biphasic and 
triphasic  
91(75.2%) 48(94.1%) χ
2
=8.275 0.005  
TP arterial waves       
No present and 
monophasic  
21 (17.4%) 0(0.0%) χ
2
=10.082 0.001 CS=0.24 
r=0.24 
Biphasic and 
triphasic  
100(82.6%) 51(100%) χ
2
=10.082 0.001  
Table 4.5: Vascular tests statistical analysis summary.** Median (interquartile Range), 
ABPI: ankle brachial pressure index; Effect size, r=Pearson’s correlation coefficient, r= 0.10 
(small effect), 0.30 (medium effect), 0.50 (large effect).CS: Cremer’s statistics interpreted like 
person’s r[368]. 
 
4.3.2.1.3 Neurological system  
As room temperature and humidity influence the neurological assessments, we 
compared both temperature (degrees Celsius) and humidity (% relative 
humidity) when collecting the data for the two different groups and found that 
conditions were not statistically different. The mean (SD) room temperature 
while collecting data for the SSc patient group was 23o (1.30) and relative 
humidity a mean (SD) 36% (9%), while when collecting data for the healthy 
participants the environmental temperature and humidity was a mean (SD) of 
23o (1.2o) and 36% (9%) respectively.  
All the neurological variables except pain threshold on the dorsum and plantar 
surfaces of the foot were non-normally distributed, therefore the Mann-Whitney 
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non-parametric test for independent samples and the Monte Carlo (2-tailed) 
method to calculate the p-value, was used to analyse data from these variables. 
The details are included in table 4.6 with median (IQR) and mean (SD) values 
as appropriate. When compared to healthy individuals, patients with SSc 
showed a reduced sensation in all tests undertaken. For the von Frey 
monofilament N9 test, patients felt the stimulus in a median of seven out of 
eight sites, while in healthy individuals the median was at all eight sites. This 
difference was statistically significant (p=0.001) and had a medium effect size(r 
=0.28). The patients with SSc also had reduced vibration perception threshold 
compared to healthy participants (1.7 vs 1.29; U = 2257;p= 0.005) with median 
difference of 0.41 microns, and a considerable reduction of heat perception 
threshold on the dorsum of the foot (38.46 vs 37.18; U = 2279; p= 0.006) and 
plantar surface of the foot (39.40 vs 38.75; U = 2432; p= 0.027) with a median 
difference of 1.28oC and 0.65oC respectively. The difference between groups 
for these three variables was statistically significant (p= 0.005; p= 0.006; p= 
0.027 respectively) with small effect size (r =0.21; r =0.21; r =0.17 respectively).  
When testing for cold perception threshold on the dorsal (27.13 vs 28.35; U = 
2130) and plantar surface of the foot (26.91 vs 26.63; U = 22620) a decreased 
perception was identified in both locations with a mean difference of 1.22oC for 
the dorsum and a 0.28oC for the plantar surface. The between-group difference 
in medians for the cold perception threshold on the dorsum of the foot was 
statistically significant (p= 0.001) and had a small to medium effect size (r 
=0.24), while the cold perception threshold on the plantar surface was not 
statistically significant (p= 0.119) with a small effect size (r =0.12).  
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For the normally distributed variables of pain threshold on the dorsum and 
plantar of the foot, the two-sample t-test with bootstrapping was used. The SSc 
patients showed an impaired perception of pain when compared to healthy 
individuals on the dorsal (45.06 vs 43.50; t =3.121) and the plantar surface 
(46.94 vs 46.80; t = 0.221), with a mean difference of 1.56oC for the dorsum 
and 0.14oC for the plantar surface. The mean difference between groups for the 
pain perception threshold on the dorsum of the foot was statistically significant 
(p= 0.008) and had a medium effect size (d=0.48; r =0.23), while for the plantar 
of the foot this difference was non-significant (p= 0.027) and had no effect size 
(d=0.03; r =0.01). Results described in Table 4.6.
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Variables 
Patients with 
SSc 
n=121 
Healthy 
participants 
n=51 
Test 
statistics 
P value 
 
Effect 
size 
Von Frey Monofilament N9 (threshold 7.3gr of 
pressure/mm2, tested in 8 sites of the foot) ** 
7  
(6 to 8) 
8  
(7 to 8) 
U = 2079 0.001 r=-0.28 
Vibration perception threshold (microns)**  1.7 
(0.9 to 4.1) 
1.29 
(0.62 to 2) 
U = 2257 0.005 r=0.21 
Heat perception threshold foot dorsum (OC)** 38.46 
(36.6 to 41.9) 
37.18 
(35.4 to 39.9) 
U = 2279 0.006 r=0.21 
Heat perception threshold foot plantar (OC)**  39.40 
(37.3 to 43.8) 
38.75 
(36.9 to 40.5) 
U = 2432 0.027 r=0.17 
Cold perception threshold foot dorsum (OC)** 27.13 
(24.5 to 28.40) 
28.35 
(26.4 to 39.6) 
U = 2130 0.001 r=0.24 
Cold perception threshold foot plantar (OC) ** 26.91 
(24.6 to 27.8) 
26.63 
(24.2 to 29.1) 
U = 2620 0.119 r=0.12 
Pain threshold foot dorsum (OC)* 45.06 
(2.7) 
43.50 
(2.99) 
t = 3.121 0.008 
d=0.48 
r=0.23 
Pain threshold foot plantar (OC)*  46.94 
(2.49) 
46.80 
(2.52) 
t = 0.221 0.844 
d=0.03 
r=0.01 
Table 4.6: Neurological tests statistical analysis summary. * Mean (Standard deviation); ** Median (interquartile Range); Effect size, 
d= Cohen’s d, 0.20 (small effect), 0.50 (medium effect) and 0.80 (large effect) [376], r=Pearson’s correlation coefficient, r= 0.10 (small 
effect), 0.30 (medium effect), 0.50 (large effect)[368]. 
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4.3.2.1.4 Musculoskeletal system      
All the variables used to assess the musculoskeletal parameters were non-
normally distributed, with the exception of plantar soft-tissue thickness, and 
vertical ground reaction force at push-off. The variables mean force heel, 
hindfoot ROM with regards to shank and forefoot ROM with regards to hindfoot, 
became normally distributed after transformation using log10 or squared root 
transformation (Table 4.7). Non-normally distributed data was analysed using 
the Mann-Whitney test for independent samples and the Monte Carlo (2-tailed) 
method. Where indicated, normally distributed and transformed variables were 
analysed using the two-sample t-test with the bootstrap method. The details are 
included in table 4.7 with median (IQR) and mean (SD) values as appropriate 
Tissue thickness at 3rd MTP joint and heel 
When compared to healthy participants, the SSc patients had a reduced mean 
soft-tissues tissue thickness at the 3rd MTP joint and heel. This might indicate a 
structural change of all or some of the soft-tissues located in these areas and 
could affect the mechanical properties these soft-tissues structures. The 
between groups mean difference was 1mm under the 3rd MTP joint and of 0.06 
mm under the heel. This mean difference was highly statistically significant (t=-
1.289; p=<0.0001), but demonstrated a minimal effect size; as indicated by the 
low values of Cohen’s d (d=0.19) and Pearson’s correlation (r=0.09) 
respectively.  
 
  149
Pressure and force at the 3rd MTP joint and heel, and stance time  
The maximum mean pressure for the 3rd MTP joint and for the heel variables 
yielded a median difference between groups of 20 kilopascals (kPa) (U=2825; 
p=0.374) and 10(kPa) (U=2750; p=0.265). Both differences were not however, 
statistically significant and effect sizes were minimal (r=0.06; r=0.08 
respectively). While excessive plantar pressures can lead to tissue damage as 
commonly see in patients with diabetes [377], reduced plantar pressures might 
be an indicator of reduced foot function, impairing loading of the ROI, or 
increased foot pain, causing avoidance of loading of the specific painful 
joint/area.  
The mean force on the plantar aspect of the 3rd MTP joint and heel were also 
reduced in patients with SSc. The mean force at the 3rd MTP joint yielded a 
median difference between groups of 1.6 N, (U=2418), which was a statistically 
significant difference (p=0.025) with a small effect size (r=0.17). The mean force 
at the plantar of the heel yielded a median difference between groups of 14N 
(t=-4.93p=0.001) and a moderate effect size (d=0.75; r=0.35.). The plantar 
mean forces contribute to the plantar pressures therefore as the force 
decreases the plantar pressures also tend to decrease. A reduction in forces 
might be an indicator of foot pathology, as implied and further explained in 
model one section 4.4.4 .  
The stance time was increased in patients with SSc. The median difference 
between groups for the stance time was of 0.1 second (s), (U=1221, 
p=<0.0001) and had a medium effect size (r=0.48). The vertical ground reaction 
force at heel strike showed a median difference between groups of 0.07N 
(U=1730; p=<0.0001) and a medium size effect (r=0.35). The variable vertical 
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ground reaction force at push-off had a mean difference between groups of 
0.09, (t=-4.30p= <0.0001), and had a size effect close to being considered large 
(d=0.22; r=0.33). The increase stance time and decrease ground reaction 
forces are indicators of reduce biomechanical function of the lower limb and/or 
an antalgic gait, as they imply reduce walking velocity.  
Ranges of motion (ROM) at the hindfoot and forefoot 
Decrease ROM of the hindfoot and forefoot was present in patients with SSc. 
From the three variables selected from the literature to represent ROM of the 
foot “segments” there were two that were statistically significant and yielded a 
small to medium effect size: the ankle ROM variable, which yielded a median 
difference between groups of 3o (U=2142; p=0.003; r=0.24), and the forefoot 
ROM relative to the hindfoot in which there was a median difference between 
groups of 1o (U=-2.972; p=0.003; d= 0.45; r=0.22). The third variable measuring 
hindfoot ROM relative to the shank demonstrated a median difference between 
groups of 1o (U=-1.44), which was not statistically significant (p=0.166) and had 
a small effect size (d= 0.22; r=0.11). Joint range of motion is one of the major 
determinants of function. A decrease range of motion in the hindfoot or forefoot 
can cause foot function impairment. 
It is important to clarify that for the log transformed data the median difference 
between groups is calculated from the raw data while the t-test and the effect 
size test are calculated from the transformed data. A summary of the 
biomechanical results is presented in Table 4.7
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Table 4.7: Musculoskeletal tests statistical analysis summary* Mean (Standard deviation); ** Median (interquartile Range; ROM: range of motion; % 
BW: percentage body weight, s: seconds; Kpa, kilopascals  Effect size, d= Cohen’s d, 0.20 (small effect), 0.50 (medium effect) and 0.80 (large effect), 
r=Pearson’s correlation coefficient, r= 0.10 (small effect), 0.30 (medium effect), 0.50 (large effect) 
Variables 
Patients with SSc 
n=121 
Healthy 
participants 
n=51 
Test 
statistics 
P value Effect size 
Plantar soft-tissue thickness 3rd MTPJ (mm) * 1.08 (0.25) 1.17 (0.17) t = -1.289 <0.0001 
d=0.19 
r=0.09 
Soft-tissue thickness heel (mm) * 1.56 (0.28) 1.62 (0.21) t = -0.884 <0.0001 
d=0.13 
r=0.07 
Max mean pressure 3rd MTPJ (kPa) ** 460 (340 to 577) 480 (370 to 605) U= 2825 0.374 r=0.06 
Max mean pressure heel (kPa) ** 380 (312 to 480) 390 (340 to 495) U=2750 0.265 r=0.08 
Mean force 3rdMTPJ (%BW) ** 30 (24 to 34) 31.6 (26 to 36) U=2418 0.025 r=0.17 
Mean force heel (%BW)** 90 (76 to 100) 104 (93 to 111) 
log10 trans. 
t=-4.930 
0.001 
d=0.75 
r=0.35 
Stance time (s)** 0.7 (0.62 to 0.75) 0.6 (0.55 to 0.62) U=1221 <0.0001 r=0.48 
Vertical ground reaction force at heel strike 
(%BW) ** 
1.02 (1 to 1.08) 
1.09 (1.05 to 
1.16) 
U= 1730 <0.0001 r=0.35 
Vertical ground reaction force at push-off  
(%BW) * 
1.02 (0.10) 1.11 (0.06) t= -4.30 <0.0001 
d=0.72 
r=0.33 
Ankle ROM (o)** 22 (20 to 25) 25 (20 to 27) U=2142 0.003 r=0.24 
Hindfoot ROM with regards to shank (o)** 9 (7 to 11) 10 (7 to 12) 
SQRT 
trans. 
t= -1.446 
0.166 
d=0.22 
r=0.11 
Forefoot ROM with regards to hindfoot (o)** 13 (10 to 15.2) 14 (12 to 17) 
log10 trans. 
t=-2.972 
0.003 
d=0.45 
r=0.22 
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 Exploration of the impact of SSc  4.3.3
The impact across a range of dimensions was captured by six PROMs as 
described in Chapter 3: the SF-36, the HADS, SSc HAQ, SSc QoL, RCS and 
the MFPDI. The RCS was removed from the analysis however, following 
concerns over data quality as patients struggled to answer the questions, 
reporting that it was difficult to remember how many Raynaud’s attacks they 
had on the day and how long they lasted. For example one of the patients said 
that she felt like “the Raynaud’s was constantly on”.  
Each of the PROMs provided numeric scores that could be used to quantify 
relevant dimensions of impact. As described in Chapter 3, the scores from the 
generic PROMs i.e. SF-36, HADS and MFPDI were compared between groups, 
by conducting formal statistical tests of difference. The Mann-Whitney test for 
independent samples and the independent t-test were used to compare healthy 
participants with patients with scleroderma; the p-values were calculated using 
the Monte Carlo (2-tailed) method or the bootstrap methods to obtain more 
robust results.  A summary of the results is presented in Table 4.8. 
4.3.3.1 Physical impact  
Not surprisingly, patients with SSc reported greater physical disability than 
healthy participants. The SF-36 summary physical score indicated highly 
significant function impairment in patients with SSc when compared to healthy 
participants (median 30 vs 56; U=532; p=<0.0001). The variables 
encompassing physical disability in the SF-36, showed that physical functioning 
(median 29 vs 55; U=532; p=<0.0001) and role limitations because of physical 
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health (median 28 vs 56; U=825; p=<0.0001) was nearly double in the SSc 
patients compared to the healthy participants. The SSc patient group also 
reported significantly worse bodily pain (median 37 vs 56; U=784; p=<0.0001), 
vitality (median 42 vs 58; U=603; p=<0.0001) and over all worse general health 
(median 33 vs 55; U=417; p=<0.0001).  
The physical impairment captured by the SF-36 was reflected in the functional 
ability that the patients reported in undertaking daily tasks. This was revealed in 
the results of the SSc HAQ scores (median 1.25; IQR= 0.37 to 2), which 
indicate that the majority of the patients had between "some difficulty" and 
"much difficulty" in undertaking basic daily-tasks, demonstrating a substantial 
negative impact on overall functional ability.   
The SSc-HAQ also included several visual analogue scales which captured the 
interference of some disease symptoms and/or pathology in the patients' daily 
activities: the results varied from indicating very low interference associated with 
the digital ulcers VAS (median 0.1; IQR= 0 to 5) to an increase interference with 
GI problems, breathing problems and pain (medians ranging from 3 to 5); with 
the highest interference being caused by Raynaud’s (medians 5; IQR= 1 to 7). 
While SSc HAQ scores concurred with the poor general health scores captured 
by the SF-36, the patients reported a relatively high overall disease severity 
(medians 5; IQR= 1 to 7 and 2 to 7). In addition to the general physical 
disability, patients with SSc reported foot related disability using the MFPDI. 
They reported significant problems with their foot function compared to healthy 
controls (11 vs 0; U=617; p=<0.0001) and much greater foot pain than the 
controls (5 vs 0; U=827; p=<0.0001). 
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4.3.3.2 Psychological and psychosocial Impact  
Even though impact on the psychological well-being was not as severe as the 
impact on physical disability, a psychological impact was reported by patients 
with SSc. The SF-36 mental health summary score indicated a highly significant 
difference in scores between patients with SSc and healthy participants (46 vs 
56; U=1741; p=<0.0001). Psychological distress was increased in patients with 
SSc contributing to reduced psychological well-being, and a lower score in the 
general mental health variable (45 vs 55; U = 1727; p=<0.0001). In addition, 
patients also reported role limitations because of emotional problems (44 vs 55; 
U = 1501; p=<0.0001). 
Compared with our healthy volunteers, patients with SSc demonstrated 
significantly worse scores for both the anxiety (8 vs 4; U = 934; p=<0.0001) and 
depression (6 vs 1; U = 934; p=<0.0001) elements of the HADS. This 
programme of work found that levels of anxiety and depression were 
disturbingly prominent; with anxiety scores being twice as high and depression 
scores being five times higher than in healthy participants.  
The reduced psychological well-being in patients with SSc seemed to contribute 
to an impact at the broader psychosocial level. The SF-36 scores for social 
functioning demonstrated that the disease interfered with social functioning (41 
vs 57; U = 1061; p=<0.0001) and with health related QoL The impact on the 
patients' quality of life and psychosocial impairment was also captured by the 
needs-base SSc QoL, which results indicated that the patients’ quality of life 
was affected to a considerable level, as the overall mean (15; SD= 9) score 
reported was higher than halve of the maximum score.  
  155
 
Table 4.8: PROMs statistical analysis summary.* Mean (Standard deviation); ** Median (interquartile Range); VAS, visual analog scale; DU, digital ulcers; 
GI, gastrointestinal; Effect size, d= Cohen’s d, 0.20(small effect), 0.50 (medium effect) and 0.80(large effect), r=Pearson’s correlation coefficient, r= 0.10 (small 
effect), 0.30 (medium effect), 0.50 (large effect) 
Variables 
Patients with SSc 
n=121 
Healthy participants 
n=51 
Test 
statistics 
P value 
Effect 
size 
SF-36 physical functioning (NBS)** (Score range 0-
100) 
29 (19 to 44)  55 (53 to 57) U = 532 <0.0001 r=0.65 
SF-36 role physical (NBS) (Score range 0-100) ** 28 (28 to 49)  56 (56 to 56) U = 825 <0.0001 r=0.62 
SF-36 bodily pain (NBS) (Score range 0-100) ** 37 (29 to 46)  56 (51 to 63) U = 784 <0.0001 r=0.59 
SF-36 general health (NBS) (Score range 0-100) ** 33 (24 to 43) 55 (53 to 60) U =417 <0.0001 r=0.68 
SF-36 vitality (NBS) (Score range 0-100)** 42 (32 to 51) 58 (56 to 63) U = 603 <0.0001 r=0.63 
SF-36 social functioning (NBS) (Score range 0-100) ** 41 (30 to 52) 57 (51 to 57) U = 1061 <0.0001 r=0.52 
SF-36 role emotional (NBS) (Score range 0-100)** 44 (24 to 55) 55 (55 to 55) U = 1501 <0.0001 r=0.44 
Sf-36 mental health (NBS) (Score range 0-100) ** 45 (37 to 54) 55 (50 to 59) U = 1727 <0.0001 r=0.34 
SF-36 summary physical (Score range 0-100) ** 30 (24 to 41) 56 (54 to 59) U = 429 <0.0001 r=0.68 
SF-36 summary mental health (Score range 0-100)** 46 (36 to 56) 56 (53 to 58) U = 1741 <0.0001 r=0.34 
HADS anxiety (Score range 0-21) ** 8 (4.49) 4.57 (3.59) t = 4.832 <0.0001 d=0.74 
r=0.35 
HADS depression (Score range 0-21) ** 6 (2 to 9) 1 (0 to 2) U = 934 <0.0001 r=0.55 
MFPDI function (Score range 0- 20) ** 11 (4 to 16) 0 (0 to 0) U = 617 <0.0001 r=0.65 
MFPDI pain (Score range 0-10) ** 5 (2 to 7) 0 (0 to 0) U = 827 <0.0001 r=0.59 
SSc HAQ (Score range 0-3) ** 1.25 (0.37 to 2) n/a n/a n/a n/a 
SSc QoL (Score range 0-29)* 15 (9) n/a n/a n/a n/a 
VAS Pain (Score range 0-10) ** 4 (2 to 7) n/a n/a n/a n/a 
VAS Raynaud’s interference (Score range 0-10) ** 5 (1 to 7) n/a n/a n/a n/a 
VAS DU interference (Score range 0-10) ** 0.1 (0 to 5) n/a n/a n/a n/a 
VAS GI problems (Score range 0-10) ** 3 (0.1 to 6) n/a n/a n/a n/a 
VAS Breathing problems (Score range 0-10) ** 3 (0.3 to 7) n/a n/a n/a n/a 
VAS Overall disease severity (Score range 0-10) ** 5 (2 to 7) n/a n/a n/a n/a 
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4.4 Phase Three: Multifactorial pathways  
This section presents the results of the analyses that were undertaken to 
explore the pathways of foot pathology and disease influences on quality of life 
in patients with SSc. Using the candidate factors identified in Phase two 
(Section 4.3), in phase three we explored the influences of these factors on foot 
pathology and quality of life using models defined a-priori, and based on ICF 
framework.  As described in Chapter 3, the data was explored first using 
exploratory analyses and the regression modelling and then tested using 
structural equation modelling (SEM). This study describes the relationships 
between quality of life and personal factors, physical and psychological 
impairment, factors associated with SSc and psychosocial factors using SEM, 
which explicitly tests the hypothesis of the thesis. 
 Participant profile 4.4.1
Data for the SEM were collected in Phase two of this programme of work and 
only included the 121 patients with SSc.  Demographics and patient 
characteristics have been presented previously in Table 4.3. All data were 
explored and checked for distribution and presence of outliers. Data for each 
individual were checked and outliers were removed, as required for SEM.  Of 
note, there was no missing data in those variables entered for the SEM so all 
121 patients were included in the final analysis. 
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 Preparation of the Data 4.4.2
The variables considered to be potential candidate factors after phases 1 and 2 
were explored for normality through graphical and statistical methods. 
Graphically a histogram and box-plot was plotted for each variable, and a test of 
significance of skewness and kurtosis was conducted. The results from the 
skewness and kurtosis tests indicated that out of 44 variables which were 
potential candidate factors, only 8 were normally distributed: age, number of 
comorbidities, HADS anxiety, plantar soft-tissue thickness 3rd MTPJ, soft-tissue 
thickness heel, pain threshold foot dorsum, pain threshold foot plantar and 
vertical ground reaction force at push-off. However, all statistical tests for 
normality are based on null hypothesis significance testing, meaning that in 
large samples they can reach significance even for small and unimportant 
effects while in small samples they lack the power to detect important effects. 
For larger sample sizes (i.e. n= ≥ 30 or in some cases 100) the test for 
normality can be avoided by applying the central limit theorem. This theorem 
indicates that in some situations we can assume normality independently of the 
shape of the data [368]. This central limit theorem is justifiable in relation to 
these study data as the sample for this study was 121 patients with SSc and 50 
healthy individuals. 
In the multiple regression models the central limit theorem was taken into 
consideration in addition to the bootstrap procedure. 
However, for the exploratory analysis between groups, a more conservative 
approach was taken when selecting the statistical tests and non-parametric 
tests were used to analyse the non-normal distributed variables. 
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Collinearity was assessed as described in section 3.4.4.1. Only three of the 44 
variables that were potential candidate factors for the SEM had a Spearman’s 
rho (rs)value above 0.80. The collinearity existed between the variable QoL and 
HADS depression ( rs= 0.84) and QoL and HAQ DI ( rs= 0.81).  
While values of above 0.8 can be deleted from analyses, these correlations 
were considered borderline as the theoretical construct is that these variables 
are not directly measuring the same underlying construct but because quality of 
life is highly affected by depression and impaired function. Consequently, HADS 
depression and HAQ DI were not excluded from SE model. Correlations are 
present on Figure 4.1.   
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        Figure 4.1 Correlation matrix for the SEM candidate factors. All values are Spearman’s rho. Variables with a rs value above 0.80 are highlighted  
rowtype_ varname_ Age Gender BMI Diagnosis Dise. Dura. N. comor. Pack years mRSS N. ulcers N. calcium Tis. thick. 3rd Tis. thick Heel M.M.Press.3rd M.M.Press. Heel M.Forc.3rd M.Forc.Heel Stance Time VGRF Heel-strike VGRF push-off Ankle Hindfoot-Shank Forefoot-Hindfoot  ABPI DP Art.Wav TP Art.Wav  Monofil.N9 Vibration Heat dorsum Heat plantar Cold dorsum Cold plantar Pain dorsum Pain plantar  Anxiety  Depression VAS Pain VAS Internal VAS Breathing VAS Raynaud's VAS Du  VAS Dis. Sev. HAQ-DI SSc-QoL MFPDI Funct. 
n 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121 121
corr Age 1
corr Gender 0.173 1
corr BMI -0.062 -0.013 1
corr Diagnosis -0.245 -0.115 -0.068 1
corr Disease duration 0.039 0.147 -0.244 -0.065 1
corr Number of comorbidities 0.213 0.144 0.104 -0.12 0.15 1
corr Pack years 0.238 -0.15 -0.103 -0.167 -0.023 0.231 1
corr mRSS -0.12 -0.102 -0.185 0.369 0.147 -0.031 -0.121 1
corr Number of current ulcers -0.109 0.024 -0.159 0.125 0.176 0.082 0.059 0.203 1
corr Number of current calcium deposits 0.014 0.139 -0.11 0.025 0.176 0.007 0.024 0.237 0.263 1
corr Soft-tissue thickness 3rd MTPJ plantar -0.092 -0.239 0.217 -0.18 -0.34 -0.137 -0.021 -0.177 -0.127 -0.208 1
corr Soft-tissue thickness Heel -0.145 -0.186 0.479 -0.094 -0.306 -0.132 -0.078 -0.237 -0.342 -0.256 0.441 1
corr MAX Mean Pressure 3rd MTPJ 0.016 0.026 0.178 -0.155 0.194 -0.004 -0.074 -0.09 -0.086 -0.038 -0.427 -0.034 1
corr Max Mean Pressure Heel -0.183 -0.169 -0.003 0.045 0.233 -0.189 -0.108 0.166 0.139 0.039 -0.161 -0.258 0.223 1
corr Mean Force 3rd MTPJ -0.026 -0.079 -0.192 -0.165 0.072 -0.032 0.12 -0.034 -0.044 -0.115 -0.089 -0.051 0.496 0.07 1
corr Mean Force  Heel -0.207 -0.261 -0.28 -0.094 0.047 -0.313 -0.132 -0.008 0.025 -0.135 0.153 0.064 0.053 0.565 0.329 1
corr Stance Time V3D 0.244 -0.02 0.269 0.034 0.01 0.278 0.283 -0.111 0.068 0.054 -0.071 -0.058 -0.056 -0.234 -0.271 -0.579 1
corr Vertical Ground Reaction Force 1 -0.205 -0.105 -0.388 -0.004 -0.137 -0.303 -0.003 0.023 -0.013 -0.086 0.053 0.029 -0.076 0.133 0.234 0.516 -0.659 1
corr Vertical Ground Reaction Force 3 -0.014 -0.001 -0.433 -0.093 -0.037 -0.324 -0.033 0.059 -0.089 -0.017 0.137 -0.071 -0.057 0.119 0.286 0.438 -0.577 0.611 1
corr Ankle Range of Motion -0.11 0.073 -0.048 -0.098 0.117 -0.134 -0.089 -0.088 0.018 0.044 0.219 0.126 -0.117 0.079 0.089 0.174 -0.048 0.115 0.165 1
corr Hindfoot with regards to Shank ROM -0.154 0.078 0.095 -0.228 -0.067 -0.054 0.021 -0.303 -0.18 -0.051 0.179 0.216 0.027 -0.214 0.123 -0.01 -0.129 0.025 -0.009 0.185 1
corr Forefoot with regards to Hindfoot ROM -0.072 0.205 -0.059 -0.12 0.006 -0.223 -0.07 -0.148 0.025 0.09 0.008 -0.016 0.062 0.006 0.071 0.073 -0.167 0.069 0.193 0.424 0.307 1
corr Ankle brachial pressure -0.089 -0.114 0.071 0.078 0.012 -0.066 -0.055 -0.104 -0.163 -0.045 0.064 0.051 0.014 0.157 0.119 0.086 -0.148 0.027 0.086 -0.011 -0.053 0.042 1
corr DP Arterial Waves 0.067 -0.1 0.198 0.105 -0.219 -0.069 -0.008 -0.154 -0.256 -0.084 -0.035 0.102 0.147 0.086 0.05 0.047 -0.05 -0.084 -0.079 -0.018 0.144 0.059 0.168 1
corr TP Arterial Waves -0.094 -0.04 0.216 0.127 -0.103 -0.028 -0.246 -0.057 -0.116 -0.252 0.083 0.097 -0.036 0.235 0.016 0.117 -0.075 -0.05 -0.047 -0.038 -0.006 -0.029 0.367 0.293 1
corr Von Frey Monofilaments N9 -0.308 0.044 -0.054 0.064 -0.093 0.064 -0.163 0.123 0.122 0.085 -0.091 -0.044 0.227 0.142 0.26 0.187 -0.329 0.118 0.13 0.049 0.076 0.107 0.147 0.116 -0.07 1
corr Vibration perception threshold 0.463 -0.064 0.015 -0.163 -0.057 0.124 0.299 -0.23 -0.083 0.017 0.036 -0.085 -0.106 -0.059 -0.069 -0.133 0.25 -0.072 -0.081 -0.116 -0.046 0.011 -0.015 0.105 0.058 -0.354 1
corr Heat perception thresholddorsum of the foot 0.23 -0.134 0.012 -0.002 0.127 0.112 0.273 -0.116 0.078 0.054 -0.008 -0.113 -0.103 -0.041 -0.095 -0.155 0.351 -0.147 -0.177 -0.041 -0.064 -0.126 -0.028 -0.088 0.058 -0.396 0.256 1
corr Heat perception threshold plantar of the foot 0.05 -0.157 0.036 0.046 0.19 0.2 0.249 -0.061 0.024 -0.008 -0.05 0.007 -0.016 0.034 -0.121 -0.097 0.31 -0.048 -0.195 0.004 -0.048 -0.265 -0.052 -0.153 0.027 -0.321 0.138 0.628 1
corr Cold perception threshold dorsum of the foot -0.241 0.055 0.129 0.043 -0.033 -0.066 -0.206 0.019 0.044 0.055 0.098 0.15 0.036 0.129 0.032 0.117 -0.247 0.053 0.127 0.187 0.056 0.2 0 0.132 0.041 0.251 -0.227 -0.432 -0.327 1
corr Cold perception threshold  plantar of the foot 0.084 0.097 0.023 -0.033 -0.078 0.077 0.032 -0.004 -0.008 0.018 -0.003 -0.073 0.113 -0.078 0.121 -0.097 -0.123 -0.136 0.101 -0.009 -0.04 0.188 -0.048 0.015 -0.059 0.139 -0.058 -0.296 -0.494 0.362 1
corr Pain threshold dorsum of the foot 0.092 0.022 -0.05 -0.122 0.165 0.004 0.032 -0.176 -0.034 0.064 -0.041 -0.064 -0.042 -0.06 -0.037 -0.029 0.111 -0.041 -0.039 0.029 0.017 -0.031 -0.038 -0.14 -0.056 -0.259 0.188 0.447 0.38 -0.205 -0.192 1
corr Pain threshold plantar of the foot -0.209 -0.114 0.198 0.057 0.032 -0.025 -0.01 -0.079 -0.032 0.031 0.218 0.159 -0.1 -0.007 -0.145 0.008 0.066 0.032 -0.108 0.206 0.055 -0.1 0.053 -0.06 0.06 -0.178 0.038 0.193 0.456 0.05 -0.297 0.343 1
corr HADS- Anxiety Score 0.01 0 0.199 -0.026 -0.107 0.327 0.019 -0.186 -0.086 -0.111 0.041 0.119 0.017 -0.178 -0.032 -0.204 0.227 -0.079 -0.309 -0.043 0.08 -0.04 0.129 0.071 0.107 0.043 0.094 0.098 0.161 -0.131 -0.086 0.088 0.064 1
corr HADS- Depression Score 0.038 -0.102 0.217 0.107 -0.048 0.418 0.2 -0.054 0.051 -0.037 0.007 -0.058 -0.101 -0.148 -0.121 -0.38 0.391 -0.274 -0.43 -0.224 -0.06 -0.175 -0.025 0.021 0.067 -0.05 0.24 0.192 0.169 -0.165 0.005 0.11 -0.002 0.683 1
corr VAS Pain -0.098 0.02 0.113 0.042 0.079 0.21 0.116 0.002 0.178 0.057 0.008 -0.045 -0.103 0.008 -0.232 -0.278 0.32 -0.249 -0.355 -0.043 -0.194 -0.145 0.078 -0.102 0.003 -0.038 0.06 0.202 0.238 0.007 0.062 0.125 0.155 0.305 0.496 1
corr VAS Internal Problems Interference 0.045 0.023 0.171 -0.036 0.106 0.365 0.13 -0.031 0.074 0.141 -0.059 0.115 -0.112 -0.135 -0.234 -0.263 0.288 -0.237 -0.335 -0.165 -0.037 -0.153 0.032 -0.048 -0.108 -0.064 0.049 0.112 0.278 -0.065 -0.178 0.081 0.125 0.388 0.412 0.501 1
corr VAS Breathing Problems Interference 0.114 -0.122 0.136 0.121 0.014 0.254 0.202 0.062 0.102 -0.025 0.062 -0.053 -0.115 -0.08 -0.151 -0.259 0.374 -0.287 -0.279 -0.034 -0.124 -0.12 0.049 0.063 0.062 -0.09 0.03 0.11 0.175 -0.104 -0.074 -0.011 0.07 0.263 0.418 0.436 0.387 1
corr VAS Raynaud's Interference -0.228 -0.11 -0.076 0.141 0.095 0.129 -0.014 0.124 0.217 0.119 0.03 -0.058 -0.23 -0.075 -0.198 -0.154 0.187 -0.048 -0.239 -0.031 -0.067 -0.161 -0.013 -0.199 0.022 -0.079 -0.138 0.123 0.196 -0.031 -0.099 0.199 0.232 0.384 0.381 0.475 0.433 0.382 1
corr VAS Du Interference -0.121 -0.088 -0.148 0.081 0.346 -0.038 -0.005 0.303 0.402 0.299 -0.124 -0.067 -0.04 0.134 -0.072 0.071 -0.019 0.035 0.001 0.066 -0.153 -0.11 -0.021 -0.177 -0.166 0.029 -0.214 0.065 0.135 0.024 -0.104 0.119 0.142 -0.081 0.007 0.252 0.314 0.177 0.419 1
corr VAS Disease Severity -0.023 -0.127 -0.007 0.013 0.028 0.274 0.127 -0.02 0.184 0.021 -0.01 -0.129 -0.14 -0.016 -0.21 -0.172 0.31 -0.17 -0.298 -0.119 -0.169 -0.185 -0.001 -0.102 0.002 -0.123 0.076 0.17 0.224 -0.128 0.03 0.101 0.114 0.374 0.544 0.713 0.489 0.613 0.612 0.271 1
corr HAQ-DI 0.014 0.019 0.137 0.147 0.129 0.458 0.195 0.074 0.272 0.039 -0.135 -0.119 -0.107 -0.084 -0.262 -0.39 0.503 -0.355 -0.481 -0.128 -0.134 -0.187 -0.066 -0.064 0 -0.129 0.089 0.235 0.253 -0.143 -0.053 0.063 0.115 0.411 0.661 0.643 0.453 0.528 0.449 0.183 0.576 1
corr SSc-QoL -0.027 -0.035 0.126 0.11 -0.024 0.411 0.146 -0.107 0.164 -0.032 -0.023 -0.114 -0.153 -0.186 -0.192 -0.34 0.411 -0.257 -0.419 -0.198 -0.052 -0.163 -0.001 0.002 0.048 -0.079 0.114 0.169 0.137 -0.197 -0.02 0.099 0.009 0.669 0.843 0.591 0.509 0.51 0.511 0.102 0.664 0.813 1
corr MFPDI Functional 0.001 0.026 0.243 0.139 0.124 0.37 0.168 -0.034 0.144 -0.01 -0.052 -0.069 -0.14 -0.114 -0.228 -0.422 0.473 -0.286 -0.502 -0.106 -0.135 -0.232 -0.024 -0.084 -0.054 -0.11 0.07 0.235 0.289 -0.123 -0.121 0.157 0.102 0.411 0.602 0.554 0.462 0.494 0.424 0.037 0.507 0.715 0.677 1
corr MFPDI Pain -0.097 0.099 0.162 0.073 0.105 0.206 0.05 0.018 0.234 -0.016 0.057 0.027 -0.113 -0.153 -0.092 -0.277 0.215 -0.088 -0.266 -0.064 -0.138 -0.124 0.082 -0.209 -0.173 -0.096 -0.043 0.211 0.171 -0.037 -0.103 0.082 0.023 0.288 0.403 0.503 0.389 0.306 0.359 0.173 0.382 0.521 0.499 0.708 1
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4.4.2.1 Multiple regression analysis 
Multiple regression analysis was initially used to further explore the potential 
suitability of the candidate factors identified in Phases 1 and 2.   
Four different regression models were constructed for each of the four systems 
assessed clinically (i.e. integumentary, vascular, neurological, and 
musculoskeletal) and using PROMS as the dependent variable including the 
QoL, HAQ, MFPDI function and MFPDI pain.  From the early iterations of these 
models the contribution of the clinical variables to the model was either non-
existing or small, as the adjusted R2 values for these clinical variables were 
within the range of 0.000 to 0.26. Of note, the adjusted R2 value tended to 
increase when other the PROMs variables such as the VAS were included as 
independent variables. The addition of other PROMS as independent variables 
resulted however in models that worked statistically but were overwhelmed by 
the PROM-based independent variables while the clinical independent variables 
were having very small effect, defeating the purpose of the modelling helping 
the selection of the clinical variables. Ultimately it was not possible to derive 
robust enough multiple regression models to enable the selection of the 
candidate factors for the SEM. Instead the selection of the candidate factors for 
entry into the SEM was based on the theoretical construct and the exploratory 
statistics.  
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 Initial Model Analysis 4.4.3
Informed by the literature review and the outcomes of the cross-sectional study 
in Phase 2, a structural equation model was constructed based on the 
theoretical construct. This mode was intended to explore the impact of the 
physical and psychosocial factors on quality of life.  This model is presented in 
Figure 4.2
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Figure 4.2 Example of an initial pre-specified theoretical model underlined by the hypothesis, that was to be 
tested by the SEM modelling 
Foot Function 
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Impact of foot 
problems   
Anxiety  
Depression  
Impact on 
QoL  
ABPI  
Max mean 
pressure 3
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MTPJ 
Vertical ground 
reaction force at heel 
strike 
Plantar soft-
tissue thickness 
3
rd
 MTPJ 
Foot pain  
Von Frey 
Monofilament  
General 
function  
MFPDI total 
score 
Pain threshold 
foot plantar 
Heat perception 
threshold foot 
dorsum 
Ankle ROM 
Skin Fibrosis  
Arterial 
waveform  
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Using AMOS, this initial theoretical model was analysed using SEM, but even 
after undertaking several modifications and iterations, including modification 
and alterations to the latent variables the initial model could not be made to 
work. While this is not unusual in SEM, it highlighted that the clinical 
assessments included under vasculopathy, neuropathy and foot function did not 
map onto a shared construct, even with substantial manipulation and review of 
the model. From this we can summarise that our initial model, while grounded in 
a reasonable theoretical construct, is not supported by the data. 
Of note, there are model types in SEM that do not use substantive latent 
variables (even though most of the SE models have error terms represented as 
latent variables). These type of models concern effects only among observed 
variables and employ a technique is known as path analysis, which is a member 
of the SEM family[282]. A path model is a structural model for observed 
variables, and a structural model represents hypothesis about effect priority i.e 
that X is a cause of Y [282].All the models obtained from this study data used 
path analysis as no substantive latent variables were obtained.   
As the data did not fit the theoretical models this left only two options, either to 
abandon the model or modify the hypothesis on which the initial model was 
based.  Therefore, in order to understand the pathways around foot pathology 
and their impact on quality of life more fully and in differing dimensions, three 
further models were developed: the first model was developed to capture the 
factors contributing to the dimension of foot pain, the second to capture the 
factors contributing to the dimension of foot function and the third model to 
capture the impact of foot problems on overall QoL in patients with SSc.  As a 
consequence of doing this refinement and developing new models, the SEM 
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approached changed to model generation, as opposed to the initial model 
confirmation. The model generation process aims to discover a model with 
three properties: i) the model makes theoretical sense, ii) it is reasonably 
parsimonious; and iii) its correspondence with the data is acceptably 
closed[282]. All the modified models achieved these three properties. 
The outcomes from each model are detailed in the subsequent sections. Of 
note, while in all three dimensions it was possible to construct working models 
with good fit statistics, none of the models contained latent variables. 
 Model One: exploration of multifactorial pathways that 4.4.4
contribute towards foot function 
As described above, a model was generated from the candidate variables to 
identify the factors that contribute to the impact of foot problems in relation to 
foot function. The initial model is presented in Figure 4.3. When we analysed 
the model, it was not supported by the data as demonstrated by a significant χ2 
statistics (χ2=79.45, df = 51, p= 0.007) and the fit statistics, which indicated a 
poor model fit (RMSEA= 0.068, GFI= 0.904;CFI= 0.914). To improve the model 
fit the model diagnostics information was assessed. The regression weights of 
each variable’s relationship were explored and those with a non-significant path 
were removed in an iterative process, starting with those paths that had the 
highest p value. After removal of the indicated path the overall model fit and the 
fit statistics were reviewed.  
Once all the non-significant variables’ relationships were removed, the 
modification indices were assessed for any suggested relationships between 
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variables that might improve the model fit. Any additional relationship that was 
suggested was included, starting with those relationships with the highest 
modification indices. During this iterative processes the standardised residuals 
covariance matrices were checked and any relationship that had a covariance 
value ≥ 2.50 was an indication that the relationship was not captured in the 
model, thus new a relationship was added. This iterative process was followed 
until the best fitting model was obtained. The iterations of the model indicating 
which relationships were removed or added are summarised in Table 4.9  
The assumption of multivariate normality among the variables in this model was 
not met. The Mardia’s coefficient was 57.71, while any value >10 indicates 
severe non-normality, therefore the use of the bootstrapping techniques was 
necessary to minimise bias and obtain more robust results [281, 372, 378]. 
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Figure 4. 3 Structural equation model testing the factors contributing to impairment of foot function in patients with SSc. The numbers at the top right 
corner of each variable represents the R
2
 value, or percentage of variance of the variable explained by the model. The arrows represent the direction in which the 
relationship is and the values on top of each line are the regression weights. The larger the regression weights the better predictor the variable is of the variable 
that the arrow is feeding into. 
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                 Table 4.9 Summary table of iterations of structural equation model for foot function.  
 
Model N Relationships Modifications χ2 df 
P 
Ideal: 
>0.05 
RMSEA 
Ideal: 
<0.05 
CFI 
Ideal: 
>0.95 
GFI 
Ideal: 
>0.95 
1 121 Initial model  79.45 51 0.007 0.068 0.940 0.914 
2 121 Remove relationship 3rd MTPJ plantar pressure foot function 80.17 52 0.007 0.067 0.940 0.912 
3 121 Remove relationship stance time VGRF push-off  80.91 53 0.008 0.066 0.941 0.910 
4 121 
Remove relationship forefoot ROM with regards to hindfoot   
3rd MTPJ plantar pressure  
80.91 54 0.010 0.064 0.943 0.911 
5 121 
Remove relationship forefoot ROM with regards to hindfoot  
foot function  
82.58 55 0.009 0.65 0.941 0.909 
6 121 Remove relationship ankle ROM stance time  83.80 56 0.009 0.064 0.941 0.907 
7 121 
Remove relationship forefoot ROM with regards to hindfoot  
mean force 3rd MTPJ 
85.08 57 0.009 0.064 0.940 0.905 
8 121 Add relationship stance time  general function  74.69   56 0.048 0.053 0.960 0.916 
9 121 Add relationship general function VGRF push-off 63.85 55 0.193 0.037 0.981 0.925 
10 121 Add relationship soft-tissue thickness 3rd MTPJ ankle ROM  54.21 54 0.466 0.006 1.000 0.936 
11 121 
Remove relationship soft-tissue thickness 3rd MTPJ  mean 
force 3rd MTPJ 
56.07 55 0.434 0.013 0.998 0.934 
12 121 Remove variable forefoot ROM with regards to hindfoot 47.05 44 0.349 0.024 0.993 0.942 
13 121 Add relationship VGRF push-off foot function 44.23 43 0.419 0.015 0.997 0.945 
14 121 Change direction relationship general function stance time  47.26 43 0.303 0.029 0.990 0.941 
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The best fitting foot function model is a complex model as it included a number 
of variables and parameters. Overall the model shows a good fit (χ2=47.267, df 
= 43, p= 0.303, RMSEA= 0.029, GFI= 0.990, CFI= 0.941), and explains half of 
the variance (R2 =0.51) that is associated with altered foot function in patients 
with SSc (graph presented in Figure 4.4). Eleven variables are identified in the 
model, two of which have a direct effect on foot pain, general function (Rgwt= 
0.58) and ground reaction force at push-off (Rgwt=- 0.12), and one (mean force 
heel) which had both a direct (Rgwt= -0.16) and indirect effect. 
The other eight variables had an indirect effect on foot function: soft-tissue 
thickness on heel and 3rd MTPJ, maximum mean pressure heel and 3rd MTPJ, 
mean force 3rd MTPJ, ground reaction force on heel strike and push-off, stance 
time and ankle ROM. As these variables had an indirect effect however, their 
impact on foot function was mediated through mediator variables. Thickness of 
the soft-tissue on the heel is associated with a direct effect on the soft-tissue 
thickness under the 3rd MTPJ (Rgwt= 0.47) and on the maximum mean heel 
plantar pressure (Rgwt= -0.39). While an increase in heel plantar pressures is 
associated with an increase in impairment of general function (Rgwt= 0.20).  
Foot function was influenced by general function, as measured by the HAQ-DI.  
General function is also directly affected by the mean force of the heel (Rgwt= -
0.41), thus those patients that have a decrease in the mean force going through 
the heel during gait are more likely to have poorer general function. An increase 
in the mean force going through the heel also has the effect of increasing the 
vertical ground reaction force going through the foot at heel strike (Rgwt= 0.38) 
and a decrease in the time spent in weight bearing (i.e. stance phase, Rgwt= -
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0.22). In addition, a decrease in the time spent in the stance phase of gait also 
decreases the vertical ground reaction force passing through the foot at heel 
strike (Rgwt= -0.40). Patients with a decreased vertical ground reaction force at 
heel strike were more likely to have a decreased vertical ground reaction force 
at the push-off phase during gait (Rgwt= 0.44); while a decrease in the later 
indicates a decrease in foot function (Rgwt= -0.12). Conversely, a decrease in 
maximum mean plantar pressure under the 3rd MTPJ predicts an increase in the 
vertical ground reaction force at push-off (Rgwt= -0.26).  
Those patients with an increased mean force going through the plantar aspect 
of the 3rd MTPJ during gait are more likely to have increased maximum plantar 
pressures under this area (Rgwt= 0.43) and an increase vertical ground reaction 
force at push off (Rgwt= 0.22).  An increase in soft-tissue thickness under the 3
rd 
MTPJ predicts a decrease in max mean plantar pressures under this region 
(Rgwt= -0.37). 
Of note, a decrease in ankle ROM predicts an increased in maximum mean 
plantar pressures under the 3rd MTPJ is (Rgwt= -0.17). While a decrease in soft-
tissue thickness under the 3rd MTPJ, is related to a decreasing ankle ROM 
(Rgwt= 0.28). Furthermore, a decrease in soft-tissue thickness under the 3
rd 
MTPJ predicts an increase of maximum mean pressure under the heel during 
gait (Rgwt= -0.17), which in turn predicts a decrease in general function (Rgwt= 
0.20). General function is one of the predictors having a direct effect on stance 
time (Rgwt= 0.23) and foot function (Rgwt= 0.58), so patients that reported 
impaired general function were more likely to have an increased stance time 
during gait and impaired foot function.    
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Figure 4.4 .Best fitting structural equation model for the factors contributing to impairment of foot function in patients with SSc. The numbers at the top right 
corner of each variable represents the R
2
 value, or percentage of variance of the variable explained by the model. The arrows represent the direction in which the 
relationship is and the values on top of each line are the regression weights. The larger the regression weights the better predictor the variable is of the variable that the 
arrow is feeding into. The variables disease duration, number of comorbidities, age, gender and diagnosis subtype when entered in the model they did not contribute to 
the model. 
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In summary, when the combined direct and indirect regression weights are 
considered, it is clear that poor general function is the highest single predictor of 
poor foot function (0.62); having a direct (0.58) and indirect effect (0.04) on foot 
function. Patients with SSc produce lower forces during walking and spend 
longer time in weight bearing; both signs that are indicative of impaired foot 
function and/or foot pain. A summary of the direct, indirect and total 
standardised effects for the variables of this model is provided in Table 4.10. 
 
 
 
 
 
 
 
Table 4.10 Standardised direct, indirect and total effect of the variables as they 
relate to foot function  
 
Variable  
Direct 
effect 
 
Indirect 
effect  
Total 
effect  
General function    0.583  0.036  0.619 
Mean force heel  -0.156 -0.238 -0.393 
Max mean pressure heel   0.000  0.125  0.125 
Vertical ground reaction force at push-off  -0.122  0.000 -0.122 
Soft-tissue thicknes heel   0.000 -0.065 -0.065 
Vertical ground reaction force at heel 
strike 
 0.000 -0.053 -0.053 
Soft-tissue thicknes plantar 3rd MTPJ     0.000 -0.035 -0.035 
Max mean pressure 3rd MTPJ   0.000  0.031  0.031 
Stance time   0.000  0.021  0.021 
Mean force 3rdMTPJ   0.000 -0.020 -0.020 
Ankle ROM  0.000 -0.005 -0.005 
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 Model Two: exploration of multifactorial pathways that 4.4.5
contribute to foot pain 
The previous section focused on foot function and so the dimension of foot pain 
was explored in a second set of models. The initial model developed to 
identifying the factors that contribute to the impact of foot pain is presented in 
Figure 4.5. Initial analysis showed a significant χ2 statistics (χ2=101.43, df = 24, 
p= 0.000) and the fit statistics indicated a poor model fit (RMSEA= 0.164, GFI= 
0.808;CFI= 0.849). To improve the model fit the model diagnostics information 
was assessed as described for the first model. Iterations of the model indicating 
which relationships were removed or added are summarised in Table 4.11 
The assumption of multivariate normality among the variables in this model was 
checked and it showed a Mardia’s coefficient of 2.155 indicating a moderate 
multivariate non-normality. Therefore the use of the bootstrapping techniques 
was again necessary to maximise the robustness of results. Boot strapping also 
complemented the fact that the model could not be replicated with additional 
sample data or cross-validated with a split sample [378].  
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Figure 4.5 Structural equation model testing the factors contributing to foot pain in patients with SSc. The numbers at the top right corner of each variable represents 
the R
2
 value, or percentage of variance of the variable explained by the model. The arrows represent the direction in which the relationship is and the values on top of each line 
are the regression weights. The larger the regression weights the better predictor the variable is of the variable that the arrow is feeding into The number of comorbidities, age, 
gender and diagnosis subtype when entered in the model they did not contribute to the model. 
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      Table 4.11 Summary table of iterations of structural equation modelling for impact of problems in relation to foot pain  
 
Model N Relationships Modifications χ2 df 
P 
Ideal: 
>0.05 
RMSEA 
Ideal: 
<0.05 
CFI 
Ideal: 
>0.95 
GFI 
Ideal: 
>0.95 
1 121 Initial model  101.41 24 0.000 0.164 0.808 0.849 
2 121 Add relationship general function  VAS pain  191.11 32 0.000 0.204 0.696 0.776 
3 121 Add relationship foot function general function 113.80 31 0.000 0.149 0.842 0.857 
4 121 Add relationship general function depression  55.697 30 0.003 0.184 0.951 0.925 
5 121 Add relationship VAS breathing problem general function 41.28 29 0.065 0.059 0.977 0.941 
6 121 Remove relationship VAS breathing interfere foot function  69.33 30 0.000 0.105 0.925 0.906 
7 121 Remove relationship anxiety foot function  75.11 31 0.000 0.109 0.916 0.898 
8 121 Remove relationship foot function general function 124.88 32 0.000 0.156 0.823 0.864 
9 121 Remove relationship foot function foot pain  190.43 33 0.000 0.199 0.700 0.813 
10 121 Remove variable foot function  33.08 24 0.102 0.056 0.976 0.942 
11 121 Add relationship general function foot pain  21.73 23 0.536 0.000 1.000 0.962 
12 121 Remove VAS DU variable  11.70 17 0.847 0.000 1.000 0.976 
13 121 Add relationship anxiety foot pain  8.68 16 0.926 0.000 1.000 0.981 
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The best fitting model obtained for foot pain (χ2=8.682, df = 16 p= 0.926, 
RMSEA= 0.000, GFI= 1.000, CFI= 0.981) demonstrated very good fit (Figure 
4.6) This model explains nearly 40% of the variance (R2 =.38) in foot pain in 
patients with SSc and contains eight variables. Four variables have a direct 
effect on foot pain: general function (Rgwt=0.28), general pain (Rgwt= 0.28), TP 
arterial waveform (Rgwt=-0.20), and anxiety (Rgwt=0.13); with general function 
and general pain being the best predictors of foot pain. The other four variables 
i.e breathing interference, Raynaud’s interference, anxiety and depression, 
have an indirect effect and contribute to foot pain in an indirect manner through 
mediator variables.  
While not directly affecting foot pain, breathing problems has a direct impact on 
general function (Rgwt=0.53). Patients with worse Raynaud’s interference 
reported poorer general function (Rgwt=0.24) and worse general pain 
(Rgwt=0.24), both of which had a direct effect on foot pain. Not surprisingly, 
patients with poorer general function also tended to report worse general pain 
(Rgwt=0.53) and higher levels of depression (Rgwt=0.62). In addition, depression 
has a large effect on anxiety (Rgwt=0.67), while increase anxiety has both an 
indirect effect, through Raynaud’s interference (Rgwt=0.26), and a direct effect 
(Rgwt=0.13) on foot pain.  
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Figure 4.6 Best fitting structural equation model for the factors contributing to foot pain in patients with SSc. The numbers at the top right corner of each variable 
represents the R
2
 value, or percentage of variance of the variable explained by the model. The arrows represent the direction in which the relationship is and the values on 
top of each line are the regression weights. The larger the regression weights the better predictor the variable is of the variable that the arrow is feeding into. The variables 
disease duration, number of comorbidities, age, gender and diagnosis subtype when entered in the model they did not contribute to the model. 
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Once again, poorer general function was the largest single predictor of foot pain 
in this model (0.51), having both a direct and indirect effect. General function 
(0.28), together with general pain (0.28) also had the highest direct effects. A 
summary of the direct, indirect and total standardised effects for the variables of 
this model is provided in Table 4.12 
 
 
Table 4.12 Standardised direct, indirect and total effect for the variables as they 
relate to foot pain 
 
Variable 
Direct 
effect
 
Indirect 
effect 
Total 
effect 
General function 0.282 0.224 0.506 
VAS pain 0.283 0.000 0.283 
VAS Breathing prob. interference 0.000 0.282 0.282 
TP arterial wave -0.197 0.000 -0.196 
VAS Raynaud’s interference 0.000 0.189 0.189 
Anxiety 0.127 0.049 0.176 
Depression 0.000 0.117 0.117 
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 Model Three: exploration of multifactorial pathways that 4.4.6
contribute to impact on quality of life 
The initial model developed to identifying the impact of foot problems on the 
QoL is presented in Figure 4.7. Initial analysis showed a significant χ2 statistics 
(χ2= 57.31, df = 38, p= 0.023) and the fit statistics indicated a poor model fit 
(RMSEA= 0.065, GFI= 0.979;CFI= 0.933). The initial model diagnostics 
information was again assessed and modifications to the model were 
undertaken until the best fitting model was obtained, following the same 
iterative process explained in model one. The iterations of the model indicating 
which relationships were removed or added are summarised in Table 4.13  
The Mardia’s coefficient for the best fitting model for impact of foot problems in 
QoL was 5.10 indicating a moderate multivariate non-normality. Therefore, 
bootstrapping was used to obtain more robust results [281, 372, 378] 
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Figure 4.7 Structural equation model testing the effects of impact of foot problems on the QoL of patients with SSc. The numbers at the top right corner of each 
variable represents the R
2
 value, or percentage of variance of the variable explained by the model. The arrows represent the direction in which the relationship is and the values 
on top of each line are the regression weights. The larger the regression weights the better predictor the variable is of the variable that the arrow is feeding into. 
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     Table 4.13 Summary table of iterations of structural equation model for the impact of foot problems on QoL 
Model N Relationships Modifications χ2 df 
P 
Ideal: 
>0.05 
RMSEA 
Ideal: 
<0.05 
CFI 
Ideal: 
>0.95 
GFI 
Ideal: 
>0.95 
1 121 Initial model  57.31 38 0.023 0.065 0.979 0.933 
2 121 Remove relationship VAS Raynaud’s  VAS pain  59.80 39 0.018 0.067 0.977 0.929 
3 121 Remove relationship VAS DU general function  81.48 41 0.000 0.091 0.956 0.904 
4 121 Add relationship VAS pain  general function  62.30 40 0.014 0.068 0.976 0.926 
5 121 Add anxiaty VAS DU interfearence  48.87 39 0.133 0.046 0.989 0.939 
6 121 Add relationship VAS DU interference  general function 44.22 38 0.225 0.037 0.993 0.943 
7 121 Add VAS GI problems interference  VAS DU interference  37.02 37 0.468 0.002 1.000 0.951 
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The best fitting model obtained for the impact of foot problems on the QoL 
(χ2=44.22, df= 38, p= 0.225, RMSEA= 0.037, GFI= 0.993, CFI= 0.943) 
demonstrates good fit (Figure 4.8). This model explains nearly 84% of the 
variance (R2 = 0.84) that affects QoL in patients with SSc. This variance is 
explained by the influence of 11 variables, three of which have a direct effect on 
QoL: general function (Rgwt=0.45), depression (Rgwt= 0.27) and anxiety 
(Rgwt=0.24); with general function being the strongest predictor of QoL. The 
other eight variables i.e patient’s perceived disease severity, breathing 
interference, Raynaud’s interference, GI problems interference, DU 
interference, general pain, foot pain and foot function, have an indirect effect 
and contribute to QoL through mediator variables.  
While not directly affecting QoL, breathing problems have a direct effect on 
Raynaud’s interference (Rgwt= 0.32), foot function (Rgwt= 0.31), patient’s 
perceived disease severity (Rgwt=0.31), general pain (Rgwt= 0.26), 
gastrointestinal problems interference (Rgwt= 0.23) and general function (Rgwt= 
0.20). Patients that report worse GI problems interference if they have DUs are 
more likely to report worse DU interference (Rgwt= 0.23), and worse general 
pain (Rgwt= 0.20). Both GI and DU interference are both directly affected by 
Raynaud’s interference in daily activities; Rgwt= 0.35 and 0.52 respectively. In 
addition Raynaud’s interference is affected by anxiety (Rgwt= 0.21), and an 
increase in Raynaud’s interference leads to an increase in patient perceived 
disease severity (Rgwt= 0.29) and in foot pain (Rgwt= 0.33).  
When patients report increase in foot pain they are more likely to report worse 
general pain (Rgwt= 0.33) and worse foot function (Rgwt= 0.68); both of which 
variables have a direct effect to general function; Rgwt= 0.28 and 0.43 
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respectively; the latter having a direct effect to QoL (Rgwt= 0.45). Therefore,  
foot pain and foot function have an indirect effect on the QoL of patients with 
SSc. 
 General function is worse in those patients that have general pain (Rgwt= 0.28), 
and general pain also worsens in patients with DU that report DU interference 
(Rgwt= 0.23). While general pain has a direct effect on patients perceived 
disease severity (Rgwt= 0.44). Patients reporting worse perceived disease 
severity are more likely to report worse QoL (Rgwt= 0.16) and worse depression 
(Rgwt= 0.18).   
Depression has also a direct effect on QoL (Rgwt= 0.27) and a large effect on 
anxiety  (Rgwt= 0.68). Perhaps surprisingly however, those patients that are 
more anxious are less likely to report worsening of the DU interference (Rgwt= -
0.40). Anxiety is also one of the variables having a direct effect on QoL (Rgwt= 
0.24). 
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Figure 4. 8 Best fitting structural equation model for the impact of foot problems of the QoL of patients with SSc. The numbers at the top right corner of each variable 
represents the R
2
 value, or percentage of variance of the variable explained by the model. The arrows represent the direction in which the relationship is and the values on top 
of each line are the regression weights. The larger the regression weights the better predictor the variable is of the variable that the arrow is feeding into. . The variables 
disease duration, number of comorbidities, age, gender and diagnosis subtype when entered in the model they did not contribute to the model, 
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Breathing problems are associated with the largest number of variables. 
General function is the highest single predictor of quality of life (0.64), followed 
by impact of breathing problems (0.49) and depression (0.43). Foot function 
and foot pain are the variables having the fourth and fifth largest effect on QoL 
(0.34 and 0.33 respectively), and interestingly they are more influential on QoL 
than six other variables including GI and Raynaud’s interference. A summary of 
the direct, indirect and total standardised effects for the variables of this model 
is provided in Table 4.14 
 
Variable  
Direct 
effect 
 
Indirect 
effect  
Total 
effect  
General function   0.454 0.186 0.640 
VAS Breathing problems interference 0.000 0.493 0.493 
Depression  0.270 0.158 0.428 
Foot function  0.000 0.343 0.343 
Foot pain  0.000 0.327 0.327 
VAS Raynaud’s interference  0.000 0.294 0.294 
VAS pain  0.000 0.284 0.284 
Vas Disease severity  0.160 0.076 0.236 
Anxiety  0.236 -0.003 0.233 
VAS DU interference  0.000 0.162 0.162 
VAS GI problems interference 0.000 0.095 0.095 
Table 4.14 Standardised direct, indirect and total effect of the variables as they 
relate to QoL, including foot problems 
 
Summary 
The results from this modelling have highlighted that SSc has both a physical 
and psychological impact. This impact is reflected in the feet as substantial foot 
problems, which are affected by complex interrelations between multiple 
factors. Foot problems are a significant contributor to the impact on the quality 
of life of patients with SSc.
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Chapter 5                                                   
Discussion and Summary  
5.1 Overview 
The studies undertaken in this thesis aimed to identify the factors that contribute 
to the development and impact of foot problems in patients with SSc. A multi-
methodological approach was used to achieve this aim.  
First, a literature review and expert clinician consultation was developed to 
identify the candidate factors that influence foot pathology in SSc; second a 
case-control cross-sectional study was undertaken to establish the prevalence 
and impact of foot pathology in this disease; and last, SEM was used to explore 
the multifactorial pathways in foot pathology and its impact on the QoL of 
patients with SSc.  
The hypothesis underpinning this thesis was that the development and impact 
of foot problems on the QoL of patients with SSc is multifactorial; involving a 
complex inter-relationship between disease, functional impairment, personal 
factors, environmental factors and psychosocial factors.  
The results from the SEM support this hypothesis. From our literature review 
and clinician consultation, we identified factors that were considered important 
in the development of foot problems, including skin, vascular, musculoskeletal 
and neurological factors. By exploring these factors in patients with SSc and 
healthy volunteers, we were able to determine that foot pathology was 
substantial in patients with SSc. Patients reported poorer general health, poorer 
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health-related quality of life and high levels of anxiety and depression. Patients 
also had increased odds of having absent or monophasic vascular waveforms, 
indicating PAD, and loss of protective sensory acuity increasing the risk of 
ulceration, poor healing and infection. There were also significant gait changes 
in patients with SSc: they had reduced forces going through the foot during gait, 
reduced plantar pressures, and reduced joint range of motion in the foot. These 
together with a slower gait, indicates that SSc patients have impaired 
biomechanics of the foot.  
As reported in Chapter 4, the initial theoretical model of the impact of foot 
problems on quality of life was not supported by the data. Modification of the 
initial model caused the models to lose its confirmatory properties of the 
theoretical model as initially stated, and the approach switched therefore to a 
model generation process [282]. 
Three models were built using the SEM. Two models explored the multifactorial 
pathway in foot pathology, focusing on foot pain and foot function, and the third 
model explored the impact of foot pathology in the patients QoL. The factors 
included in the foot pain model predicted 38% of variance of foot pain, while 
those included in the foot function model predicted 51% of the variance of foot 
function. The third model identified the factors that predicted a substantial 84% 
of the impact on the Qol of patients with SSc, of which foot function and foot 
pain were highly associated with poorer quality of life. All three models 
represented well-defined models. 
The models of foot pain and foot function indicated that each are predicted by 
multiple, inter-related factors. Furthermore, foot pain and foot function had an 
indirect effect contributing to QoL through mediator variables. Foot function and 
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foot pain became the fourth and fifth variable with the biggest contribution to the 
impact on QoL after general function, patient perceived breathing problems 
interference and depression. 
5.2 Major findings  
This programme of work has produced several important findings. These 
findings will be discussed in this chapter under the following four themes. 
I. Patients with SSc have substantial foot problems  
II. Systemic sclerosis has both physical and psychosocial impact 
III. Foot pathology in patients with SSc is multifactorial  
IV. Foot pathology is a significant contributor to the impact on the Qol of 
patients with SSc. 
 Patients with SSc have substantial foot problems. 5.2.1
As described in Chapter Two, SSc is a complex heterogeneous disorder, which 
involves several systems.  The multisystem nature of the disease manifests in 
the patient as different signs and symptoms affecting many body organs and 
structures. Some of these manifestations are physical and others psychological, 
and together they have an effect at the psychosocial level. The different 
systems involved in the disease systemically include integumentary, vascular, 
nervous and musculoskeletal, cardio-pulmonary, renal and gastrointestinal 
systems. However the systems that have a direct effect on the foot are the 
integumentary, vascular, nervous and musculoskeletal systems, and the results 
have indicated a significant role of the last three in foot pathology.  
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Whilst previous literature has reported the effects of the disease in the lower 
limb, ours is the first study to investigate the impact and interactions of different 
systems contributing to foot problems. 
Skin involvement in foot pathology  
While skin pathology is a defining, central feature in SSc [89, 187], it is also 
known that the clinical presentation of skin involvement can vary. In our group 
of patients with SSc, the overall skin involvement as measured by the mRSS 
can be considered mild. When compared to other cohorts from published 
literature the mRSS scores are relatively low [276, 379-381]. The lower scores 
in our cohort reflect a predominantly lcSSc cohort although additional factors 
including milder involvement (especially in the dcSSc patients) and longer 
disease duration may also be relevant,(although the latter was similar to the 
other studies). However, we know that the mRSS has better intra-observer 
reproducibility than inter-observer reproducibility [305, 382], which introduces 
difficulties in comparing scores between studies and limits the legitimacy of 
drawing firm conclusions about the scores in different studies. 
It has also been identified that in addition to the skin involvement, there are 
other soft-tissue subcutaneous structures that are affected by the disease 
pathology, such as subcutaneous-fat atrophy [25, 374]. This was partially 
supported in this study as evidenced by the measurable soft-tissue changes on 
the plantar aspect of the foot quantified with ultrasound. The decrease in soft-
tissue thickness in patients with SSc could be as a result of plantar fat-pad 
atrophy through the same pathological process that affects subcutaneous fat 
atrophy in other areas of the body [149], or it could be as a result of muscle 
atrophy as shown in other cohorts of  people with toe deformities [383, 384]; 
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muscle atrophy is also known to occur in patients with SSc [257, 263]. These 
findings should be interpreted with caution however as the difference in soft-
tissue thickness under the 3rd MTPJ and heel, while statistically significantly 
different compared to healthy participants, was very small. Particularly at the 
heel, the measured difference in means between groups was smaller than the 
measurement error identified in the intra-rater reliability testing (Appendix 1).  
Vascular involvement on foot pathology 
In SSc, although both microvascular and macrovascular pathology has been 
reported, microvascular abnormality is a primary process underpinning the 
disease [15, 96]. 
In this study, measuring microvascular involvement with clinically accessible 
assessments proved to be difficult. It had been intended to measure toe 
brachial pressures (TBP) and photoplethysmography (PPG) of the digits to 
detect blood flow changes in the microvascular bed of the toes. After taking 
these measurements in the first five patients however, it became clear that the 
measures were unrealistically time consuming. In addition, the SSc disease 
process confounded obtaining reliable readings. These two tests were excluded 
from the battery of vascular tests for the remaining 116 cases. An alternative to 
this test and a more reliable way of assessing the microvascular pathology in 
patients with SSc may have been to use capillaroscopy of the nail fold of the 
toes. This test has been used in the toes although is not formally validated, and 
is also a lengthy test to conduct, requiring extensive training and experience 
[385] . It is therefore accepted that the lack of any microvascular measurement 
is a limitation in this study. 
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The tests used in this study to assess macrovascular disease in the lower limb 
have a good validity and reliability [308-310]. In SSc patients the ABPI analysis 
suggested that the macrovascular system in patients with SSc remains 
relatively normal.  While the current results concur with some published studies 
[386], they also differ from others [15, 387]. In most of the previous literature, 
with the exception of a study by Bichile et al [387], patients were selected 
without any specifications regarding the presence or absence of lower limb 
vascular symptoms or disease.  Bichile et al [387], however, recruited from 
patients with symptomatic peripheral vascular disease (PVD), and 50% of their 
sample had abnormal ABPI. Consequently, the presentation of abnormal ABPI 
in patients with SSc remains unclear and it cannot be determined whether PAD 
of large vessels is more prevalent in patients with SSc. On the other hand, the 
arterial wave analysis, which also assesses PAD, showed that there was a 
significant association between the presence of PAD and whether the 
participant had SSc or not. The odds ratio of having PAD as defined by absent 
or monophasic arterial waveforms were five times higher in the participants with 
SSc than in the healthy participants. This could indicate that patients with SSc 
are more likely to develop occlusive peripheral arterial disease than healthy 
individuals or they could have vascular calcification, which has been previously 
reported in patients with SSc [8]; although if the latter option was the case then 
one would have expected to obtain ABPI results above 1.30, as they are 
indicative of calcified arteries, and this was not the case. The basis for PAD in 
SSc is an area that could be expanded with future research but would require 
populations carefully controlled for usual risk factors associated with large 
vessel atherosclerotic disease.  
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Neurological involvement in foot pathology  
Unlike the vascular involvement in SSc, neurological involvement in the disease 
has been considered less common; although acknowledged as being present in 
some cases. Amongst other neurological abnormalities (described in Chapter 2) 
there is some evidence for the presence of peripheral neuropathy involving the 
feet [169-171]. The results from the current study agree with the published 
literature, as patients with SSc when compared to healthy individuals showed 
sensory deficiency in their feet.  
The results from the neurological tests conducted in the current study to 
determine the sensory deficiency were different in some ways from those 
published in the literature. For instance, Schady et all [237] reported that there 
was no difference between patients with SSc and healthy participants in terms 
of vibration and pain thresholds, while the results from this thesis found that 
vibration and heat induced pain threshold from the dorsum of the foot was 
poorer in patients with SSc compared to healthy volunteers with reported higher 
pain and vibration thresholds in the cases.  An explanation for this discrepancy 
could be due to difference in the anatomical area being tested. Schady et al 
[237] carried out the test under the lateral malleolus while in this thesis the test 
for vibration was carried out on the dorsum the foot. Testing a distal part of the 
foot might be more likely to detect sensory abnormalities as peripheral 
neuropathy in SSc usually has a distal pattern.  
There were some quantitative sensory tests (QST) results from this thesis, 
which were similar to those previously published. The results for the tests on 
light touch, cold perception threshold on the dorsum of the foot and heat 
perception threshold on the dorsum and plantar of the foot indicated that 
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patients with SSc had a significantly reduced sensation in perceiving touch on 
the foot and heat on the dorsum and plantar aspect of the foot, and a highly 
significant reduction in cold sensation on the dorsum of the foot. Schady et al 
[237] also identified empirically that some patients with SSc had a reduced 
touch and heat sensation. These results must be interpreted with caution 
however, as the authors reported the percentage of patient having 'abnormal 
readings' but did not quantify the difference between groups.    
Interestingly, even though patients with SSc also had reduced sensation when 
perceiving heat induced pain or cold on the plantar aspect of the foot, the 
difference between groups did not reach statistical significance. Conversely the 
heat perception threshold test on the plantar surface, which did reach 
significance, was based on a difference between groups smaller than that 
obtained from the dorsum. As this difference was less than one degree and had 
a small effect size this poses the question of how big the difference needs to be 
for it to be considered pathological/clinically meaningful.  
It has been proposed that sensory deficit is more likely to be significant in the 
dorsum of the foot than on the plantar aspect as a result of skin fibrosis 
damaging the sensory skin receptors via incarceration of the nerves in 
collagen[226]. It is known that involvement of the dorsum of the foot, although 
less frequent than the dorsum of the hands, can result in fibrosis, while fibrotic 
changes on the plantar of the foot are not well documented. Alternatively, the 
neuropathy could be associated with a vasculopathy or inflammatory process 
but with these two mechanisms one would expect to observe similar affects in 
both areas of the foot.  
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Even though there are limited published neurological data on the difference 
between patients with SSc and controls with which to specifically compare the 
results from the current study, there are published normative data [388-391] 
which is relatively consistent with the data obtained from the healthy 
participants in this study, It is important to note however, that for some tests a 
statistically significant difference between groups and a moderate statistical 
effect size, might not be clinically significant because of a very small difference. 
For example, the light touch test yielded a systematic difference of a median of 
one site per participant (i.e patients with SSc had slightly reduced sensation 
because they did not feel the monofilament in one out of eight sites on 
average). This raises the question of what thresholds from this tests can 
determine what is pathological and how should such tests be used in clinical 
assessment. 
Overall, the significant results from the neurological QST investigations indicate 
that patients with SSc have some large and small fibre neuropathy. The 
vibration and light pressure perception results imply large fibre neuropathy, 
affecting the myelinated (A-alpha and A-beta) fibres. The heat, cold and pain 
perception results indicate small fibre neuropathy, affecting the non-myelinated 
(C) fibres and the thinly myelinated (A-delta) fibres. Impaired sensations related 
to the skin, numbness, increased sensibility and loss of sensory functions all 
were identified in a Central–European qualitative study, as some of the factors 
perceived by the patients with SSc to be impairment of body function and 
structures, as classified by the ICF criteria [4].  
 Musculoskeletal involvement in foot pathology 
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The disease pathology has an effect on the musculoskeletal system involving 
intra-articular, periarticular and muscular structures [169, 241, 243]. This 
musculoskeletal involvement has also been observed in the feet [189, 254] but 
its effects on spatiotemporal gait parameters and foot function-related 
impairment  has not been described in depth in the literature. The results from 
this thesis provide some insight into foot function and impairment in SSc.  
Foot function and impairment was measured by capturing different 
spatiotemporal gait parameters and patient reported outcomes measures, which 
has not previously been reported in the literature. A significant reduction ankle 
ROM in the sagittal plane (plantarflexion-dorsiflexion) and reduce ROM of the 
forefoot with regards to hindfoot in the coronal plane movement (inversion-
eversion) was observed. During gait, patients with SSc had a significantly 
reduced ROM in the ankle and reduce ROM of the forefoot relative to the 
hindfoot in terms of inversion-eversion. This reduction in ROM could be as a 
result of skin fibrosis, intra-articular and periarticular joint involvement as 
observed in previous studies [189]  and/or as a result of an altered gait because 
of foot pain; as patient reported significant foot pain in this thesis. The hindfoot 
and forefoot reduce ROM can have an effect on other gait parameters, which 
together may explain the high levels of impairment in foot function reported by 
the patients with SSc in this study. In addition, the patients also had a reduced 
mean force under the heel and the 3rd MTPJ and a reduction in the ground 
reaction force at heel strike and push-off. In healthy participants a reduction in 
these forces during gait are indicative of slower gait [392]. In patients with SSc 
therefore, reduction in mean force and ground reaction force together with an 
increase in time spent in the stance phase suggests that patients with SSc walk 
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more slowly than healthy participants and possibly spend more time in double 
stance. This would also corroborate the findings from a previous study carried 
out by the candidate, in which walking speed and stride length was noted to be 
reduced and the double support period was increased in patients with SSc [10]. 
Interestingly, the earlier study also found that patients with SSc had increased 
plantar pressures at the 1st MPT joint while the current study found no 
difference in plantar pressure at the 3rd MTP joint between groups. It is relevant 
however that the pressure measurement used in this thesis was maximum 
mean pressure as opposed to pressure time integral; although even though 
these two measurement were different it does not account for the large 
difference in the results. Of note however, the regions of interest were different; 
the current study looked at the plantar pressures at pre-specified sties under 
the 3rd MTPJ and heel because of wanting to explore the relationship between 
plantar soft-tissues thickness in this areas and plantar pressures. Furthermore, 
the 3rd MTP joint was selected over the 1st because the latter is commonly 
affected by other pathologies that are not specific to the SSc disease e.g. hallux 
abductor valgus, therefore acting as a confounders. Further analysis of the 
current data looking at the average plantar pressure across the MTP joints 
would be possible after completion of the main study and would be necessary 
to determine whether patients with SSc have increased pressures across the 
forefoot.  
The impairment of foot function during gait reflects the presence of foot 
problems and/or foot pain. Through the MFPDI, the patients have also reported 
both of these factors to be significant.  
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The direct or indirect interrelations of these gait parameters are further 
described in model one, section 4.4.4  
For some of the neurological and musculoskeletal variables, which yielded 
differences between cases and controls that were significant and had at least a 
small effect size, the difference between means and medians was small. In part 
at least this could have been due to the heterogeneous nature of the disease, 
which introduces greater variance within the SSc sample, thereby masking 
some of the cases with larger differences. Nevertheless, the small magnitude of 
the overall between-group differences does raise the question as to whether 
these differences are clinically meaningful. The current study was not 
constructed to provide that answer but it provides the basis for future research, 
to build upon the results and explore further the factors identified to contribute 
to foot pathology in patients with SSc.  
 Systemic sclerosis has both physical and psychosocial 5.2.2
involvement 
It is well established in the literature that SSc is a disease that affects many 
systems of the body. The complex and multisystem nature of the disease can 
have a profound affect on both the structures and functions of the body. 
Together with the personal and environmental factors this combination can 
have a consequence on the patient activity and cause participation restriction 
leading to perception of disability [367]. Physical disability does not always 
reflect the full impact of the disease however, as psychological involvement is 
also relevant [272-274] and together with the physical impairment has a 
psychosocial impact. One of the objectives of this study was to capture the 
  197
patients’ perception of their physical, psychological and psychosocial impact 
caused by the disease.  
To explore the impact of SSc relative to other conditions the responses from the 
current SSc cohort were compared with another six conditions using the SF-36. 
Patients with SSc scored on average lower (or poorer scores) than many other 
diseases; with scoring ranging from 29 to 65 across the different domains 
(Figure 5.0). Patients with SSc reported the worse physical function, bodily pain, 
general health, vitality, social interference and mental health amongst the six 
conditions. They reported having similar role physical and role emotional 
problem than patients with angina pectoris, who score the lowest on these two 
domains. In addition, our patients with SSc reported a highly significant physical 
and mental health disability when compared to healthy participants. Both MCS 
and PCS SF-36 summary scores for patients with SSc obtained in the current 
study are similar to those reported in the literature [393]. Furthermore, the 
scores obtained for the SF-36 summary of physical function in this study were 
particularly low. As a reference for the meaning of the scores, in a U.S. general 
population has been reported that scores between 8-34 relate to higher rates of 
job disability, job loss within a year, subsequent hospitalisations, greater 
disease burden, and greater likelihood of death within five years, when 
compared to those with higher scores. In relation to the five-year mortality, 
scores between 25-34 were associated to have an increase in mortality of 
15.1%. While for the SF-36 summary of mental health scores lower than 54 
were more likely to screen positive for depression and more likely to report 
lower satisfaction with their life in comparison to those scoring higher [394]. 
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However, this data has not been published for patients with SSc therefore in 
this population the scores could yield different results.    
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 Figure 5.0 SF-36 scores for a range of conditions, including systemic sclerosis (SSc). Graph modified from Redmond et al[395], CMT: 
Charcot-Marie-Tooth. 
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The SF-36 as a generic outcome provided information to compare the generic 
impact of the disease [344, 345], while the disease specific and symptom 
specific tools captured a more specific impact, which could have been missed 
by the generic tools. These results are consistent with those in the published 
literature [197, 396]. When exploring the impact of specific organ symptoms of 
activities of daily–living the results varied according to the related symptoms. 
Impact ranged from very low interference with ADLs associated with the digital 
ulcers to an increase in interference in daily activities in ADLs associated with 
GI problems, breathing problems, pain and Raynaud’s’ symptoms, with the 
highest interference caused by Raynaud’s’ symptoms. For the overall disease 
interference that represents part of the patients’ perceived impact of the disease 
in their life, the median score was 5/10 which compared to the severity implied 
by the scores of the SF-36 summary physical function, may have been 
expected to result in higher scores. The overall rating of the disease 
interference might be influenced however, by aspects of personality, 
psychosocial adjustment to illness and/or social support, and might not 
therefore reflect the indices of illness severity and more a complex interaction 
between different factors, as it is the case for depressive symptoms [272].     
As a note, it is important to highlight that the VAS scales in the SSc-HAQ do not 
provide an option for the response to be non-applicable, and if the patients did 
not suffer from the specific symptom therefore their answer was zero. This 
response pattern can be misinterpreted as it is not reflecting the interference of 
this symptom/disease with the daily activities, but indicates that they did not 
suffer from it. A good example for this is the VAS for digital ulcers as only 49% 
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of the participants have ever had an ulcer therefore the 51% of participants 
scored zero.   
In addition to the physical impairment noted previously, SSc also leads to a 
psycological impact. In the current study the SSc patients had significantly 
higher levels of anxiety and depression than the healthy individuals, and many 
reached the threshold required to be considered clinically anxious; with a score 
≥ 8 being identified as diagnostic of anxiety or depression [346, 352]. These 
results are in agreement with the published literature, as it is well documented 
that patients with SSc suffer from higher rates of depression and anxiety; both 
of which conditions have been reported to be the most predominant 
psychological symptoms [150, 354]. 
Any form of disability from a physical or psychological level tends to have an 
impact on the person’s QoL. The results from the PROMs in this study showed 
the considerable impact of this disease on the patients’ daily life and to their 
QoL. The disease therefore was shown to considerably affect the patients’ QoL, 
as the mean scores were higher than half of the maximum score. The factors 
contributing to the impact in the patients’ QoL have been identified and 
described in model three in section 4.4.6
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 Foot pathology in patients with SSc is multifactorial  5.2.3
Usually, when pathology is present, it is because the homeostasis of the body 
has been disrupted causing an imbalance between the complex interactions of 
different body structures, at a physical and/or psychological level. This can be 
observed in the complex interactions of the multiple factors that have been 
identified in this study to contribute to foot pathology.  
In this study regional foot pathology was conceptualised theoretically as 
influencing foot function and one of the major symptoms of pathology, foot pain.  
The factors identified to predict patient-perceived foot function, predicted 51% 
of the variance in foot function; meaning that in this model over half of what is 
considered to affect foot function is determined by these factors. General 
functional ability (as measured by HAQ-SSc) was the major contributor to 
variance in foot-specific function, followed by the mean force at the heel during 
gait. The fact that general function was the major predictor of foot function was 
not a surprise, because in a person with impaired general function caused by 
the disease which might also affects the feet in similar ways, then the general 
function is likely to affect foot function. This theoretical link was also supported 
by the fact that general function also had a direct effect on ground reaction 
forces at push-off indicating that if there is impairment in general function, this 
function also has an affected foot function, specifically relating to a variable that 
is indicative of the level of dynamic propulsion during walking. On the other 
hand, it is more difficult to explain all the interactions that occur during gait 
between some other factors. During walking forces acting on the foot are 
affected by the external ground reaction force occurring from when the heel 
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strikes the ground to when the forefoot pushes-off, and affected by the dynamic 
accelerations and decelerations of the body. This biomechanical process 
explains why the force going through the heel during gait and the ground 
reaction forces are predictors of foot function as any pathology that affects 
acceleration or deceleration of the body such a myopathy, intra-articular or 
periarticular pathology will have an effect on reducing the forces, which in turn 
will have an effect on the other gait parameters. This is reflected in plantar foot 
pressures which have been reported to be correlated with gait velocity in 
healthy participants, with lower velocities leading to lower forces and hence 
lower pressures [334]. In addition, the foot function model from this current 
study identified that plantar foot pressures of the heel and 3rdMTPJ also were 
affected by plantar soft-tissue thickness, and even though soft-tissue thickness 
had only a small indirect effect on foot function, heel plantar pressure was the 
third most influential predictor of impact on foot function. Soft-tissue thickness 
has been previously reported to affect plantar pressures in healthy participants 
[383, 384], and the provision of a cushioning insole has been shown to be 
effective in modifying plantar pressures[397], indicating that tailored 
interventions can improve foot function.    
Interestingly, from the three variables capturing ROM of the foot joints, only 
ankle ROM contributed to the model although its effect on foot function was 
indirect and very small. 
The results from the foot function model have to be interpreted with some 
caution as the multivariate normality assumption in this model was violated. The 
bootstrapping technique was used to deal with the multivariate non-normality   
but in small samples (i.e. N=100) bootstrapped estimates might not be accurate 
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[282]. The sample size from this thesis was N=121 and so although is larger 
than the required minimum, it is acknowledged that the sample is close to the 
minimum N=100.     
Foot pathology is often accompanied with symptoms and in particular, foot pain. 
The SEM identified eight factors that with their interrelated interactions 
explained nearly 40% of the foot pain pathway. 
Foot pain was predicted by factors resulting from physical pathology such as 
the TP arterial waves representing PAD, psychological factors such as 
depression and anxiety, patient-perceived general function and patient-reported 
symptom interference such as breathing problems, RP and general pain. 
Interestingly, a major predictor of foot pain was general function, followed by 
pain and breathing problems. The complex nature of the interaction between 
factors can be observed in the following example from the model: when general 
function is impaired it has an effect on depression which in turn worsens 
anxiety, and an increase in anxiety causes an increase in perception of foot 
pain. General pain was also affected by general function in this model. 
Conversely, Benrud-Larson et al reported depressive symptoms and pain to be 
determinants of physical functioning but not the other way around [22]. In the 
current model, general pain was also affected by Raynaud’s interference and 
this relationship has been described as correlational previously [398]. The 
current data indicate that Raynaud’s interference in daily activities is worsened 
in the presence of anxiety. This interaction agrees with previous results from the 
literature [94], and seems to support the fact that worsening of the Raynaud’s 
interference is as a result of a physiological involvement triggered by anxiety, as 
opposed to anxious patients simply perceiving worse Raynaud’s interference in 
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daily activities, if this were not the case it could be expected that breathing 
problems might also be worsened by anxiety.  
Two interesting relationships found in this model were the large effect of 
breathing problems and Raynaud’s on general function.  
Pain in general was identified by patients with SSc as an impairment and is 
classified on the ICF under disability of a body function and structures[4], 
implying that the presence of pain can cause disability. In patients with SSc 
disability in body function as a result of pain has been previously reported, as 
pain has been identified as a predictor of physical functioning [22].  
The fact that pain is represented by an interaction between physical, 
psychological and patient-perceived impairments indicates that foot pain is a 
complex interaction of many factors. When treating foot pain therefore, for the 
treatment to achieve a satisfactory outcome, the clinician has to consider and 
possibly address other factors that can have an indirect effect on pain.  
 Foot pathology is one of the major contributors to the impact 5.2.4
on the QoL of patients with SSc 
One of the key findings of this thesis is that QoL in SSc is associated with a 
complex interaction between physical and psychosocial factors; and that foot 
pathology, represented in this study by foot function and foot pain, is one of the 
major predictors of overall QoL.  
It is well established in the literature that general function is affected in SSc 
[399], and that poor general function affects psychosocial adjustment to 
illness[273] and worsens psychological symptoms [197]. The results from this 
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current study are the first to suggest that in SSc general function is possibly the 
main contributor to impaired QoL.  
General function was also affected by a number of other factors, among which 
were foot-specific function and foot pain. Through their effects on general 
function both of these factors made a substantial contribution to reduced overall 
QoL. Interestingly, worse foot function impairment and increased foot pain had 
a bigger impact on QoL than Raynaud’s, general pain, patient reported disease 
interference in daily activities, anxiety, DU interference in daily activities and GI 
problems interference, in this order. This highlights that foot pathology needs to 
be assessed in the clinical setting on a regular basis, as addressing foot 
problems when present, can contribute to the improvement of the patients QoL. 
Furthermore, patents with SSc identified mobility as an impairment of body 
function and structures, as classified by the ICF criteria [4]. This in turn 
reinforces the fact that special attention needs to be given to the prevention 
and/or improvement of function in this patient group.  
Breathing problems also affected general function and due to the significance of 
indirect effects on other factors, was the second biggest predictor of overall 
QoL, followed by depression.  
Of the psychological factors, anxiety and depression both had a direct and 
indirect contribution to QoL, this also is in line with published literature, which 
reports that depression and anxiety in SSc has an impact on patients' lives 
[197]. Of the two factors, depression had greater influence on QoL than anxiety, 
which was the opposite of what was observed in the foot pain model, where 
anxiety was more influential. These results might indicate that anxiety worsens 
somatic symptoms but depression is associated with overall poor quality of life. 
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In general anxious people are more likely to suffer from disability[400] and 
depression as a comorbidity incrementally worsens health [401],  and 
consequently both of these conditions have a big impact on the patients health 
and QoL. The current model indicates that foot function and general function 
both have an effect on depression. Impaired function has previously been 
reported to contribute to depression in SSc [197, 278, 396], and in other 
rheumatic disease such as RA depression has been associated with worse 
function [22, 402, 403]. It has also been reported however that HAQ-DI was not 
associated with depression in SSc [404]. Amongst other factors, depressive 
symptoms have been identified as having a psychosocial impact, as they are 
associated with lower satisfaction with social support, poorer emotion-focus 
coping, helplessness and higher fear of disease progression[404]. This may in 
part explain why depression is one of the main predictors affecting QoL.   
Throughout the development and analysis of the models, general function has 
been a factor that has recurred as a principal predictor in all three models. Thus 
especial attention needs to be paid clinically to improve patients’ general 
function and those factors that affect it, as general function appears to be a key 
factor for the improvement of foot-specific function, foot pain and overall QoL.  
The final model exploring predictors of overall QoL had a very good fit to the 
data and the interactions between the physical and psychosocial variables 
estimated a high proportion of the variance of QoL in SSc. Eighty-four per cent 
of the variance in QoL was explained by the model, which can be considered a 
high proportion of prediction, as there are published models that only explain 
25% of the variance in the outcome. Furthermore, to the candidate's knowledge 
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this is the first model produced that explains the impact of foot-specific 
problems on the overall QoL of patients with SSc.  
It is important to note that while all of the final models tested fitted the data well, 
there is always the possibility that other models would have also fitted the data. 
When interpreting the results from the model one has to bear in mind two 
things. First, SEM and path analysis model probabilistic causality as opposed to 
deterministic causality, which means that SEM allows for change to occur in 
affected variables, as opposed to the same consequence being observed in all 
cases for the affected variable; which is the case in deterministic causality. 
Second, that it must be appreciated that the initial models were modified and 
therefore the modelling approach became exploratory as opposed to 
confirmatory[282].  
5.3 Limitations of the study 
The findings from this study have to be interpreted in light of the limitations of 
the study described. 
For the cross-sectional study comparing patients with SSc to healthy 
volunteers, the ratio of patients with SSc to healthy participants was two to one.  
While other studies have also used this ratio, one to one, or one patient with 
SSc to 2 healthy volunteers are arguably more robust because of the related 
increase in sample size. This might have led to this study reporting absence of 
a significant difference were there was one in truth, as a result of not having 
enough power to detect a real difference (i.e type II error). 
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The factors identified as potential candidate factors for the SEM were selected 
in a systematic manner, but it is acknowledged that they might not have 
captured the full burden of the pathology especially with regard to foot specific 
factors, where selection might not have been as comprehensive. For example, 
the data obtained for the vascular assessment relates mainly to macrovascular 
disease, and therefore microvascular involvement and associated vasculopathy, 
which is a major underpinning pathogenic process in SSc is less well 
represented in these models. Due to the excessive time burden on participants 
and poor quality of resulting data, a conscious decision was taken to abandon 
the two tests that captured microvascular pathology, and it may be that these 
would need to be explored in future stand-alone studies of microvasculopathy.  
Even though the potential candidate factors were selected in a systematic 
manner through expert consultation, the factors selected may have been 
different if a Delphi approach using a larger expert panel was used.   
While we tried to recruit a sample with ethnic diversity, it is a limitation that the 
majority of the participants were British Caucasians nonetheless, as a 
consequence the results from the case-control cross-sectional study and from 
the models might not be representative of a population with different ethnic 
composition.  
Interpretation of the he SEM/path analysis needs to consider a number of 
limitations. First, the sample size was smaller than recommended (N=200), 
which often results in models, which do not work.  Due to SSc being a rare 
disease however, it can be acceptable to use smaller sample sizes. 
Consequently, although the sample size was smaller than recommended, the 
models have shown to demonstrate a very good fit across a range of different fit 
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statistics. The sample size also affected the validation of the model as the 
sample size was not big enough to retest and validate the final model, however 
the model can be validated by another sample any other time.  
Second, some of the factors included in the models were ordinal or categorical 
variables, which is not optimal for the modelling. Ideally the ordinal data should 
have been Rasch transformed into continuous data, although transformations 
are not yet available for the variables explored in this study.  
Finally, foot function, foot pain or QoL might be affected by un-model factors, 
i.e. factors that contribute to these outcomes but were not included in the 
model, such as fatigue, microvascular vasculopathy, fear of disease 
progression, or social support.   
5.4 Directions for future research 
This study has provided a platform for further research into foot pathology and 
quality of life in SSc.  
i. Development of target interventions  
The results from the model provided an initial insight into the factors that affect 
foot function, foot pain and QoL. Future research should be aiming to define 
which factors from the models are modifiable and non-modifiable, through 
general consensus using a panel of experts. Once the modifiable factors are 
identified they should be assessed for suitability for targeted intervention and a 
range of therapeutic options should be defined. From the defined therapeutic 
intervention, one or more proof of concept studies should be undertaken to 
explore the feasibility of the targeted approaches and investigate the 
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mechanism of action for any observed effect. Depending on the result of the 
feasibility study, randomised control trials should be developed to test the 
interventions to inform evidence based clinical practice and improve foot 
pathology and patients’ quality of life. This structured future research plan can 
be applied to any of the results of the three models.  
ii. Development of composites outcomes measure  
The results from the clinical testing protocols also highlighted that for some 
neurological and musculoskeletal tests there are inadequate criteria to 
determine the clinically meaningful thresholds for each test that determine cut-
points for normal versus pathology. Future research could focus therefore on 
determining relevant thresholds and developing composite outcome measures 
that capture and determine the severity of neuropathy, vasculopathy, and 
musculoskeletal involvement in the feet, and to aid clinical and research 
assessments.  
iii. Exploration of foot pathology in patients reporting foot problems.   
The heterogeneity of the disease across the sample in the study might have 
caused some of the difference in foot pathology between SSc patients and 
healthy participants to be missed. Future studies could be carried out exploring 
in depth the pathology of the disease in those patients with SSc that specifically 
report foot problems.  
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5.5 Summary  
The major findings of this thesis can be summarised as follow:  
i. SSc has an impact on the individual at many levels. Some people with 
SSc have significant foot disability, which is associated with significant 
detrimental physical and psychological consequences. 
ii. Foot pathology in SSc involves inter-related features affecting the 
integumentary, vascular, neurological and musculoskeletal systems. 
iii. Foot pathology in patients with SSc has multifactorial drivers, with 
physical and psychological factors contributing to the foot pathology. 
V. Foot pathology is one of the major contributors to the impact on the 
overall QoL of patients with SSc, influencing QoL at a higher level than 
other systemic symptoms.  
VI. General function is the major predictor of foot function, foot pain and 
QoL, and especial attention should be paid in the clinic to address the 
relevant factors. 
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Appendix                                                                                          
Intra-Rater Reliability of Ultrasound Measurement of 
Plantar Soft-Tissue Thickness  
5.1 Introduction 
To ensure that the candidate was able to obtain reliable ultrasound 
measurements of the plantar soft-tissue thickness under the 3rd MTP joint and 
heel, an intra-rater reliability study was undertaken.  The ultrasound 
measurements were considered necessary to assess whether the plantar soft-
tissues are affected by the same pathophysiological process of fibrosis that 
affects other subcutaneous tissues in patients with SSc. The reliability with 
which the candidate measures the thickness of the plantar soft-tissue in the 
Regions Of Interest  (ROI) is important to ensure that the measurements 
represent features of the disease rather than measurement artefact.  Reliability 
is an important consideration when using ultrasound because the technique is 
known to be operator dependent.  
It is useful to quantify the repeatability or reproducibility of the observations, as 
repeatability is a measure of consistency. Measurements of repeatability are 
variously referred as reliability, reproducibility, consistency, test-retest variability 
or stability [405, 406]. For the purposes of the current study the concept of 
repeatability is being explored only through reliability analysis and in particular 
focuses on the intra-rater reliability. The candidate’s intra-rater reliability in 
obtaining measures of the soft tissue thickness in the plantar soft tissues is 
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quantified by taking measurements from relevant areas in the same group of 
participants at two different time points. 
5.2 Participants and methods  
 Participants  5.2.1
i. Sample size  
This study aimed to recruit 35 participants as this sample size is recommended 
as an adequate sample size for intra-rater reliability studies on validated tests 
[407]. From these 35 participants the target was to recruit 30 healthy 
participants, as the purpose was to investigate the technique of the operator 
rather than the clinical use, and also 5 patients with SSc to confirm the 
technique in patients but causing them minimum inconvenience. 
ii. Recruitment  
Recruitment was undertaken at Chapel Allerton Hospital (Leeds Teaching 
Hospitals NHS Trust). The healthy participants were members of the staff from 
the Leeds Teaching Hospitals NHS Trust approached directly by the candidate 
regarding taking part in the study. Those that indicated willingness to participate 
were given a brief verbal explanation of the study and if they wished to 
participate consent was obtained. The patients with SSc were approached by 
the candidate when they were attending their routine care at the connective 
tissue disease clinics. Patients indicating a willingness to participate were given 
a brief verbal explanation of the study, and consent was obtained. 
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iii. Inclusion/ exclusion criteria  
All participants had to be aged ≥18 years old, and assent freely to participate in 
the study. The healthy participants had to have general good health, i.e free of 
any chronic disease; while the only requirement for the patients was to have a 
physician diagnosis of SSc (ARA/ACR 1980 criteria). 
 Methods 5.2.2
All measurements were carried out using high-resolution diagnostic ultrasound 
(GE Voluson, GE Healthcare, Chalfont, UK) with an 18 Mhz probe.  
The regions of interest (ROI) from the plantar aspect of the foot were the 3rd 
metatarsophalangeal (MTP) joint and heel. The soft-tissue thickness in both 
regions were measured by the candidate at two different time points, at least 
two weeks apart.  
 To measure the plantar soft-tissues thickness at the 3rd MTP joint, 
measurements were taken from the closest point of the metatarsal head to the 
ultrasound transducer, to the most superficial point of the epidermis as 
illustrated in Figure A.1. When taking the measurements, the longitudinal axis of 
the ultrasound transducer was aligned to the longitudinal axis of the metatarsal 
head. 
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Figure A.1 Measurement of the plantar soft-tissue thickness under the 3
rd
 MTP joint 
To measure the plantar soft-tissues thickness at the heel, measurements were 
taken from the closest point of the calcaneus to the ultrasound transducer, to 
the most superficial point of the epidermis as illustrated in Figure A.2. When 
taking the measurements the longitudinal axis of the ultrasound transducer was 
aligned to the longitudinal axis of the calcaneus.  
 
Figure A.2 Measurement of the plantar soft-tissue thickness under the heel 
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To obtain the most accurate possible reading, compression with the ultrasound 
probe of the skin was avoided, as the slightest compression would cause 
reduction of the soft-tissues thickness being measured. Compression was 
avoided by ensuring a visible layer of gel remained between the transducer 
head and the out layer of the epidermis on the B mode image.   
5.3 Statistical Analysis  
Three statistical approaches were used to assess the intra-rater reliability: 
Intraclass Correlation Coefficient (ICC) to examine reliability; Standard Error of 
the Measure to obtain an absolute index of reliability[405, 406, 408]; Bland–
Altman plot to examine agreement and stability of the measure over the range 
of values [409, 410].  
The ICC is a relative measure of repeatability that provides a reliability index, 
which is indicative of the overall measurement error. In this reliability study the 
ICC was used to quantify the relative consistency between measurements [411] 
by estimating the proportion of the total variance that is accounted for by the 
variation between subjects, while the remaining variance was attributed to the 
variation obtain from the repeated measurements within subjects [406, 408].  
To assess the intra-rater, between-day repeatability the ICC model used was 
the one-way, single measure model [412, 413]. This is recommended for use in 
determining the intra-rater reliability of repeated measurements and is the most 
conservative of all the ICC models [411-415]. The ICC provides a reliability 
coefficient, but it cannot easily be interpreted clinically because it does not 
indicate the magnitude of disagreement between measurements. Thus, it has 
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been suggested that ICCs should be complemented by also calculating the 
Standard Error of the Measure which assesses the within subject test-retest 
variation and offers a value for the absolute range in which a subject’s ‘true’ 
measurement is likely to lie [405, 406, 411]. The Standard Error of the Measure 
was calculated using the ICC and as indicated by the following formula: 
				
	ℎ		 =
			

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The Bland–Altman plot, also known as the Mean-vs-difference plot, was plotted 
with the 95% limits of agreement. The Bland–Altman plot was used to assess 
agreement between the two measurements, and to identify whether there was 
any systematic variation in the difference as the magnitude of the measurement 
(skin thickness) varied across the measures within the cohort. Agreement is an 
important component of the intra-rater reliability. For agreement to occur the 
bias and variation has to be uniform throughout the range of measurements.  
The 95% limits of agreement provided the range within 95% of the difference 
between measurements were expected to lie [409, 410].   
5.4 Results  
Of the 35 recruits 30 participants completed both sessions of the reliability 
study. The final sample was composed of 27 healthy participants and 3 
participants with SSc. Three healthy participants and two patients with SSc 
were lost at follow-up because of inability or unwillingness to attend.   
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Of the 30 participants, 22 were female and 8 were male. The mean age of the 
participants was 42 (SD  ±12.) and the mean time between measurements was 
13.5 days (SD 15.9). 
i. Intra-rater reliability results for the 3rd MTPJ   
The results from the ICC of the 3rd MTPJ was 0.58 (95%CI 0.28 to 0.77) 
indicating a moderate reliability in the measurement of the 3rd MTPJ [416]. The 
Standard Error of the Measure, yielded a measurement error for the 3rd MTPJ of 
0.30cm indicating that the candidate’s measurement error for this ROI was 
3mm.  
The Bland–Altman plot consisted of the mean of the two groups of 
measurements plotted against the difference between the two measurements  
(Figure A.3). For the 3rd MTPJ soft-tissue thickness, the Bland-Altman plots 
showed that the mean of the difference was very close to 0, at -0.031cm, 
indicating that there was little systematic variability between the two 
measurements. The 95% limits of agreement, ± 0.303cm supported the 
Standard Error of the Measure results indicating that the candidate was able to 
re-measure skin thickness at the two sites within 3mm [410]. The differences 
from the mean were also consistent over the range of skin thicknesses 
measured indicating stability in this degree of error. 
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 Figure A.3 Bland-Altman plot 3rd MTPJ. The constant line represents the difference 
of the means at -0.031cm, the two discontinued lines represent the 95% limits of 
agreement (mean±2SD) at ± 0.303cm  
ii. Intra-rater reliability results for the heel    
The ICC value for intra-rater testing at heel was 0.79 (95%CI 0.60 to 0.89) 
indicating that the reliability in the measurement of the heel thickness is 
substantial [416]. The Standard Error of the Measure, yielded a measurement 
error for the heel of 0.34cm, indicating that the candidate’s measurement error 
for the heel was again approximately 3mm.  
The Bland–Altman plot for the heel soft-tissues thickness (Figure A.4) showed 
similar results to those from the 3rd MTPJ. The mean of the difference was also 
very close to 0 (-0.033cm), again indicating that there was little systematic 
variability between the two measurements. The difference between the two 
measurements was relatively close to the mean of the difference, indicating 
good agreement. The 95% limits of agreement, ±0.289cm for the heel plot, 
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again supported the Standard Error of the Measure results indicating that the 
candidate was able to re-measure skin thickness at the heel to within 
approximately 3mm [410]. Again the differences from the mean were consistent 
over the range of values indicating stability in the magnitude of error. 
 
 
Figure A.4 Bland-Altman plot heel: The constant line represents the difference of 
the means at -0.033cm, the two discontinued lines represent the 95% limits of 
agreement (mean±2SD) at ± 0.289cm. 
 
Both graphs showed the variability being constant throughout the range of 
measurements and the absence of any trend indicating systematic bias. 
5.5 Discussion 
The test-retest results indicate that US readings of plantar soft-tissue thickness 
at the 3rd MTPJ and at the heel, taken by the candidate two weeks apart, were 
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adequately reliable and yielded a measurement error of approximately 3mm. 
Clinically, a 3mm measurement error is considered small compared to the 
magnitude of the values obtained from the soft-tissues thickness of the ROI 
which ranged from 0.9cm to 2.3cm. The implications of the measurement error 
for the thesis are that any between-group difference in soft-tissue thickness 
identified in the main study, would need to exceed 3mm to be considered a 
‘true’ difference and not simply to represent measurement error. 
In addition, the Bland-Altman plots indicated that the variability and bias are 
consistent throughout the range of measurements and that the candidate is 
able to measure a range of different soft-tissues thickness within the ROI 
reliably and independent of the thickness of the soft-tissues.     
 When interpreting this reliability study, the limitations of this study have to be 
considered. The candidate used only a single measurement of the soft-tissues 
from the ROI at two-time points, as opposed to an average of multiple repeat 
measurements. Although using single measurements is acceptable for reliability 
studies [413, 417], the use of averaged measures would have increased the 
consistency of the measurements and strengthened the technical reliability 
overall. This would not however have reflected the approach used in the main 
study, which employed a single measure due to the time constraints introduced 
by the collection of data from multiple body systems. It was considered more 
appropriate in the current study therefore to explore the reliability of the protocol 
to be used in the main study.  
It is acknowledged that there was a small representation of participants with 
SSc in the sample, with only 3 out of 30 participants having SSc. As there was a 
small representation of the population that was to be evaluated in the main 
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study the possibility remains that the measurements of the plantar soft–tissues 
thickness may not to be as reliable in patients with SSc as it is for healthy 
participants. This is not likely however, as the ultrasound measure is technical, 
rather than disease –specific and the results from the Bland-Altman plot showed 
that the candidate is able to measure a range of different soft-tissues thickness 
on the ROI in a reliable way, independently of the thickness of the soft-tissues. 
This indicating that if the plantar soft-tissue thickness varies systematically in 
patients with SSc compared to controls, the candidate should be able to 
measure the thickness with the same reliability as per the healthy participants.   
5.6 Conclusion  
The results obtained from the tests undertaken to assess the different 
components of the intra-rater reliability have shown that the candidate’s 
ultrasound measurements of the plantar soft-tissues of the 3rd MTPJ and heel 
are adequately reliable as shown by moderate and substantial reliability indices 
indicated by the ICC, good agreement demonstrated by the Band-Altman plots 
and the small Standard Error of the Measure and reliability coefficients. This 
indicates that the candidate was able undertake the ultrasound measurements 
in a repeatable enough manner to warrant their inclusion in the main study. 
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